10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-13-323794.txt : 20130807 0001193125-13-323794.hdr.sgml : 20130807 20130807135916 ACCESSION NUMBER: 0001193125-13-323794 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20130630 FILED AS OF DATE: 20130807 DATE AS OF CHANGE: 20130807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 131016874 BUSINESS ADDRESS: STREET 1: 2525 28TH STREET STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 2525 28TH STREET STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 10-Q 1 d547025d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended June 30, 2013.

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from to .

Commission file number: 001-35347

Clovis Oncology, Inc.

(Exact name of Registrant as specified in its charter)


Delaware		90-0475355
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

2525 28^th Street, Suite 100 Boulder, Colorado		80301
(Address of principal executive offices)		(Zip Code)

(303) 625-5000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of August 1, 2013 was 30,171,392.

CLOVIS ONCOLOGY, INC.

FORM 10-Q

TABLE OF CONTENTS


PART I. Financial Information		3
ITEM 1.	Financial Statements (unaudited)	3
	Consolidated Statements of Operations and Comprehensive Loss — for the three months and six months ended June 30, 2013 and 2012 and the cumulative period from April 20, 2009 (inception) through June 30, 2013	3
	Consolidated Balance Sheets — as of June 30, 2013 and December 31, 2012	4
	Consolidated Statements of Cash Flows — for the six months ended June 30, 2013 and 2012 and the cumulative period from April 20, 2009 (inception) through June 30, 2013	5
	Notes to Unaudited Consolidated Financial Statements	6
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	18
ITEM 4.	Controls and Procedures	18
PART II. Other Information		19
ITEM 1.	Legal Proceedings	19
ITEM 1A.	Risk Factors	19
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	19
ITEM 3.	Defaults Upon Senior Securities	19
ITEM 4.	Mine Safety Disclosures	19
ITEM 5.	Other Information	19
ITEM 6.	Exhibits	20
SIGNATURES		23

PART I. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

CLOVIS ONCOLOGY, INC.

(A Development Stage Enterprise)

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except per share amounts)


	Three Months Ended June 30,						Six Months Ended June 30,						Cumulative from April 20, 2009 (Inception) to June 30,
	2013			2012			2013			2012			2013
Revenues	$	—		$	—		$	—		$	—		$	—
Operating Expenses:
Research and development		15,816			12,590			27,938			25,152			151,643
General and administrative		3,492			2,680			6,710			5,105			30,719
Acquired in-process research and development		—			250			250			4,250			36,585

Operating loss		(19,308	)		(15,520	)		(34,898	)		(34,507	)		(218,947	)
Other income (expense), net		(33	)		(172	)		(111	)		(176	)		(544	)

Loss before income taxes		(19,341	)		(15,692	)		(35,009	)		(34,683	)		(219,491	)
Income taxes		—			35			—			27			—

Net loss	$	(19,341	)	$	(15,657	)	$	(35,009	)	$	(34,656	)	$	(219,491	)

Basic and diluted net loss per common share	$	(0.72	)	$	(0.61	)	$	(1.33	)	$	(1.45	)	$	(20.98	)

Basic and diluted weighted average common shares outstanding		26,717			25,744			26,377			23,892			10,460

Comprehensive loss	$	(19,338	)	$	(15,661	)	$	(35,015	)	$	(34,658	)	$	(219,444	)

See accompanying notes.

CLOVIS ONCOLOGY, INC.

(A Development Stage Enterprise)

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except for share amounts)


	June 30, 2013			December 31, 2012
Assets
Current assets:
Cash and cash equivalents	$	372,240		$	144,097
Prepaid research and development expenses		605			116
Other current assets		598			659

Total current assets		373,443			144,872
Property and equipment, net		1,030			1,084
Other assets		751			38

Total assets	$	375,224		$	145,994

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,589		$	2,297
Accrued research and development expenses		8,199			7,161
Other accrued expenses		2,224			2,702

Total current liabilities		12,012			12,160
Non-current liabilities		211			338
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2013 and December 31, 2012		—			—
Common stock, $0.001 par value per share, 100,000,000 shares authorized at June 30, 2013 and December 31, 2012; 30,169,815 and 26,207,190 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively		30			26
Additional paid-in capital		582,415			317,899
Accumulated other comprehensive income		47			53
Deficit accumulated during development stage		(219,491	)		(184,482	)

Total stockholders’ equity		363,001			133,496

Total liabilities and stockholders’ equity	$	375,224		$	145,994

See accompanying notes.

CLOVIS ONCOLOGY, INC.

(A Development Stage Enterprise)

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(Dollars in thousands)


	Six Months Ended June 30,						Cumulative from April 20, 2009 (Inception) to June 30,
	2013			2012			2013
Operating activities
Net loss	$	(35,009	)	$	(34,656	)	$	(219,491	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		123			176			750
Share-based compensation expense		3,872			2,114			10,218
Amortization of premiums and discounts on available for sale securities		—			10			471
Loss on disposal of equipment		—			—			1,162
Gain on sale of available for sale securities		—			—			(34	)
Non-cash acquired in-process research and development		—			—			7,000
Changes in operating assets and liabilities:
Prepaid and accrued research and development expenses		(165	)		1,922			6,879
Other operating assets		121			531			(96	)
Accounts payable		(755	)		(1,655	)		1,543
Other accrued expenses		(474	)		(888	)		2,133

Net cash used in operating activities		(32,287	)		(32,446	)		(189,465	)
Investing activities
Purchases of property and equipment		(66	)		(908	)		(2,610	)
Purchases of available for sale securities		—			—			(27,008	)
Maturities and sales of available for sale securities		—			2,000			26,571

Net cash provided by (used in) investing activities		(66	)		1,092			(3,047	)
Financing activities
Proceeds from sale of convertible preferred stock, net of issuance costs		—			—			75,499
Proceeds from sale of common stock, net of issuance costs		259,146			69,976			458,481
Proceeds from exercise of stock options and employee stock purchase plan		1,368			42			2,834
Proceeds from issuance of convertible promissory notes, net of issuance costs		—			—			27,902

Net cash provided by financing activities		260,514			70,018			564,716
Effect of exchange rate changes on cash and cash equivalents		(18	)		3			36

Increase in cash and cash equivalents		228,143			38,667			372,240
Cash and cash equivalents at beginning of period		144,097			138,236			—

Cash and cash equivalents at end of period	$	372,240		$	176,903		$	372,240

Non-cash items:
Conversion of convertible preferred stock to common stock	$	—		$	—		$	75,499
Conversion of convertible promissory notes and accrued interest to common stock	$	—		$	—		$	35,851
Assets recorded for which payment (has)/has not yet occurred	$	(39	)	$	(684	)	$	24

See accompanying notes.

CLOVIS ONCOLOGY, INC.

(A Development Stage Enterprise)

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of Business and Basis of Presentation

Clovis Oncology, Inc. (the “Company”), a corporation in the development stage, was incorporated in Delaware on April 20, 2009, and commenced operations in May 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and other international markets. The Company has and intends to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, the Company generally expects to provide the licensor with a combination of up-front payments, milestone payments and royalties on future sales. In addition, the Company generally expects to assume the responsibility for future drug development and commercialization costs. The Company currently operates in one segment. Since inception, the Company’s operations have consisted primarily of developing in-licensed compounds and their companion diagnostics, evaluating new product acquisition candidates, raising capital and corporate organization activities. The Company has never earned revenue from these activities, and accordingly, the Company is considered to be in the development stage as of June 30, 2013.

Basis of Presentation

The information reported within the Company’s financial statements from April 20, 2009 to December 31, 2010 was based solely on the accounts of Clovis Oncology, Inc. Effective January 1, 2011, Clovis Oncology UK Limited, a wholly owned subsidiary of the Company, commenced operations. All financial information presented after December 31, 2010 was consolidated and includes the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Changes in or reclassifications out of accumulated other comprehensive loss are not disclosed in our notes to the unaudited financial statements due to the insignificance of the activity. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial information prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. The Company evaluates subsequent events up to the time of filing with the SEC. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2012 for a broader discussion of our business and the opportunities and risks inherent in such business.

Use of Estimates

The preparation of these unaudited consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, other comprehensive loss and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to clinical trial accruals and share-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

Liquidity

The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through public and private equity financings, and management expects operating losses and negative cash flows to continue for at least the next several years. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless or until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through cash and investments on hand and additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources.

2. Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 2 of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

3. Financial Instruments and Fair Value Measurement

Cash, Cash Equivalents and Available for Sale Securities

The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.

Marketable securities with original maturities greater than three months are considered to be available for sale securities and historically consisted of U.S. agency obligations, U.S. government obligations and corporate debt obligations. Available for sale securities are reported at fair market value and unrealized gains and losses are included as a separate component of stockholders’ equity. Realized gains, realized losses, the amortization of premiums and discounts, interest earned and dividends earned are included in other income (expense). The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on management’s intent to fund current operations with these securities or to make them available for current operations. A decline in the market value of a security below its cost value that is deemed to be other than temporary is charged to earnings, and results in the establishment of a new cost basis for the security.

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include:


Level 1:		Quoted prices in active markets for identical assets or liabilities. The Company’s Level 1 assets and liabilities consist of money market investments.

Level 2:		Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company does not have Level 2 assets or liabilities.

Level 3:		Unobservable inputs that are supported by little or no market activity. The Company does not have Level 3 assets or liabilities.

The following table identifies the Company’s assets that were measured at fair value on a recurring basis (in thousands):


	Balance		Level 1		Level 2		Level 3
June 30, 2013
Money market	$	147,985	$	147,985	$	—	$	—

Total assets at fair value	$	147,985	$	147,985	$	—	$	—

December 31, 2012
Money market	$	135,385	$	135,385	$	—	$	—

Total assets at fair value	$	135,385	$	135,385	$	—	$	—

There were no security transfers between Levels 1 and 2 during the six month period ended June 30, 2013.

4. Other Accrued Expenses

Other accrued expenses are comprised of the following (in thousands):


	June 30, 2013		December 31, 2012
Accrued personnel costs	$	1,811	$	2,441
Accrued corporate legal fees and professional services		350		63
Accrued expenses – other		63		198

Other accrued expenses	$	2,224	$	2,702

5. Convertible Promissory Notes

In May 2011, the Company issued $20.0 million of 5% Convertible Promissory Notes to existing investors for cash. In June 2011, the Company issued $15.0 million of 5% Convertible Promissory Notes to Pfizer, which was comprised of a $7.0 million note issued to acquire the global rights to develop and market rucaparib and an $8.0 million note issued for cash (the “Notes”). The Notes accrued interest at an annual rate of 5% and had a maturity date of May 25, 2012. In connection with the completion of the Company’s initial public offering in November 2011, the principal balance and all accrued and unpaid interest due on the Notes was converted into 2,757,788 shares of the Company’s common stock.

6. Convertible Preferred Stock and Stockholders’ Equity

Common Stock

In May 2009, the Company issued 1,206,899 shares of its common stock to the original founders at a purchase price of $.0029 per share. The shares were issued under restricted stock purchase agreements, which allowed the Company, at its discretion, to repurchase unvested shares if the founders terminated their employment with the Company. As of June 30, 2013, all common stock shares issued to the founders under the restricted stock purchase agreements were fully vested.

In November 2011, the Company sold 10,700,000 shares of its common stock in an initial public offering at a price of $13.00 per share. The Company received net proceeds from the offering of $129.4 million, after deduction of $6.9 million of underwriting commissions and $2.8 million of offering expenses.

In April 2012, the Company sold 3,750,000 shares of its common stock in a public offering at $20.00 per share. The net offering proceeds realized after deducting offering expenses and underwriters’ discounts and commissions was $70.0 million.

In June 2013, the Company sold 3,819,444 shares of its common stock in a public offering at $72.00 per share. The net offering proceeds realized after deducting offering expenses and underwriters’ discounts and commissions was $259.1 million.

The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders of the Company. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by the Company’s Board of Directors.

Preferred Stock

In May 2009, the Company entered into the Series A-1, A-2, B and C Preferred Stock Purchase Agreement with various investors (the “Preferred Stock Purchase Agreement”). The Preferred Stock Purchase Agreement provided for the issuance of up to $146.3 million of the Company’s convertible preferred stock, subject to various terms and conditions. During 2009, the Company issued shares of Series A-1, Series A-2 and Series B convertible preferred stock resulting in total aggregate cash proceeds to the Company of $75.5 million, net of $174,000 related stock issuance costs.

In connection with the completion of the Company’s initial public offering in November 2011, all of the outstanding shares of convertible preferred stock were automatically converted into 7,244,523 shares of the Company’s common stock. The Series A-1, A-2 and B convertible preferred stock converted at a rate of 2.9 for 1 into common stock based upon the election of the convertible preferred stock holders immediately prior to the closing of the initial public offering.

7. Share-Based Compensation

Share-based compensation expense for all equity based programs, including stock options and the employee stock purchase plan, for the three and six months ended June 30, 2013 and 2012, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Research and development	$	1,103	$	592	$	1,957	$	1,032
General and administrative		1,005		576		1,915		1,082

Total share-based compensation expense	$	2,108	$	1,168	$	3,872	$	2,114

The Company did not recognize a tax benefit related to share-based compensation expense during the three and six months ended June 30, 2013 and 2012, respectively, as the Company maintains net operating loss carryforwards and has established a valuation allowance against the entire net deferred tax asset as of June 30, 2013. No share-based compensation expense was capitalized on our Consolidated Balance Sheets as of June 30, 2013 and December 31, 2012.

The following table summarizes the activity relating to the Company’s options to purchase common stock for the six month period ended June 30, 2013:


	Option Shares Outstanding			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Balance at December 31, 2012		1,599,044		$	14.05
Granted		1,046,158			28.53
Exercised		(130,732	)		9.09
Forfeited		(29,400	)		16.75

Balance at June 30, 2013		2,485,070		$	20.38		8.79	$	116,427,809

Vested and expected to vest at June 30, 2013		2,261,717		$	19.90		8.72	$	107,015,622

Vested at June 30, 2013		721,162		$	11.00		7.84	$	40,368,071

The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $66.98 as of June 30, 2013, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.


	Three Months Ended June 30,
	2013		2012
Weighted-average grant-date fair value per share	$	43.22	$	12.60
Intrinsic value of options exercised	$	5,540,488	$	162,845
Cash received from stock option exercises	$	1,101,935	$	32,108


	Six Months Ended June 30,
	2013		2012
Weighted-average grant-date fair value per share	$	17.61	$	15.02
Intrinsic value of options exercised	$	5,716,374	$	223,319
Cash received from stock option exercises	$	1,188,312	$	42,149

As of June 30, 2013, the unrecognized share-based compensation expense related to nonvested options, adjusted for expected forfeitures was $23.7 million and the estimated weighted-average remaining vesting period was 2.8 years.

8. License Agreements

CO-1686

In May 2010, the Company entered into a worldwide license agreement with Avila Therapeutics, Inc. (“Avila”) to discover, develop and commercialize a covalent inhibitor of mutant forms of the epidermal growth factor receptor gene product. In March 2012, Avila was acquired by Celgene Corporation (“Celgene”). CO-1686 was identified as the lead drug candidate to be developed under the license agreement. The Company is responsible for all preclinical, clinical, regulatory and other activities necessary to develop and commercialize CO-1686. The Company made an up-front payment of $2.0 million upon execution of the license agreement which was recognized as acquired in-process research and development expense. The Company is obligated to pay royalties on net sales of CO-1686, based on the volume of annual net sales achieved. Celgene has the option to increase royalty rates by electing to reimburse a portion of the development expenses incurred by the Company. This option must be exercised within a limited period of time after Celgene is notified of our intent to pursue regulatory approval of CO-1686 in the United States or European Union as a first line therapy.

In January 2012, the U.S. Food and Drug Administration (FDA) accepted our investigational new drug (IND) application to begin clinical investigation of CO-1686. Following the FDA’s acceptance of the IND application, the Company made a milestone payment of $4.0 million to Avila as required by the license agreement and recognized the payment as acquired in-process research and development expense. The Company may be required to pay up to an additional aggregate of $115.0 million in development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, the Company may be required to pay up to an aggregate of $120.0 million in sales milestones if certain annual sales targets are achieved.

In January 2013, the Company entered into an exclusive license agreement with Gatekeeper Pharmaceuticals, Inc. (“Gatekeeper”) to acquire exclusive rights under patent applications associated with mutant epidermal growth factor receptor (“EGFR”) inhibitors and methods of treatment. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. If CO-1686 is approved for commercial sale, the Company will pay royalties to Gatekeeper on future net sales.

Rucaparib

In June 2011, the Company entered into a worldwide license agreement with Pfizer Inc. to acquire exclusive development and commercialization rights to Pfizer’s drug candidate known as rucaparib. This drug candidate is a small molecule inhibitor of poly (ADP-ribose) polymerase, or PARP, which the Company is developing for the treatment of selected solid tumors. Pursuant to the terms of the license agreement, the Company made an up-front payment by issuing to Pfizer a $7.0 million convertible promissory note with a 5% annual interest rate, due in 2012. Upon completion of the Company’s initial public offering in November 2011, the principal balance and all accrued and unpaid interest due on this note of $7.2 million was converted into 551,222 shares of common stock. The Company is responsible for all development and commercialization costs of rucaparib and, if approved, Pfizer will receive royalties on the net sales of the product. In addition, Pfizer is eligible to receive up to $259 million of further payments, in aggregate, if certain development, regulatory and sales milestones are achieved.

In April 2012, the Company entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of rucaparib for the uses claimed by these patents. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. The Company may be required to pay up to an aggregate of $0.7 million in milestone payments if certain regulatory filings, acceptances and approvals are achieved. If approved, AstraZeneca will also receive royalties on any net sales of rucaparib.

CO-101

In November 2009, the Company entered into a license agreement with Clavis Pharma ASA (“Clavis”) to develop and commercialize CO-101 in North America, Central America, South America and Europe. Under terms of the license agreement, the Company made an up-front payment to Clavis in the amount of $15.0 million, which was comprised of $13.1 million for development costs incurred prior to the execution of the agreement that was recognized as acquired in-process research and development and $1.9 million for the prepayment of preclinical activities to be performed by Clavis. In November 2010, the license agreement was amended to expand the license territory to include Asia and other international markets. The Company made a payment of $10.0 million to Clavis for the territory expansion and recognized the payment as acquired in-process research and development. As part of the amended license agreement, Clavis also agreed to reimburse up to $3.0 million of the Company’s research and development costs for certain CO-101 development activities subject to the Company incurring such costs, all of which was completed in 2011.

On November 12, 2012, the Company reported results from a pivotal study for CO-101 as compared to gemcitabine in metastatic pancreatic cancer. The study results failed to demonstrate a difference in overall survival between the two study arms. Based on the results of the study, the Company has ceased development of CO-101 and terminated the license agreement.

Drug Discovery Collaboration Agreement

In July 2012, the Company entered into a drug discovery collaboration agreement with Array BioPharma Inc. for the discovery of a novel cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. Under the terms of the agreement, the Company is responsible to fund all costs of the discovery program, as well as costs to develop and commercialize any clinical candidates discovered. If any clinical candidates are discovered and the Company seeks to pursue clinical development of such clinical candidates, the Company may be required to pay Array up to an aggregate of $192.0 million in milestone payments if certain development and regulatory objectives and annual net sales targets are achieved.

9. Net Loss Per Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, stock options are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):


	Three and Six Months Ended June 30,
	2013		2012
Common shares under option		2,343		1,718

Total potential dilutive shares		2,343		1,718

10. Commitments and Contingencies

Royalty and License Fee Commitments

The Company has entered into certain license agreements, as identified in Note 8, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. The Company’s payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly no amounts have been recorded in the Company’s accompanying Consolidated Balance Sheets at June 30, 2013 and December 31, 2012.

Development and Manufacturing Agreement Commitments

In February 2013, the Company entered into a development and manufacturing agreement with a third-party supplier for the production of the active ingredient for rucaparib. Under the Development and Manufacturing Agreement, the Company will provide the third-party supplier a rolling 24-month forecast that will be updated by the Company on a quarterly basis. The Company is obligated to order the quantity specified in the first twelve months of any forecast. As of June 30, 2013, $2.6 million of purchase commitments were established under this agreement.

11. Subsequent Events

The Company evaluated events up to the filing date of these interim financial statements and determined that no subsequent activity required disclosure.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Information

This Quarterly Report on Form 10-Q and the information incorporated herein by reference includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Quarterly Report on Form 10-Q and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned preclinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, our results of operations, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and industry change and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained herein.

Any forward-looking statements that we make in this Quarterly Report on Form 10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

You should also read carefully the factors described in the “Risk Factors” section of this Quarterly Report on Form 10-Q to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements. You are advised, however, to consult any further disclosures we make on related subjects in our other reports filed with the SEC and on our website.

Overview

We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients that are most likely to benefit from their use. We are currently developing two product candidates for which we hold global marketing rights: CO-1686, an orally available, small molecule epidermal growth factor receptor, or EGFR, covalent inhibitor that is in Phase I/II clinical development for the treatment of non-small cell lung cancer, or NSCLC, in patients with activating EGFR mutations, including the initial activating mutations, as well as the primary resistance mutation, T790M; and rucaparib, an orally available, small molecule poly (ADP-ribose) polymerase, or PARP, inhibitor being developed for various solid tumors that is currently in Phase I/II clinical trials. We have also entered into a drug discovery agreement for the discovery of a novel cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. If any clinical candidates are discovered, we would seek to pursue clinical development of such clinical candidates.

We were incorporated in Delaware in April 2009 and commenced operations in May 2009. To date, we have devoted substantially all of our resources to identifying and in-licensing product candidates, performing development activities with respect to those product candidates, and the general and administrative support of these operations. We have generated no revenues and, through June 30, 2013, have principally funded our operations using the $75.5 million of net proceeds from the sale of convertible preferred stock, the issuance of $35.0 million aggregate principal amount of convertible promissory notes, and $458.5 million of net proceeds from public offerings of our common stock completed in November 2011, April 2012 and June 2013. The convertible preferred stock and outstanding principal amount of the convertible promissory notes and all accrued and unpaid interest converted into shares of our common stock immediately prior to the closing of our initial public offering in November 2011.

We have never been profitable and, as of June 30, 2013, we had an accumulated deficit of $219.5 million. We expect to incur significant and increasing losses for the foreseeable future as we advance our product candidates through clinical development to seek regulatory approval and, if approved, commercialize such product candidates. We will need additional financing to support our operating activities. We will seek to fund our operations through public or private equity or debt financings or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We expect that research and development expenses will increase as we continue the development of our product candidates. We will need to generate significant revenues to achieve profitability and we may never do so.

Product License Agreements

CO-1686

In May 2010, we entered into a worldwide license agreement with Avila (now part of Celgene Corporation) to discover, develop and commercialize a covalent inhibitor of mutant forms of the EGFR gene product. CO-1686 was identified as the lead inhibitor candidate under the license agreement. We are responsible for all preclinical, clinical, regulatory and other activities necessary to develop and commercialize CO-1686. We made an up-front payment of $2.0 million to Avila upon execution of the license agreement and an additional $4.0 million milestone payment in the first quarter of 2012 upon the acceptance by the U.S. Food and Drug Administration, or FDA, of our investigational new drug, or IND, application for CO-1686. We recognized both payments as acquired in-process research and development expense. We are obligated to pay royalties on net sales of CO-1686, based on the volume of annual net sales achieved. Celgene has the option to increase royalty rates by electing to reimburse a portion of our development expenses. This option must be exercised within a limited period of time after Celgene is notified by us of our intent to pursue regulatory approval of CO-1686 in the United States or the European Union as a first-line treatment. We may be required to pay up to an additional aggregate of $115.0 million in additional development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we may be required to pay up to an aggregate of $120.0 million in sales milestone payments if certain annual sales targets are achieved.

In January 2013, the Company entered into an exclusive license agreement with Gatekeeper Pharmaceuticals, Inc. (“Gatekeeper”) to acquire exclusive rights under patent applications associated with mutant EGFR inhibitors and methods of treatment. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. If CO-1686 is approved for commercial sale, the Company will pay royalties to Gatekeeper on future net sales.

Rucaparib

In June 2011, we entered into a license agreement with Pfizer to acquire exclusive global development and commercialization rights to Pfizer’s drug candidate known as rucaparib. This drug candidate is a small molecule PARP inhibitor which we are developing for the treatment of selected solid tumors. Pursuant to the terms of the license agreement, we made an up-front payment by issuing Pfizer $7.0 million principal amount of a 5% convertible promissory note due in 2012, which was subsequently converted to common stock immediately prior to our initial public offering. We are responsible for all development and commercialization costs of rucaparib and, if approved, we will be required to pay Pfizer royalties on sales of the product. In addition, we may be required to pay Pfizer up to an aggregate of $259.0 million in milestone payments if certain development, regulatory and sales milestones are achieved.

Drug Discovery Collaboration Agreement

CO-101

In November 2009, we entered into a license agreement with Clavis to develop and commercialize CO-101 in North America, Central America, South America and Europe. Under the terms of the license agreement, we made an up-front payment to Clavis in the amount of $15.0 million, which was comprised of $13.1 million for development costs incurred prior to the execution of the agreement, which we recognized as acquired in-process research and development and $1.9 million for the prepayment of preclinical activities to be performed by Clavis. In November 2010, the license agreement was amended to expand the license territory to include Asia and other international markets. We paid Clavis $10.0 million for the territory expansion and recognized that payment as acquired in-process research and development expense. As part of the amendment to the license agreement, Clavis agreed to reimburse up to $3.0 million of our research and development costs for certain CO-101 development activities subject to our incurring such costs.

On November 12, 2012, the Company reported results from a pivotal study of CO-101 versus gemcitabine in metastatic pancreatic cancer, which failed to demonstrate a difference in overall survival between the two study arms. Based on the results of the study, the Company has ceased development of CO-101 and terminated the license agreement.

Financial Operations Overview

Revenue

To date, we have not generated any revenues. In the future, we may generate revenue from the sales of product candidates that are currently under development. Based on our current development plans, we do not expect to generate significant revenues for the foreseeable future. If we fail to complete the development of our product candidates and, together with our partners, companion diagnostics or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, will be adversely affected.

Research and Development Expenses

Research and development expenses consist of costs incurred for the development of our product candidates and companion diagnostics, which include:

•

license fees and milestone payments related to the acquisition of in-licensed products, which are reported on our statements of operations as acquired in-process research and development;

•

employee-related expenses, including salaries, benefits, travel and share-based compensation expense;

•

expenses incurred under agreements with CROs and investigative sites that conduct our clinical trials and preclinical studies;

•

the cost of acquiring, developing and manufacturing clinical trial materials;

•

costs associated with preclinical activities and regulatory operations; and

•

activities associated with the development of companion diagnostics for our product candidates.

Research and development costs are expensed as incurred. License fees and milestone payments related to in-licensed products and technology are expensed if it is determined that they have no alternative future use. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors.

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials. We plan to increase our research and development expenses for the foreseeable future as we seek to expand our clinical and companion diagnostic development activities for our CO-1686 and rucaparib product candidates and perform drug discovery activities for a cKIT inhibitor targeting resistance mutations for the treatment of GIST.

The following table identifies research and development costs and acquired in-process research and development costs on a program-specific basis for our product candidates in-licensed through June 30, 2013, their companion diagnostics, and the cKIT inhibitor drug discovery program. Personnel-related costs, depreciation and share-based compensation are not allocated to specific programs as they are deployed across multiple projects under development and, as such, are separately classified as personnel and other expenses in the table below.


	Three Months Ended June 30,				Six Months Ended June 30,				Cumulative from April 20, 2009 (Inception) to June 30,
	2013		2012		2013		2012		2013
	(in thousands)
CO-101 Expenses
Acquired in-process R&D	$	—	$	—	$	—	$	—	$	23,085
Research and development		342		5,464		966		11,345		61,467

CO-101 Total		342		5,464		966		11,345		84,552
CO-1686 Expenses
Acquired in-process R&D		—		—		250		4,000		6,250
Research and development		3,740		1,316		7,376		2,328		23,745

CO-1686 Total		3,740		1,316		7,626		6,328		29,995
Rucaparib Expenses
Acquired in-process R&D		—		250		—		250		7,250
Research and development		4,668		1,655		7,305		3,587		19,119

Rucaparib Total		4,668		1,905		7,305		3,837		26,369
cKIT Inhibitor Expenses
Acquired in-process R&D		—		—		—		—		—
Research and development		1,136		—		2,263		—		4,360

cKIT Inhibitor Total		1,136		—		2,263		—		4,360
Personnel and other expenses		5,930		4,155		10,028		7,892		42,952

Total	$	15,816	$	12,840	$	28,188	$	29,402	$	188,228

General and Administrative Expenses

General and administrative expenses consist principally of salaries and related costs for personnel in executive, finance, business development, legal, investor relations and information technology functions. Other general and administrative expenses include facility costs, communication expenses, corporate insurance, and professional fees for legal, consulting and accounting services.

Other Income and Expense

Other income is comprised of interest income earned on cash, cash equivalents and available for sale securities, gain on the sale of available for sale securities, and a federal grant awarded to us under the Qualifying Therapeutic Discovery Project Program in 2010. Other expense includes interest expense associated with the convertible notes payable outstanding during 2011. In addition, we hold cash balances at financial institutions denominated in currencies other than the U.S. dollar to fund research and development activities performed by various third-party vendors. The translation of these currencies into U.S. dollars results in foreign currency gains or losses, depending on the change in value of these currencies against the U.S. dollar. These gains and losses are included in Other Income and Expense.

Critical Accounting Policies and Significant Judgments and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and share-based compensation. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For a description of our critical accounting policies, please see Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012. There have not been any material changes to our critical accounting policies since December 31, 2012.

Results of Operations

Comparison of Three Months Ended June 30, 2013 and 2012:

The following table summarizes the results of our operations for the three months ended June 30, 2013 and 2012:


	Three Months Ended June 30,
	2013			2012			Increase (Decrease)			Percent Change
	(in thousands)
Revenues	$	—		$	—		$	—
Operating Expenses:
Research and development		15,816			12,590			3,226			25.6	%
General and administrative		3,492			2,680			812			30.3	%
Acquired in-process research and development		—			250			(250	)		(100.0	%)

Operating loss		(19,308	)		(15,520	)		3,788			24.4	%
Other income (expense), net		(33	)		(172	)		(139	)		(80.8	%)

Loss before income taxes		(19,341	)		(15,692	)		3,649			23.3	%
Income taxes		—			35			35			100.0	%

Net loss	$	(19,341	)	$	(15,657	)	$	3,684			23.5	%

Research and Development Expenses. The increase in research and development expenses for the three months ended June 30, 2013 compared to the three months ended June 30, 2012 was due to development expenses associated with our CO-1686 and rucaparib product candidates, less a reduction of $5.1 million in CO-101 development expenses associated with the wind down of this program. Research and development expenses for CO-1686 increased by $2.4 million due primarily to increased enrollment in the ongoing Phase I study for CO-1686, as well as expenses incurred for drug formulation development. Research and development expenses for rucaparib increased by $3.0 million due primarily to the initiation of two new clinical studies during the second quarter of 2013. In the third quarter of 2012, we also initiated a drug discovery program for cKIT inhibitors, resulting in an increase of $1.1 million over the second quarter of 2012. The remaining increase is attributable to personnel costs, including a $0.5 million increase in share-based compensation expense for research and development personnel.

General and Administrative Expenses. The increase in general and administrative expenses for the three months ended June 30, 2013 compared to the three months ended June 30, 2012 was primarily attributable to an increase in share-based compensation expense of $0.4 million. The increase was also due to larger personnel, professional services, and facilities costs in 2013 to support the Company’s growth.

Acquired In-Process Research and Development Expenses. The decrease in acquired in-process research and development expenses for the three months ended June 30, 2013 compared to the three months ended June 30, 2012 was due to the absence of milestone payments made to partners related to in-licensing agreements in the second quarter of 2013. In April 2012, we entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. Pursuant to the terms of the license agreement, we made an up-front payment of $250,000 upon execution of the agreement.

Other Income (Expense), Net. The decrease in other income (expense), net for the three months ended June 30, 2013 compared to the three months ended June 30, 2012 was due to a reduction of foreign currency transaction losses. The value of the Euro and Pound Sterling in relation to the U.S. Dollar was less volatile in the second quarter of the current year while both foreign currencies weakened in the same quarter of the prior year.

Comparison of Six Months Ended June 30, 2013 and 2012:

The following table summarizes the results of our operations for the six months ended June 30, 2013 and 2012:


	Six Months Ended June 30,
	2013			2012			Increase (Decrease)			Percent Change
	(in thousands)
Revenues	$	—		$	—		$	—
Operating Expenses:
Research and development		27,938			25,152			2,786			11.1	%
General and administrative		6,710			5,105			1,605			31.4	%
Acquired in-process research and development		250			4,250			(4,000	)		(94.1	%)

Operating loss		(34,898	)		(34,507	)		391			1.1	%
Other income (expense), net		(111	)		(176	)		(65	)		(36.9	%)

Loss before income taxes		(35,009	)		(34,683	)		326			0.9	%
Income taxes		—			27			27			100.0	%

Net loss	$	(35,009	)	$	(34,656	)	$	353			1.0	%

Research and Development Expenses. The increase in research and development expenses for the six months ended June 30, 2013 compared to the six months ended June 30, 2012 was due to an increase in development expenses associated with our CO-1686 and rucaparib product candidates, offset by a reduction of $10.4 million in CO-101 development expenses associated with the wind down of this program. Research and development expenses for CO-1686 increased by $5.0 million due primarily to drug formulation development activities and increased clinical trial costs as we initiated clinical development activities for this program in March 2012. Research and development expenses for rucaparib increased by $3.7 million due primarily to the initiation of two new clinical studies during the second quarter of 2013 and clinical supply manufacturing activities. In the third quarter of 2012, we also initiated a drug discovery program for cKIT inhibitors, resulting in an increase of $2.3 million over the first six months of 2012. The remaining increase is attributable to personnel costs, including a $0.9 million increase in share-based compensation expense for research and development personnel.

General and Administrative Expenses. The increase in general and administrative expenses for the six months ended June 30, 2013 compared to the six months ended June 30, 2012 was primarily attributable to an increase in share-based compensation expense of $0.8 million. The increase was also due to larger personnel and facilities costs in 2013 to support the Company’s growth.

Acquired In-Process Research and Development Expenses. The decrease in acquired in-process research and development expenses for the six months ended June 30, 2013 compared to the six months ended June 30, 2012 was due to a reduction in payments made to partners related to in-licensing agreements. In January 2012, we made a regulatory milestone payment of $4.0 million to Avila Therapeutics, Inc. for the FDA’s acceptance of our IND application to begin clinical investigation of CO-1686.

Other Income (Expense), Net. The decrease in other income (expense), net for the six months ended June 30, 2013 compared to the six months ended June 30, 2012 was due to a reduction in foreign currency transaction losses resulting from an increase in the value of the Euro in relation to the U.S. Dollar.

Liquidity and Capital Resources

Through June 30, 2013, we funded our operations through the private placement of preferred stock and convertible debt securities and the public offering of our common stock. As of June 30, 2013, we have received $75.5 million in net proceeds from the issuance of convertible preferred stock, $27.9 million through the issuance of convertible promissory notes, $458.5 million in net proceeds from the issuance of common stock and $2.8 million in proceeds from stock option exercises. The outstanding principal amount and all accrued and unpaid interest associated with the convertible promissory notes were converted into shares of our common stock immediately prior to the closing of our initial public offering at the initial public offering price of $13.00 per share, in November 2011. As of June 30, 2013, we had cash and cash equivalents totaling $372.2 million.

The following table sets forth the primary sources and uses of cash for the six months ended June 30, 2013 and 2012:


	Six Months Ended June 30,
	2013			2012
	(in thousands)
Net cash used in operating activities	$	(32,287	)	$	(32,446	)
Net cash provided by (used in) investing activities		(66	)		1,092
Net cash provided by financing activities		260,514			70,018
Effect of exchange rate changes on cash and cash equivalents		(18	)		3
Net increase in cash and cash equivalents	$	228,143		$	38,667

Operating Activities

The cash used in operating activities for all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital. The cash used in operating activities for all periods reflects the continued development of our product candidates as described in “Results of Operations” above.

Investing Activities

The cash provided by (used in) investing activities for all periods primarily reflects the maturities and sales of available for sale securities, offset by the purchase of property and equipment. The decrease of $1.2 million in cash provided by (used in) investing activities for the six months ended June 30, 2013 compared to the prior year’s respective period was due to a reduction in available for sale security sales and maturities of $2.0 million, offset by a decrease of $0.8 million used for the purchase of property and equipment.

Financing Activities

The cash provided by financing activities for the six months ended June 30, 2013 represents the receipt of $1.4 million in proceeds from the exercise of stock options and employee stock purchase plan and the receipt of $259.1 million in net proceeds from the sale of our common stock in June 2013. The cash provided by financing activities for the six months ended June 30, 2012 reflects the receipt of $70.0 million in net proceeds from the sale of our common stock in April 2012.

Operating Capital Requirements

We anticipate that we will continue to generate significant losses for the foreseeable future as we incur expenses to complete our development activities for each of our programs, including clinical trial activities, companion diagnostic development, drug development, establishing our commercial capabilities, and expanding our general and administrative functions to support the growth in our research and development and commercial organizations.

The net proceeds raised from the sale of securities to date will not be sufficient to fund our operations through successful development and commercialization of our product candidates. As a result, we will need to raise additional capital to fund our operations and continue to conduct clinical trials to support additional development and potential regulatory approval, make milestone payments to our licensors and commercialize our product candidates.

We believe that our existing cash and cash equivalents, will allow us to fund our operating plan through at least the next 12 months. If our available cash and cash equivalents are insufficient to satisfy our liquidity requirements, we may seek to sell additional equity or debt securities or obtain a credit facility. The sale of additional equity and debt securities may result in additional dilution to our shareholders.

In addition, if we raise additional funds through the issuance of debt securities or preferred stock, these securities may have rights senior to those of our common stock and could contain covenants that would restrict our operations. Furthermore, any such required additional capital may not be available on reasonable terms, if at all. If we were unable to obtain additional financing, we may be required to reduce the scope of, delay, or eliminate some or all of our planned development and commercialization activities, which could harm our business.

Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amounts of our working capital requirements. Our future funding requirements will depend on many factors, including but not limited to:

•

the number and characteristics of the product candidates, companion diagnostics, and indications we pursue;

•

the achievement of various development, regulatory and commercial milestones resulting in required payments to partners pursuant to the terms of our license agreements;

•

the scope, progress, results and costs of researching and developing our product candidates and related companion diagnostics and conducting clinical and preclinical trials;

•

the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates and companion diagnostics;

•

the cost of manufacturing any of our product candidates; and

•

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims

Contractual Obligations and Commitments

For a discussion of our contractual obligations, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2012 Annual Report on Form 10-K. There have not been any material changes to such contractual obligations or potential milestone payments since December 31, 2012 aside from those disclosed in Note 10 to the Notes to Unaudited Consolidated Financial Statements included elsewhere in this report.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk related to changes in interest rates. As of June 30, 2013, we had cash and cash equivalents of $372.2 million, consisting of bank demand deposits and money market funds that primarily invest in U.S. government obligations. The primary objectives of our investment policy are to preserve principal and maintain proper liquidity to meet operating needs. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.

We contract with CROs, investigational sites, and contract manufacturers globally. We may be subject to fluctuations in foreign currency rates in connection with these agreements. While we periodically hold foreign currencies, primarily Euro and Pound Sterling, we do not use other financial instruments to hedge our foreign exchange risk. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. As of June 30, 2013 and December 31, 2012, approximately 14% and 26%, respectively, of our total liabilities were denominated in currencies other than our functional currency.

ITEM 4.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, or Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. With the participation of our Chief Executive Officer and Chief Financial Officer, management performed an evaluation as of June 30, 2013 of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2013, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2013 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

We are not currently a party to any material legal proceedings.

ITEM 1A.

RISK FACTORS

Our business faces significant risks and uncertainties. Certain factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to carefully consider the risk factors described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012 and in our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.

There has not been a material change from the risk factors included in our previously filed Annual Report on Form 10-K for the year ended December 31, 2012. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial also may negatively impact our business.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Use of Proceeds from Sales of Registered Securities

Our initial public offering of common stock was effected through a Registration Statement on Form S-1 (File No. 333-175080) that was declared effective by the Securities and Exchange Commission on November 15, 2011 and registered an aggregate of 11,500,000 shares of our common stock. On November 21, 2011, 10,000,000 shares of common stock were sold on our behalf at an initial public offering price of $13.00 per share, for aggregate gross proceeds of $130.0 million. On November 30, 2011, in connection with the exercise of the underwriters’ over-allotment option, 700,000 additional shares of common stock were sold on our behalf at the initial public offering price of $13.00 per share, for aggregate gross proceeds of $9.1 million. Following the sale of the 10,700,000 shares of common stock, the offering terminated.

We paid to the underwriters underwriting discounts and commissions of approximately $6.9 million in connection with the offering. In addition, we incurred expenses of approximately $2.8 million in connection with the offering, which when added to the underwriting discounts and commissions paid by us, amounts to total expenses of approximately $9.7 million. Thus, the net offering proceeds to us, after deducting underwriting discounts and commissions and offering expenses, were approximately $129.4 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.

As of June 30, 2013, we had used approximately $100.3 million of the net proceeds from our initial public offering to fund operations, capital expenditures, working capital and other general corporate purposes. The remainder of the proceeds have been invested into money market funds.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

INDEX TO EXHIBITS


Exhibit Number		Exhibit Description

3.1(5)		Amended and Restated Certificate of Incorporation of Clovis Oncology, Inc.

3.2(5)		Amended and Restated Bylaws of Clovis Oncology, Inc.

4.1(3)		Form of Common Stock Certificate of Clovis Oncology, Inc.

4.2(1)		Clovis Oncology Inc. Investor Rights Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and certain investors named therein.

10.1*(4)		Amended and Restated Strategic License Agreement, dated as of June 16, 2011, by and between Clovis Oncology, Inc. and Avila Therapeutics, Inc.


Exhibit Number		Exhibit Description

10.2*(4)		License Agreement, dated as of June 2, 2011, by and between Clovis Oncology, Inc. and Pfizer Inc.

10.3+(1)		Clovis Oncology, Inc. 2009 Equity Incentive Plan.

10.4+(4)		Clovis Oncology, Inc. 2011 Stock Incentive Plan.

10.5+(1)		Form of Clovis Oncology, Inc. 2009 Equity Incentive Plan Stock Option Agreement.

10.6+(4)		Form of Clovis Oncology, Inc. 2011 Stock Incentive Plan Stock Option Agreement.

10.7+(3)		Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.8+(3)		Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Erle T. Mast.

10.9+(3)		Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

10.10+(3)		Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Andrew R. Allen.

10.11+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Paul Klingenstein.

10.12+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and James C. Blair.

10.13+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Edward J. McKinley.

10.14+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Thorlef Spickschen.

10.15+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and M. James Barrett.

10.16+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Brian G. Atwood.

10.17+(1)		Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.18+(1)		Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Erle T. Mast.

10.19+(1)		Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

10.20+(1)		Indemnification Agreement, dated as of May 13, 2009, between Clovis Oncology, Inc. and Andrew R. Allen.

10.21+(1)		Restricted Stock Purchase Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.22+(1)		Restricted Stock Purchase Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Erle T. Mast.

10.23+(1)		Restricted Stock Purchase Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

10.24+(1)		Restricted Stock Purchase Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Andrew R. Allen.

10.25*(4)		Companion Diagnostics Agreement, dated as of April 19, 2011, by and between Clovis Oncology, Inc. and Roche Molecular Systems, Inc.

10.26+(4)		Clovis Oncology, Inc. 2011 Employee Stock Purchase Plan.

10.27+(4)		Clovis Oncology, Inc. 2011 Cash Bonus Plan.

10.28+(6)		Employment Agreement, dated as of March 22, 2012, by and between Clovis Oncology, Inc. and Steven L. Hoerter.

10.29+(6)		Indemnification Agreement, dated as of March 22, 2012, by and between Clovis Oncology, Inc. and Steven L. Hoerter.

10.30+(2)		Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Ginger L. Graham.

10.31+(2)		Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Keith Flaherty.

31.1		Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

31.2		Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

32.1		Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.


32.2		Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following materials from Clovis Oncology, Inc.’s Quarterly Report on Form 10-Q for the period ended June 30, 2013, formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Statements of Operations, (ii) the Consolidated Balance Sheets, (iii) the Consolidated Statements of Cash Flows and (iv) Notes to Unaudited Consolidated Financial Statements.

(1)	Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on June 23, 2011.

(2)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on June 14, 2013.

(3)	Filed as an exhibit with Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on August 31, 2011.

(4)	Filed as an exhibit with Amendment No. 3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on October 31, 2011.

(5)	Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on March 15, 2012.

(6)	Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-180293) on March 23, 2012.

+	Indicates management contract or compensatory plan.

*	Confidential treatment has been granted with respect to portions of this exhibit, which portions have been omitted and filed separately with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: August 7, 2013	CLOVIS ONCOLOGY, INC.

	By:	/s/ Patrick J. Mahaffy
		Patrick J. Mahaffy
		President and Chief Executive Officer; Director

	By:	/s/ Erle T. Mast
		Erle T. Mast
		Executive Vice President and Chief Financial Officer

EX-31.1 2 d547025dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

I, Patrick J. Mahaffy, certify that:

I have reviewed this quarterly report on Form 10-Q of Clovis Oncology, Inc. for the quarter ended June 30, 2013;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2013

/s/ PATRICK J. MAHAFFY

Patrick J. Mahaffy

President and Chief Executive Officer

EX-31.2 3 d547025dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

I, Erle T. Mast, certify that:

I have reviewed this quarterly report on Form 10-Q of Clovis Oncology, Inc. for the quarter ended June 30, 2013;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2013

/s/ ERLE T. MAST

Erle T. Mast

Executive Vice President and Chief Financial Officer

EX-32.1 4 d547025dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Clovis Oncology, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended June 30, 2013, as filed with the Securities and Exchange Commission (the “Report”), Patrick J. Mahaffy, as Chief Executive Officer of the Company, does hereby certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), that to his knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 7, 2013

/s/ PATRICK J. MAHAFFY

Patrick J. Mahaffy

President and Chief Executive Officer

EX-32.2 5 d547025dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Clovis Oncology, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended June 30, 2013, as filed with the Securities and Exchange Commission (the “Report”), Erle T. Mast, as Chief Financial Officer of the Company, does hereby certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), that to his knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 7, 2013

/s/ ERLE T. MAST

Erle T. Mast

Executive Vice President and Chief Financial Officer

EX-101.INS 6 clvs-20130630.xml XBRL INSTANCE DOCUMENT

1900000

13.00

2.9

20.00

30171392 146300000 0.0029

20000000

8000000

15000000

7000000

0.05

7000000

176903000

30169815

0.05

20.38

2485070

721162

0.001

19.90

100000000

0.001

10000000

11.00

2261717

30169815

12012000

47000

1811000

63000

582415000

1589000

350000

363001000

2224000

2600000

211000

30000

375224000

751000

605000

147985000

23700000

1030000

375224000

107015622

372240000

219491000

116427809

598000

40368071

373443000

66.98 8199000

72.00

147985000

138236000

26207190

14.05

1599044

0.001

100000000

0.001

10000000

26207190

12160000

53000

2441000

198000

317899000

2297000

63000

133496000

2702000

338000

26000

145994000

38000

116000

135385000

1084000

145994000

144097000

184482000

659000

144872000

7161000

135385000

-189465000

10460000

-20.98

2610000

27008000

96000

-219491000

-544000

-219444000

-218947000

34000

-1162000

75499000

-219491000

-471000

35851000

36585000

2133000

564716000

30719000

10218000

372240000

-3047000

36000

1543000

458481000

151643000

26571000

750000

2834000

75499000 27902000 -6879000 7000000 24000 CLVS CLOVIS ONCOLOGY, INC. false Accelerated Filer 2013 10-Q 2013-06-30 0001466301 --12-31 Q2

16.75

<div> Liquidity The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through public and private equity financings, and management expects operating losses and negative cash flows to continue for at least the next several years. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless or until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through cash and investments on hand and additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. </div>

<div> The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="70%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three and Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom">  </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Common shares under option </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,343</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,718</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total potential dilutive shares </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,343</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,718</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

P8Y9M15D

<div> 5. Convertible Promissory Notes In May 2011, the Company issued $20.0 million of 5% Convertible Promissory Notes to existing investors for cash. In June 2011, the Company issued $15.0 million of 5% Convertible Promissory Notes to Pfizer, which was comprised of a $7.0 million note issued to acquire the global rights to develop and market rucaparib and an $8.0 million note issued for cash (the “Notes”). The Notes accrued interest at an annual rate of 5% and had a maturity date of May 25, 2012. In connection with the completion of the Company’s initial public offering in November 2011, the principal balance and all accrued and unpaid interest due on the Notes was converted into 2,757,788 shares of the Company’s common stock. </div>

<div> The following table summarizes the activity relating to the Company’s options to purchase common stock for the six month period ended June 30, 2013:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="56%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Option  Shares Outstanding</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted- Average Remaining Contractual Term (Years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,599,044</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14.05</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,046,158</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28.53</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(130,732</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.09</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(29,400</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16.75</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,485,070</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20.38</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.79</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">116,427,809</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Vested and expected to vest at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,261,717</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19.90</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.72</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">107,015,622</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Vested at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">721,162</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.84</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40,368,071</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

28.53

-32287000

<div> The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $66.98 as of June 30, 2013, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Weighted-average grant-date fair value per share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">43.22</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12.60</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Intrinsic value of options exercised </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,540,488</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">162,845</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Cash received from stock option exercises </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,101,935</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32,108</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Weighted-average grant-date fair value per share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17.61</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15.02</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Intrinsic value of options exercised </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,716,374</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">223,319</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Cash received from stock option exercises </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,188,312</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">42,149</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

<div> 3. Financial Instruments and Fair Value Measurement Cash, Cash Equivalents and Available for Sale Securities The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.   Marketable securities with original maturities greater than three months are considered to be available for sale securities and historically consisted of U.S. agency obligations, U.S. government obligations and corporate debt obligations. Available for sale securities are reported at fair market value and unrealized gains and losses are included as a separate component of stockholders’ equity. Realized gains, realized losses, the amortization of premiums and discounts, interest earned and dividends earned are included in other income (expense). The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on management’s intent to fund current operations with these securities or to make them available for current operations. A decline in the market value of a security below its cost value that is deemed to be other than temporary is charged to earnings, and results in the establishment of a new cost basis for the security. Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="6%"></td> <td valign="bottom" width="2%"></td> <td width="92%"></td> </tr> <tr> <td valign="top">Level 1:</td> <td valign="bottom">  </td> <td valign="bottom">Quoted prices in active markets for identical assets or liabilities. The Company’s Level 1 assets and liabilities consist of money market investments.</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="2"></td> </tr> <tr> <td valign="top">Level 2:</td> <td valign="bottom">  </td> <td valign="bottom">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company does not have Level 2 assets or liabilities.</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="2"></td> </tr> <tr> <td valign="top">Level 3:</td> <td valign="bottom">  </td> <td valign="bottom">Unobservable inputs that are supported by little or no market activity. The Company does not have Level 3 assets or liabilities.</td> </tr> </table> The following table identifies the Company’s assets that were measured at fair value on a recurring basis (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="70%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Balance</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Money market </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total assets at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Money market </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total assets at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> There were no security transfers between Levels 1 and 2 during the six month period ended June 30, 2013. </div>

2012-05-25

<div> The following table identifies the Company’s assets that were measured at fair value on a recurring basis (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="70%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Balance</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Money market </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total assets at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Money market </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total assets at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Other accrued expenses are comprised of the following (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">June 30, 2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Accrued personnel costs </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,811</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,441</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Accrued corporate legal fees and professional services </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">350</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Accrued expenses – other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">198</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,224</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,702</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> 4. Other Accrued Expenses Other accrued expenses are comprised of the following (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">June 30, 2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Accrued personnel costs </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,811</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,441</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Accrued corporate legal fees and professional services </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">350</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Accrued expenses – other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">198</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,224</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,702</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

26377000

<div> 6. Convertible Preferred Stock and Stockholders’ Equity Common Stock In May 2009, the Company issued 1,206,899 shares of its common stock to the original founders at a purchase price of $.0029 per share. The shares were issued under restricted stock purchase agreements, which allowed the Company, at its discretion, to repurchase unvested shares if the founders terminated their employment with the Company. As of June 30, 2013, all common stock shares issued to the founders under the restricted stock purchase agreements were fully vested. In November 2011, the Company sold 10,700,000 shares of its common stock in an initial public offering at a price of $13.00 per share. The Company received net proceeds from the offering of $129.4 million, after deduction of $6.9 million of underwriting commissions and $2.8 million of offering expenses. In April 2012, the Company sold 3,750,000 shares of its common stock in a public offering at $20.00 per share. The net offering proceeds realized after deducting offering expenses and underwriters’ discounts and commissions was $70.0 million. In June 2013, the Company sold 3,819,444 shares of its common stock in a public offering at $72.00 per share. The net offering proceeds realized after deducting offering expenses and underwriters’ discounts and commissions was $259.1 million. The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders of the Company. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by the Company’s Board of Directors. Preferred Stock In May 2009, the Company entered into the Series A-1, A-2, B and C Preferred Stock Purchase Agreement with various investors (the “Preferred Stock Purchase Agreement”). The Preferred Stock Purchase Agreement provided for the issuance of up to $146.3 million of the Company’s convertible preferred stock, subject to various terms and conditions. During 2009, the Company issued shares of Series A-1, Series A-2 and Series B convertible preferred stock resulting in total aggregate cash proceeds to the Company of $75.5 million, net of $174,000 related stock issuance costs. In connection with the completion of the Company’s initial public offering in November 2011, all of the outstanding shares of convertible preferred stock were automatically converted into 7,244,523 shares of the Company’s common stock. The Series A-1, A-2 and B convertible preferred stock converted at a rate of 2.9 for 1 into common stock based upon the election of the convertible preferred stock holders immediately prior to the closing of the initial public offering. </div>

17.61

P8Y8M19D

<div> 9. Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, stock options are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="70%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three and Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom">  </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Common shares under option </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,343</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,718</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total potential dilutive shares </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,343</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,718</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

130732

<div> 2. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2 of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. </div>

29400

2343000

<div> Share-based compensation expense for all equity based programs, including stock options and the employee stock purchase plan, for the three and six months ended June 30, 2013 and 2012, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,103</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">592</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,957</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,032</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,005</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">576</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,915</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,082</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total share-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,108</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,168</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,872</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,114</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Use of Estimates The preparation of these unaudited consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, other comprehensive loss and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to clinical trial accruals and share-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. </div>

<div> 1. Nature of Business and Basis of Presentation Clovis Oncology, Inc. (the “Company”), a corporation in the development stage, was incorporated in Delaware on April 20, 2009, and commenced operations in May 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and other international markets. The Company has and intends to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, the Company generally expects to provide the licensor with a combination of up-front payments, milestone payments and royalties on future sales. In addition, the Company generally expects to assume the responsibility for future drug development and commercialization costs. The Company currently operates in one segment. Since inception, the Company’s operations have consisted primarily of developing in-licensed compounds and their companion diagnostics, evaluating new product acquisition candidates, raising capital and corporate organization activities. The Company has never earned revenue from these activities, and accordingly, the Company is considered to be in the development stage as of June 30, 2013. Basis of Presentation The information reported within the Company’s financial statements from April 20, 2009 to December 31, 2010 was based solely on the accounts of Clovis Oncology, Inc. Effective January 1, 2011, Clovis Oncology UK Limited, a wholly owned subsidiary of the Company, commenced operations. All financial information presented after December 31, 2010 was consolidated and includes the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Changes in or reclassifications out of accumulated other comprehensive loss are not disclosed in our notes to the unaudited financial statements due to the insignificance of the activity. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial information prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. The Company evaluates subsequent events up to the time of filing with the SEC. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2012 for a broader discussion of our business and the opportunities and risks inherent in such business. Use of Estimates The preparation of these unaudited consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, other comprehensive loss and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to clinical trial accruals and share-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Liquidity The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through public and private equity financings, and management expects operating losses and negative cash flows to continue for at least the next several years. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless or until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through cash and investments on hand and additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. </div>

-1.33

9.09

1046158

<div> 11. Subsequent Events The Company evaluated events up to the filing date of these interim financial statements and determined that no subsequent activity required disclosure. </div>

P2Y9M18D

<div> 7. Share-Based Compensation Share-based compensation expense for all equity based programs, including stock options and the employee stock purchase plan, for the three and six months ended June 30, 2013 and 2012, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,103</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">592</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,957</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,032</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,005</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">576</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,915</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,082</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total share-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,108</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,168</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,872</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,114</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The Company did not recognize a tax benefit related to share-based compensation expense during the three and six months ended June 30, 2013 and 2012, respectively, as the Company maintains net operating loss carryforwards and has established a valuation allowance against the entire net deferred tax asset as of June 30, 2013. No share-based compensation expense was capitalized on our Consolidated Balance Sheets as of June 30, 2013 and December 31, 2012. The following table summarizes the activity relating to the Company’s options to purchase common stock for the six month period ended June 30, 2013:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="56%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Option  Shares Outstanding</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted- Average Remaining Contractual Term (Years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,599,044</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14.05</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,046,158</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28.53</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(130,732</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.09</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(29,400</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16.75</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,485,070</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20.38</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.79</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">116,427,809</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Vested and expected to vest at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,261,717</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19.90</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.72</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">107,015,622</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Vested at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">721,162</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.84</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40,368,071</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table>     The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $66.98 as of June 30, 2013, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Weighted-average grant-date fair value per share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">43.22</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12.60</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Intrinsic value of options exercised </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,540,488</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">162,845</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Cash received from stock option exercises </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,101,935</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32,108</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Weighted-average grant-date fair value per share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17.61</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15.02</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Intrinsic value of options exercised </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,716,374</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">223,319</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Cash received from stock option exercises </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,188,312</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">42,149</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> As of June 30, 2013, the unrecognized share-based compensation expense related to nonvested options, adjusted for expected forfeitures was $23.7 million and the estimated weighted-average remaining vesting period was 2.8 years. </div>

P7Y10M2D

<div> 10. Commitments and Contingencies Royalty and License Fee Commitments The Company has entered into certain license agreements, as identified in Note 8, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. The Company’s payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly no amounts have been recorded in the Company’s accompanying Consolidated Balance Sheets at June 30, 2013 and December 31, 2012. Development and Manufacturing Agreement Commitments In February 2013, the Company entered into a development and manufacturing agreement with a third-party supplier for the production of the active ingredient for rucaparib. Under the Development and Manufacturing Agreement, the Company will provide the third-party supplier a rolling 24-month forecast that will be updated by the Company on a quarterly basis. The Company is obligated to order the quantity specified in the first twelve months of any forecast. As of June 30, 2013, $2.6 million of purchase commitments were established under this agreement. </div>

66000

-121000

-35009000

-111000

-35015000

-34898000

-35009000

250000

-474000

260514000

6710000

3872000

228143000

-66000

1188312

-18000

5716374

-755000

259146000

27938000

123000

1368000

<div> Basis of Presentation The information reported within the Company’s financial statements from April 20, 2009 to December 31, 2010 was based solely on the accounts of Clovis Oncology, Inc. Effective January 1, 2011, Clovis Oncology UK Limited, a wholly owned subsidiary of the Company, commenced operations. All financial information presented after December 31, 2010 was consolidated and includes the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Changes in or reclassifications out of accumulated other comprehensive loss are not disclosed in our notes to the unaudited financial statements due to the insignificance of the activity. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial information prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. The Company evaluates subsequent events up to the time of filing with the SEC. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2012 for a broader discussion of our business and the opportunities and risks inherent in such business. </div> <div> 8. License Agreements CO-1686 In May 2010, the Company entered into a worldwide license agreement with Avila Therapeutics, Inc. (“Avila”) to discover, develop and commercialize a covalent inhibitor of mutant forms of the epidermal growth factor receptor gene product. In March 2012, Avila was acquired by Celgene Corporation (“Celgene”). CO-1686 was identified as the lead drug candidate to be developed under the license agreement. The Company is responsible for all preclinical, clinical, regulatory and other activities necessary to develop and commercialize CO-1686. The Company made an up-front payment of $2.0 million upon execution of the license agreement which was recognized as acquired in-process research and development expense. The Company is obligated to pay royalties on net sales of CO-1686, based on the volume of annual net sales achieved. Celgene has the option to increase royalty rates by electing to reimburse a portion of the development expenses incurred by the Company. This option must be exercised within a limited period of time after Celgene is notified of our intent to pursue regulatory approval of CO-1686 in the United States or European Union as a first line therapy. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> In January 2012, the U.S. Food and Drug Administration (FDA) accepted our investigational new drug (IND) application to begin clinical investigation of CO-1686. Following the FDA’s acceptance of the IND application, the Company made a milestone payment of $4.0 million to Avila as required by the license agreement and recognized the payment as acquired in-process research and development expense. The Company may be required to pay up to an additional aggregate of $115.0 million in development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, the Company may be required to pay up to an aggregate of $120.0 million in sales milestones if certain annual sales targets are achieved. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> In January 2013, the Company entered into an exclusive license agreement with Gatekeeper Pharmaceuticals, Inc. (“Gatekeeper”) to acquire exclusive rights under patent applications associated with mutant epidermal growth factor receptor (“EGFR”) inhibitors and methods of treatment. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. If CO-1686 is approved for commercial sale, the Company will pay royalties to Gatekeeper on future net sales. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 18px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> Rucaparib <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> In June 2011, the Company entered into a worldwide license agreement with Pfizer Inc. to acquire exclusive development and commercialization rights to Pfizer’s drug candidate known as rucaparib. This drug candidate is a small molecule inhibitor of poly (ADP-ribose) polymerase, or PARP, which the Company is developing for the treatment of selected solid tumors. Pursuant to the terms of the license agreement, the Company made an up-front payment by issuing to Pfizer a $7.0 million convertible promissory note with a 5% annual interest rate, due in 2012. Upon completion of the Company’s initial public offering in November 2011, the principal balance and all accrued and unpaid interest due on this note of $7.2 million was converted into 551,222 shares of common stock. The Company is responsible for all development and commercialization costs of rucaparib and, if approved, Pfizer will receive royalties on the net sales of the product. In addition, Pfizer is eligible to receive up to $259 million of further payments, in aggregate, if certain development, regulatory and sales milestones are achieved. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> In April 2012, the Company entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of rucaparib for the uses claimed by these patents. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. The Company may be required to pay up to an aggregate of $0.7 million in milestone payments if certain regulatory filings, acceptances and approvals are achieved. If approved, AstraZeneca will also receive royalties on any net sales of rucaparib. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 0px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> CO-101 <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> In November 2009, the Company entered into a license agreement with Clavis Pharma ASA (“Clavis”) to develop and commercialize CO-101 in North America, Central America, South America and Europe. Under terms of the license agreement, the Company made an up-front payment to Clavis in the amount of $15.0 million, which was comprised of $13.1 million for development costs incurred prior to the execution of the agreement that was recognized as acquired in-process research and development and $1.9 million for the prepayment of preclinical activities to be performed by Clavis. In November 2010, the license agreement was amended to expand the license territory to include Asia and other international markets. The Company made a payment of $10.0 million to Clavis for the territory expansion and recognized the payment as acquired in-process research and development. As part of the amended license agreement, Clavis also agreed to reimburse up to $3.0 million of the Company’s research and development costs for certain CO-101 development activities subject to the Company incurring such costs, all of which was completed in 2011. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> On November 12, 2012, the Company reported results from a pivotal study for CO-101 as compared to gemcitabine in metastatic pancreatic cancer. The study results failed to demonstrate a difference in overall survival between the two study arms. Based on the results of the study, the Company has ceased development of CO-101 and terminated the license agreement. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 18px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> Drug Discovery Collaboration Agreement <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> In July 2012, the Company entered into a drug discovery collaboration agreement with Array BioPharma Inc. for the discovery of a novel cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. Under the terms of the agreement, the Company is responsible to fund all costs of the discovery program, as well as costs to develop and commercialize any clinical candidates discovered. If any clinical candidates are discovered and the Company seeks to pursue clinical development of such clinical candidates, the Company may be required to pay Array up to an aggregate of $192.0 million in milestone payments if certain development and regulatory objectives and annual net sales targets are achieved. </div> 0 165000 -39000

1915000

1957000

2343000

120000000 115000000 259000000

-32446000

23892000

15.02

1718000

-1.45

908000

-531000

-34683000

-176000

-34658000

-34507000

-34656000

-10000

4250000

-888000

70018000

5105000

2114000

38667000

1092000

42149

-27000

3000

223319

-1655000

69976000

25152000

2000000

176000

42000

-1922000 -684000

1082000

1032000

1718000

P12M P24M

13100000

15000000 10000000 3000000

2757788

7244523

10700000

2800000

129400000

6900000

551222

7200000

3750000

70000000

250000 700000

3819444

259100000

4000000

192000000 250000

1206899

2000000

174000

75500000

25744000

12.60

1718000

-0.61

-15692000

-172000

-15661000

-15520000

-15657000

250000

2680000

1168000

32108

-35000

162845

12590000

576000

592000

1718000

26717000

43.22

2343000

-0.72

-19341000

-33000

-19338000

-19308000

-19341000

3492000

2108000

1101935

5540488

15816000

1005000

1103000

2343000

0001466301 us-gaap:EmployeeStockOptionMember 2013-04-01 2013-06-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2013-04-01 2013-06-30 0001466301 us-gaap:GeneralAndAdministrativeExpenseMember 2013-04-01 2013-06-30 0001466301 2013-04-01 2013-06-30 0001466301 us-gaap:EmployeeStockOptionMember 2012-04-01 2012-06-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2012-04-01 2012-06-30 0001466301 us-gaap:GeneralAndAdministrativeExpenseMember 2012-04-01 2012-06-30 0001466301 2012-04-01 2012-06-30 0001466301 2012-01-01 2012-12-31 0001466301 us-gaap:ConvertiblePreferredStockMember 2009-01-01 2009-12-31 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorAvilaTherapeuticsMemberclvs:UpFrontLicensePaymentMemberclvs:LicenseAgreementsCoOneSixEightSixMember 2010-05-01 2010-05-31 0001466301 us-gaap:CommonStockMember 2009-05-01 2009-05-31 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorGatekeeperMemberclvs:UpFrontLicensePaymentMemberclvs:LicenseAgreementsCoOneSixEightSixMember 2013-01-01 2013-01-31 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorArrayBioPharmaIncMemberclvs:LicenseAgreementsKITMember 2012-07-01 2012-07-31 0001466301 clvs:LicenseAgreementsLicensorAvilaTherapeuticsMemberclvs:RegulatoryMilestonePaymentMemberclvs:LicenseAgreementsCoOneSixEightSixMember 2012-01-01 2012-01-31 0001466301 us-gaap:CommonStockMember 2013-06-01 2013-06-30 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorAstraZenecaUKLtdMemberclvs:LicenseAgreementsRucaparibMember 2012-04-01 2012-04-30 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorAstraZenecaUKLtdMemberclvs:UpFrontLicensePaymentMemberclvs:LicenseAgreementsRucaparibMember 2012-04-01 2012-04-30 0001466301 us-gaap:CommonStockMember 2012-04-01 2012-04-30 0001466301 clvs:LicenseAgreementsLicensorPfizerMember 2011-11-01 2011-11-30 0001466301 us-gaap:CommonStockMember 2011-11-01 2011-11-30 0001466301 us-gaap:ConvertiblePreferredStockMember 2011-11-01 2011-11-30 0001466301 2011-11-01 2011-11-30 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorClavisPharmaMemberclvs:LicenseAgreementsCoOneZeroOneMember 2010-11-01 2010-11-30 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorClavisPharmaMemberclvs:PaymentOnTerritoryExpansionMemberclvs:LicenseAgreementsCoOneZeroOneMember 2010-11-01 2010-11-30 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorClavisPharmaMemberclvs:UpFrontLicensePaymentMemberclvs:LicenseAgreementsCoOneZeroOneMember 2009-11-01 2009-11-30 0001466301 clvs:LicenseAgreementsLicensorClavisPharmaMemberclvs:UpFrontLicensePaymentMemberclvs:LicenseAgreementsCoOneZeroOneMember 2009-11-01 2009-11-30 0001466301 2013-02-01 2013-02-28 0001466301 us-gaap:EmployeeStockOptionMember 2012-01-01 2012-06-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-06-30 0001466301 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-06-30 0001466301 2012-01-01 2012-06-30 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorPfizerMemberclvs:LicenseAgreementsRucaparibMember 2013-01-01 2013-06-30 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorAvilaTherapeuticsMemberclvs:LicenseAgreementsCoOneSixEightSixMember 2013-01-01 2013-06-30 0001466301 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-06-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-06-30 0001466301 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-06-30 0001466301 2013-01-01 2013-06-30 0001466301 2009-04-20 2013-06-30 0001466301 us-gaap:FairValueInputsLevel1Member 2012-12-31 0001466301 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2012-12-31 0001466301 us-gaap:MoneyMarketFundsMember 2012-12-31 0001466301 2012-12-31 0001466301 2011-12-31 0001466301 us-gaap:FairValueInputsLevel1Member 2013-06-30 0001466301 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2013-06-30 0001466301 us-gaap:MoneyMarketFundsMember 2013-06-30 0001466301 us-gaap:CommonStockMember 2013-06-30 0001466301 2013-06-30 0001466301 2012-06-30 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorPfizerMemberclvs:UpFrontLicensePaymentMemberclvs:LicenseAgreementsRucaparibMember 2011-06-30 0001466301 clvs:LicenseAgreementsLicensorPfizerMemberclvs:UpFrontLicensePaymentMemberclvs:LicenseAgreementsRucaparibMember 2011-06-30 0001466301 us-gaap:DevelopedTechnologyRightsMemberus-gaap:ConvertibleNotesPayableMember 2011-06-30 0001466301 clvs:PfizerIncorporationMemberus-gaap:ConvertibleNotesPayableMember 2011-06-30 0001466301 us-gaap:CashMemberus-gaap:ConvertibleNotesPayableMember 2011-06-30 0001466301 clvs:ExistingInvestorsMemberus-gaap:CashMemberus-gaap:ConvertibleNotesPayableMember 2011-05-31 0001466301 us-gaap:CommonStockMember 2009-05-31 0001466301 us-gaap:ConvertiblePreferredStockMember 2009-05-31 0001466301 2013-08-01 0001466301 us-gaap:CommonStockMember 2012-04-30 0001466301 us-gaap:CommonStockMember 2011-11-30 0001466301 clvs:LicenseAgreementsLicensorClavisPharmaMemberclvs:UpFrontLicensePaymentMemberclvs:LicenseAgreementsCoOneZeroOneMember 2009-11-30 iso4217:USD iso4217:USD shares shares pure

EX-101.SCH 7 clvs-20130630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Statements of Operations And Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Nature of Business and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Financial Instruments and Fair Value Measurement link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Other Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Convertible Promissory Notes link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Convertible Preferred Stock and Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Share-Based Compensation link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - License Agreements link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Net Loss Per Share link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Nature of Business and Basis of Presentation (Policies) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Financial Instruments and Fair Value Measurement (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Other Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Share-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Net Loss Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Assets Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Financial Instruments and Fair Value Measurement - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Other Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Convertible Promissory Notes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Summary of Stock Options Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - License Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Commitments And Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 clvs-20130630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 clvs-20130630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 clvs-20130630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable And Accrued Liabilities Disclosure [Text Block] Other Accrued Expenses Accounts Payable Current Accounts payable Accretion Amortization Of Discounts And Premiums Investments Amortization of premiums and discounts on available for sale securities Accrued Liabilities Current Other accrued expenses Other accrued expenses Accrued Liabilities [Line Items] Accrued Liabilities [Line Items] Accrued Liabilities [Line Items] Accrued Liabilities [Table] Accrued Liabilities [Table] Accrued Liabilities [Table] Accrued Professional Fees Current Accrued corporate legal fees and professional services Accrued research and development expenses Accrued Research And Development Expenses Accrued research and development expenses Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated other comprehensive income Additional Paid In Capital Additional paid-in capital Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Amendment Flag Amendment Flag Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Total potential dilutive shares Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Assets Total assets Assets [Abstract] Assets Assets Current Total current assets Assets Current [Abstract] Current assets: Assets Fair Value Disclosure Recurring Assets at fair value Assets recorded for which payment has not yet occurred. Assets Recorded For Which Payment Has Not Yet Occurred Assets recorded for which payment (has)/has not yet occurred Available For Sale Securities Gross Realized Gain Loss Net Gain on sale of available for sale securities Basis of presentation. Basis Of Presentation Policy [Text Block] Basis of Presentation Cash And Cash Equivalents At Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash And Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash And Cash Equivalents Period Increase Decrease Increase in cash and cash equivalents Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Non-cash items: Cash [Member] Cash Class Of Stock [Domain] Class of Stock [Domain] Commitments And Contingencies Commitments and contingencies (Note 10) Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies [Table] Commitments And Contingencies [Table] Commitments and Contingencies [Table] Common Stock [Member] Common Stock Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock Value Common stock, $0.001 par value per share, 100,000,000 shares authorized at June 30, 2013 and December 31, 2012; 30,169,815 and 26,207,190 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively Comprehensive Income Net Of Tax Comprehensive loss Contractual Agreement Obligated Forecast Period Contractual Agreement Obligated Forecast Period Contractual agreement obligated forecast period Contractual Agreement Quarterly Forecasts Required Period Contractual Agreement Quarterly Forecasts Required Period Contractual agreement quarterly forecasts required period Conversion Of Stock Amount Issued 1 Conversion of convertible preferred stock to common stock Conversion Of Stock Shares Converted 1 Conversion of convertible preferred stock into common stock Conversion of notes into common stock Convertible Notes Payable Convertible promissory note Convertible Notes Payable [Member] Convertible Notes Payable Convertible Preferred Stock [Member] Convertible Preferred Stock Convertible Preferred Stock Shares Issued Upon Conversion Rate of conversion of convertible stock into common stock Current Fiscal Year End Date Current Fiscal Year End Date Debt Conversion Converted Instrument Amount 1 Conversion of convertible promissory notes and accrued interest to common stock Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Convertible Promissory Notes Debt Instrument Face Amount Notes issued Debt Instrument Interest Rate Stated Percentage Interest rate on promissory note Notes accrued interest rate Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument Maturity Date Notes accrued maturity date Debt Instrument [Table] Schedule of Long-term Debt Instruments [Table] Depreciation Depreciation Developed Technology Rights [Member] Developed Technology Rights Development Stage Enterprise Deficit Accumulated During Development Stage Deficit accumulated during development stage Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Share-Based Compensation Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Text Block] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award Document Document and Entity Information [Abstract] Document Document And Entity Information [Abstract] Document Documentand Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share Basic And Diluted Basic and diluted net loss per common share Earnings Per Share [Text Block] Net Loss Per Share Effect Of Exchange Rate On Cash And Cash Equivalents Effect of exchange rate changes on cash and cash equivalents Employee Related Liabilities Current Accrued personnel costs Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount Capitalized share-based compensation expense Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options Cash received from stock option exercises Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1 Weighted average remaining vesting period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Unrecognized share-based compensation expense Employee Service Share Based Compensation Tax Benefit From Compensation Expense Share-based compensation expense, tax benefit recognized Employee Stock Option [Member] Stock Options Entities [Table] Entities [Table] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Existing investors. Existing Investors [Member] Existing Investors Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair value assets level one and level two transfers amount. Fair Value Assets Level One And Level Two Transfers Amount Security transfers between Levels 1 and 2 Fair Value Assets Measured On Recurring Basis [Text Block] Assets Measured at Fair Value on Recurring Basis Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Asset Class [Domain] Fair Value By Asset Class [Axis] Asset Class [Axis] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value, Hierarchy [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Financial Instruments and Fair Value Measurement Fair Value Inputs Level 1 [Member] Fair Value, Inputs, Level 1 Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Finite Lived Intangible Assets By Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite Lived Intangible Assets Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Future expected development and regulatory payment. Future Expected Development And Regulatory Payment Future expected development and regulatory payment Future expected development, regulatory and sales milestone payments. Future Expected Development Regulatory And Sales Milestone Payments Future expected development, regulatory and sales milestone payments Gain Loss On Disposition Of Assets Loss on disposal of equipment General And Administrative Expense General and administrative General And Administrative Expense [Member] General and Administrative Expense Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Loss before income taxes Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Tax Expense Benefit Income taxes Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease In Other Accrued Liabilities Other accrued expenses Increase Decrease In Other Operating Assets Other operating assets Prepaid and accrued research and development expenses. Increase Decrease In Prepaid And Accrued Research And Development Expenses Prepaid and accrued research and development expenses The amount of costs incurred under in-licensing arrangements for up-front payments In Licensing Arrangement Costs Up Front Payment Up-front payment Investors Type [Axis] Investors Type [Axis] Investors Type [Axis] Investors Type [Domain] Investors Type [Domain] Investors Type [Domain] Legal Entity [Axis] Legal Entity [Axis] Liabilities And Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity [Abstract] Liabilities and stockholders' equity Liabilities Current Total current liabilities Liabilities Current [Abstract] Current liabilities: Liabilities Noncurrent Non-current liabilities License Agreement License Terms [Axis] License Agreement License Terms [Axis] License Agreement License Terms [Axis] License Agreement License Terms [Domain] License Agreement License Terms [Domain] License Agreement License Terms [Domain] License agreements CO-1686. License Agreements Co One Six Eight Six [Member] CO-1686 License agreements CO-101. License Agreements Co One Zero One [Member] CO-101 License agreements KIT. License Agreements K I T [Member] License Agreements KIT License Agreements Licensor Array Bio Pharma Inc. License Agreements Licensor Array Bio Pharma Inc [Member] License Agreements Licensor Array Bio Pharma Inc License agreements licensor Astra Zeneca UK Ltd Member. License Agreements Licensor Astra Zeneca U K Ltd [Member] License Agreements Licensor Astra Zeneca U K Ltd License agreements licensor Avila Therapeutics. License Agreements Licensor Avila Therapeutics [Member] License Agreements Licensor Avila Therapeutics License agreements licensor Clavis Pharma. License Agreements Licensor Clavis Pharma [Member] License Agreements Licensor Clavis Pharma License Agreements Licensor Gatekeeper [Member] License Agreements Licensor Gatekeeper [Member] License Agreements Licensor Gatekeeper License agreements licensor Pfizer. License Agreements Licensor Pfizer [Member] License Agreements Licensor Pfizer License Agreements Licensors Name [Axis] License Agreements Licensors Name [Axis] License Agreements Licensors Name [Axis] License Agreements Licensors Name [Domain] License Agreements Licensors Name [Domain] License Agreements Licensors Name [Domain] License Agreements Payment Type [Axis] License Agreements Payment Type [Axis] License Agreements Payment Type [Axis] License Agreements Payment Type [Domain] License Agreements Payment Type [Domain] License Agreements Payment Type [Domain] License agreements, Rucaparib. License Agreements Rucaparib [Member] Rucaparib License Agreements License Agreements [Text Block] License Agreements License Agreements Type [Axis] License Agreements Type [Axis] License Agreements Type [Axis] License Agreements Type [Domain] License Agreements Type [Domain] License Agreements Type [Domain] License Agreement Terms [Member] License Agreement Terms Liquidity Disclosure [Text Block] Liquidity Maximum issuable value of preferred stock. Maximum Issuable Value Of Preferred Stock Maximum issuable value of preferred stock Maximum amount of development costs to be reimbursed by Licensor per in-licensing agreement. Maximum Licensor Development Costs Reimbursable Maximum licensor reimbursement of development costs incurred Money Market Funds [Member] Money Market Net Cash Provided By Used In Financing Activities [Abstract] Financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Net cash provided by financing activities Net Cash Provided By Used In Investing Activities [Abstract] Investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Net cash provided by (used in) investing activities Net Cash Provided By Used In Operating Activities [Abstract] Operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Net cash used in operating activities Net Income Loss Net loss Net loss Non-cash acquired in-process research and development. Noncash Acquired In Process Research And Development Non-cash acquired in-process research and development Operating Expenses [Abstract] Operating Expenses: Operating Income Loss Operating loss Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Nature of Business and Basis of Presentation Other Accrued Liabilities Current Accrued expenses - other Other Assets Current Other current assets Other Assets Noncurrent Other assets Other Nonoperating Income Expense Other income (expense), net Parties To Contractual Arrangement [Axis] Parties to Contractual Arrangement [Axis] Parties To Contractual Arrangement [Member] Parties to Contractual Arrangement [Domain] Payables And Accruals [Abstract] Payables and Accruals [Abstract] Payment on territory expansion. Payment On Territory Expansion [Member] Payment On Territory Expansion Payments Of Stock Issuance Costs Issuance costs Payments To Acquire Available For Sale Securities Debt Purchases of available for sale securities Payments To Acquire Property Plant And Equipment Purchases of property and equipment Pfizer Incorporation. Pfizer Incorporation [Member] Pfizer Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, shares issued Preferred Stock Shares Outstanding Preferred stock, shares outstanding Preferred Stock Value Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2013 and December 31, 2012 Prepaid Expense Current Prepaid research and development expenses Prepayment of preclinical Activities Principal balance and all accrued and unpaid interest due on convertible promissory note. Principal Balance And Accrued Unpaid Interest Principal balance and all accrued and unpaid interest on notes converted to common stock Proceeds From Issuance Initial Public Offering Net proceeds from issuance of common stock, initial public offering Proceeds From Issuance Of Common Stock Proceeds from sale of common stock, net of issuance costs Proceeds From Issuance Of Convertible Preferred Stock Cash proceeds on issuance of convertible preferred stock Proceeds from sale of convertible preferred stock, net of issuance costs. Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Cost Proceeds from sale of convertible preferred stock, net of issuance costs Proceeds from issuance of convertible promissory notes, net of issuance costs. Proceeds From Issuance Of Convertible Promissory Notes Net Of Issuance Costs Proceeds from issuance of convertible promissory notes, net of issuance costs Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Proceeds from exercise of stock options and employee stock purchase plan Proceeds From Sale And Maturity Of Available For Sale Securities Maturities and sales of available for sale securities Property Plant And Equipment Net Property and equipment, net Purchase Commitment Excluding Longterm Commitment [Line Items] Purchase Commitment, Excluding Long-term Commitment [Line Items] Purchase Commitment Remaining Minimum Amount Committed Purchase commitment Regulatory milestone payment. Regulatory Milestone Payment [Member] Regulatory Milestone Payment Research And Development [Abstract] Research and Development [Abstract] Research And Development Arrangement Contract To Perform For Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] EX-101.PRE 11 clvs-20130630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R8.xml IDEA: Financial Instruments and Fair Value Measurement 2.4.0.8109 - Disclosure - Financial Instruments and Fair Value Measurementtruefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_FairValueDisclosuresTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 3. Financial Instruments and Fair Value Measurement Cash, Cash Equivalents and Available for Sale Securities The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.   Marketable securities with original maturities greater than three months are considered to be available for sale securities and historically consisted of U.S. agency obligations, U.S. government obligations and corporate debt obligations. Available for sale securities are reported at fair market value and unrealized gains and losses are included as a separate component of stockholders’ equity. Realized gains, realized losses, the amortization of premiums and discounts, interest earned and dividends earned are included in other income (expense). The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on management’s intent to fund current operations with these securities or to make them available for current operations. A decline in the market value of a security below its cost value that is deemed to be other than temporary is charged to earnings, and results in the establishment of a new cost basis for the security. Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="6%"></td> <td valign="bottom" width="2%"></td> <td width="92%"></td> </tr> <tr> <td valign="top">Level 1:</td> <td valign="bottom">  </td> <td valign="bottom">Quoted prices in active markets for identical assets or liabilities. The Company’s Level 1 assets and liabilities consist of money market investments.</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="2"></td> </tr> <tr> <td valign="top">Level 2:</td> <td valign="bottom">  </td> <td valign="bottom">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company does not have Level 2 assets or liabilities.</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="2"></td> </tr> <tr> <td valign="top">Level 3:</td> <td valign="bottom">  </td> <td valign="bottom">Unobservable inputs that are supported by little or no market activity. The Company does not have Level 3 assets or liabilities.</td> </tr> </table> The following table identifies the Company’s assets that were measured at fair value on a recurring basis (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="70%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Balance</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Money market </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total assets at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Money market </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total assets at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> There were no security transfers between Levels 1 and 2 during the six month period ended June 30, 2013. </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13537-108611 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13433-108611 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13504-108611 false0Financial Instruments and Fair Value MeasurementfalseFinancial Instruments and Fair Value MeasurementUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock11 XML 13 R6.xml IDEA: Nature of Business and Basis of Presentation 2.4.0.8107 - Disclosure - Nature of Business and Basis of Presentationtruefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 1. Nature of Business and Basis of Presentation Clovis Oncology, Inc. (the “Company”), a corporation in the development stage, was incorporated in Delaware on April 20, 2009, and commenced operations in May 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and other international markets. The Company has and intends to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, the Company generally expects to provide the licensor with a combination of up-front payments, milestone payments and royalties on future sales. In addition, the Company generally expects to assume the responsibility for future drug development and commercialization costs. The Company currently operates in one segment. Since inception, the Company’s operations have consisted primarily of developing in-licensed compounds and their companion diagnostics, evaluating new product acquisition candidates, raising capital and corporate organization activities. The Company has never earned revenue from these activities, and accordingly, the Company is considered to be in the development stage as of June 30, 2013. Basis of Presentation The information reported within the Company’s financial statements from April 20, 2009 to December 31, 2010 was based solely on the accounts of Clovis Oncology, Inc. Effective January 1, 2011, Clovis Oncology UK Limited, a wholly owned subsidiary of the Company, commenced operations. All financial information presented after December 31, 2010 was consolidated and includes the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Changes in or reclassifications out of accumulated other comprehensive loss are not disclosed in our notes to the unaudited financial statements due to the insignificance of the activity. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial information prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. The Company evaluates subsequent events up to the time of filing with the SEC. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2012 for a broader discussion of our business and the opportunities and risks inherent in such business. Use of Estimates The preparation of these unaudited consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, other comprehensive loss and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to clinical trial accruals and share-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Liquidity The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through public and private equity financings, and management expects operating losses and negative cash flows to continue for at least the next several years. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless or until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through cash and investments on hand and additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -SubTopic 15 -URI http://asc.fasb.org/subtopic&trid=2122524 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2197480 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 235 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2209116 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2134480 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2122150 false0Nature of Business and Basis of PresentationfalseNature of Business and Basis of PresentationUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock11 XML 14 R17.htm IDEA: XBRL DOCUMENT

Nature of Business and Basis of Presentation (Policies)	6 Months Ended
Nature of Business and Basis of Presentation (Policies)	Jun. 30, 2013
Basis of Presentation	*Basis of Presentation* The information reported within the Company’s financial statements from April 20, 2009 to December 31, 2010 was based solely on the accounts of Clovis Oncology, Inc. Effective January 1, 2011, Clovis Oncology UK Limited, a wholly owned subsidiary of the Company, commenced operations. All financial information presented after December 31, 2010 was consolidated and includes the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Changes in or reclassifications out of accumulated other comprehensive loss are not disclosed in our notes to the unaudited financial statements due to the insignificance of the activity. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial information prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. The Company evaluates subsequent events up to the time of filing with the SEC. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2012 for a broader discussion of our business and the opportunities and risks inherent in such business.
Use of Estimates	*Use of Estimates* The preparation of these unaudited consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, other comprehensive loss and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to clinical trial accruals and share-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.
Liquidity	*Liquidity* The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through public and private equity financings, and management expects operating losses and negative cash flows to continue for at least the next several years. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless or until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through cash and investments on hand and additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources.

- Definition

Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.

+ References+ Details

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	30,169,815	26,207,190
Common stock, shares outstanding	30,169,815	26,207,190

XML 16 R10.htm IDEA: XBRL DOCUMENT

Convertible Promissory Notes

6 Months Ended

Jun. 30, 2013

Convertible Promissory Notes

5. Convertible Promissory Notes

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details

XML 17 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 18 R24.htm IDEA: XBRL DOCUMENT

Other Accrued Expenses (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Accrued Liabilities [Line Items]
Accrued personnel costs	$ 1,811	$ 2,441
Accrued corporate legal fees and professional services	350	63
Accrued expenses - other	63	198
Other accrued expenses	$ 2,224	$ 2,702

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

XML 19 R29.xml IDEA: Summary of Stock Options Activity (Detail) 2.4.0.8130 - Disclosure - Summary of Stock Options Activity (Detail)truefalsefalse1false USDfalsefalse$eol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Share-based Compensation Arrangement by Share-based Payment Award [Line Items]2false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberus-gaap_truenainstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse15990441599044falsefalsefalsexbrli:sharesItemTypesharesNumber of options outstanding, including both vested and non-vested options.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false1Beginning Balance, Option Shares Outstanding3false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse10461581046158falsefalsefalsexbrli:sharesItemTypesharesGross number of share options (or share units) granted during the period.No definition available.false1Granted, Option Shares Outstanding4false 4us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercisedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-130732-130732falsefalsefalsexbrli:sharesItemTypesharesNumber of share options (or share units) exercised during the current period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28,29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Exercised, Option Shares Outstanding5false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-29400-29400falsefalsefalsexbrli:sharesItemTypesharesThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false1Forfeited, Option Shares Outstanding6false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse24850702485070falsefalsefalsexbrli:sharesItemTypesharesNumber of options outstanding, including both vested and non-vested options.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false1Ending Balance, Option Shares Outstanding7false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumberus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse22617172261717falsefalsefalsexbrli:sharesItemTypesharesAs of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false1Vested and expected to vest, Option Shares Outstanding8false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumberus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse721162721162falsefalsefalsexbrli:sharesItemTypesharesThe number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false1Vested, Option Shares Outstanding9false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceus-gaap_truenainstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse14.0514.05USD$falsetruefalsenum:perShareItemTypedecimalWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false3Beginning Balance, Weighted Average Exercise Price10false 4us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse28.5328.53USD$falsetruefalsenum:perShareItemTypedecimalWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.No definition available.false3Granted, Weighted Average Exercise Price11false 4us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePriceus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse9.099.09USD$falsetruefalsenum:perShareItemTypedecimalWeighted average price at which option holders acquired shares when converting their stock options into shares.No definition available.false3Exercised, Weighted Average Exercise Price12false 4us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse16.7516.75USD$falsetruefalsenum:perShareItemTypedecimalWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.No definition available.false3Forfeited, Weighted Average Exercise Price13false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse20.3820.38USD$falsetruefalsenum:perShareItemTypedecimalWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false3Ending Balance, Weighted Average Exercise Price14false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePriceus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse19.9019.90USD$falsetruefalsenum:perShareItemTypedecimalAs of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false3Vested and expected to vest, Weighted Average Exercise Price15false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePriceus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse11.0011.00USD$falsetruefalsenum:perShareItemTypedecimalAs of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false3Vested, Weighted Average Exercise Price16false 4us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse008 years 9 months 15 daysfalsefalsefalsexbrli:durationItemTypenaWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Outstanding, Weighted Average Remaining Contractual Term (Years)17false 4us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse008 years 8 months 19 daysfalsefalsefalsexbrli:durationItemTypenaWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Vested and expected to vest, Weighted Average Remaining Contractual Term (Years)18false 4us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse007 years 10 months 2 daysfalsefalsefalsexbrli:durationItemTypenaWeighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Vested, Weighted Average Remaining Contractual Term (Years)19false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse116427809116427809USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false2Outstanding, Aggregate Intrinsic Value20false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse107015622107015622falsefalsefalsexbrli:monetaryItemTypemonetaryAmount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false2Vested and expected to vest, Aggregate Intrinsic Value21false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse4036807140368071USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false2Vested, Aggregate Intrinsic ValuefalseSummary of Stock Options Activity (Detail) (USD $)NoRoundingNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/DisclosureSummaryOfStockOptionsActivity121 XML 20 R18.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value Measurement (Tables)

6 Months Ended

Jun. 30, 2013

Assets Measured at Fair Value on Recurring Basis

The following table identifies the Company’s assets that were measured at fair value on a recurring basis (in thousands):


	Balance		Level 1		Level 2		Level 3
June 30, 2013
Money market	$	147,985	$	147,985	$	—	$	—

Total assets at fair value	$	147,985	$	147,985	$	—	$	—

December 31, 2012
Money market	$	135,385	$	135,385	$	—	$	—

Total assets at fair value	$	135,385	$	135,385	$	—	$	—

XML 21 R32.xml IDEA: Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share (Detail) 2.4.0.8133 - Disclosure - Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share (Detail)truefalseIn Thousands, unless otherwise specifiedfalse1false falsefalseeol_PE807381--1310-Q0005_STD_91_20130630_0http://www.sec.gov/CIK0001466301duration2013-04-01T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares02false falsefalseeol_PE807381--1310-Q0005_STD_91_20120630_0http://www.sec.gov/CIK0001466301duration2012-04-01T00:00:002012-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares03false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares04false falsefalseeol_PE807381--1310-Q0005_STD_182_20120630_0http://www.sec.gov/CIK0001466301duration2012-01-01T00:00:002012-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares01true 3us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]2false 4us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse23430002343falsefalsefalse2truefalsefalse17180001718falsefalsefalse3truefalsefalse23430002343falsefalsefalse4truefalsefalse17180001718falsefalsefalsexbrli:sharesItemTypesharesSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Antidilution -URI http://asc.fasb.org/extlink&oid=6505113 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Diluted Earnings Per Share -URI http://asc.fasb.org/extlink&oid=6510752 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Contingent Stock Agreement -URI http://asc.fasb.org/extlink&oid=6508534 false1Total potential dilutive shares3false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5false truefalseeol_PE807381--1310-Q0005_STD_91_20130630_0_712382x708980http://www.sec.gov/CIK0001466301duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseStock Optionsus-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_EmployeeStockOptionMemberus-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instanceshares0nanafalse0Stock Options4true 3us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]5false 4us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse23430002343falsefalsefalse2truefalsefalse17180001718falsefalsefalse3truefalsefalse23430002343falsefalsefalse4truefalsefalse17180001718falsefalsefalsexbrli:sharesItemTypesharesSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Antidilution -URI http://asc.fasb.org/extlink&oid=6505113 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Diluted Earnings Per Share -URI http://asc.fasb.org/extlink&oid=6510752 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Contingent Stock Agreement -URI http://asc.fasb.org/extlink&oid=6508534 false1Total potential dilutive sharesfalseShares Outstanding Excluded from Calculation of Diluted Net Loss Per Share (Detail)UnKnownThousandsUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/DisclosureSharesOutstandingExcludedFromCalculationOfDilutedNetLossPerShare45 XML 22 R25.xml IDEA: Convertible Promissory Notes - Additional Information (Detail) 2.4.0.8126 - Disclosure - Convertible Promissory Notes - Additional Information (Detail)truefalseIn Millions, except Share data, unless otherwise specifiedfalse1false falsefalseeol_PE807381--1310-Q0005_STD_30_20111130_0http://www.sec.gov/CIK0001466301duration2011-11-01T00:00:002011-11-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares02false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:00pureStandardhttp://www.xbrl.org/2003/instancepure03false USDtruefalse$eol_PE807381--1310-Q0005_STD_0_20110630_0_708293x711289_716819x708807http://www.sec.gov/CIK0001466301instant2011-06-30T00:00:000001-01-01T00:00:00falsefalseConvertible Notes Payableus-gaap_ShortTermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ConvertibleNotesPayableMemberus-gaap_ShortTermDebtTypeAxisexplicitMemberfalsefalseCashus-gaap_CashAndCashEquivalentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CashMemberus-gaap_CashAndCashEquivalentsAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDtruefalse$eol_PE807381--1310-Q0005_STD_0_20110630_0_714938x713419_716819x708807http://www.sec.gov/CIK0001466301instant2011-06-30T00:00:000001-01-01T00:00:00falsefalseConvertible Notes Payableus-gaap_ShortTermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ConvertibleNotesPayableMemberus-gaap_ShortTermDebtTypeAxisexplicitMemberfalsefalseDeveloped Technology Rightsus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_DevelopedTechnologyRightsMemberus-gaap_FiniteLivedIntangibleAssetsByMajorClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDtruefalse$eol_PE807381--1310-Q0005_STD_0_20110630_0_711809x755349_716819x708807http://www.sec.gov/CIK0001466301instant2011-06-30T00:00:000001-01-01T00:00:00falsefalseConvertible Notes Payableus-gaap_ShortTermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ConvertibleNotesPayableMemberus-gaap_ShortTermDebtTypeAxisexplicitMemberfalsefalsePfizerus-gaap_PartiesToContractualArrangementAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_PfizerIncorporationMemberus-gaap_PartiesToContractualArrangementAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false USDtruefalse$eol_PE807381--1310-Q0005_STD_0_20110531_0_708293x711289_716819x708807_837519x801949http://www.sec.gov/CIK0001466301instant2011-05-31T00:00:000001-01-01T00:00:00falsefalseConvertible Notes Payableus-gaap_ShortTermDebtTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ConvertibleNotesPayableMemberus-gaap_ShortTermDebtTypeAxisexplicitMemberfalsefalseExisting Investorsclvs_InvestorsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_ExistingInvestorsMemberclvs_InvestorsTypeAxisexplicitMemberfalsefalseCashus-gaap_CashAndCashEquivalentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CashMemberus-gaap_CashAndCashEquivalentsAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_DebtInstrumentLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Debt Instrument [Line Items]2false 4us-gaap_DebtInstrumentFaceAmountus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse80000008.0USD$falsetruefalse4truefalsefalse70000007.0USD$falsetruefalse5truefalsefalse1500000015.0USD$falsetruefalse6truefalsefalse2000000020.0USD$falsetruefalsexbrli:monetaryItemTypemonetaryFace (par) amount of debt instrument at time of issuance.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400 false2Notes issued3false 4us-gaap_DebtInstrumentInterestRateStatedPercentageus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsetruefalse00falsefalsefalse2truetruefalse0.050.05falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalsenum:percentItemTypepureContractual interest rate for funds borrowed, under the debt agreement.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false0Notes accrued interest rate4false 4us-gaap_DebtInstrumentMaturityDateus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse002012-05-25falsefalsetrue3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalsexbrli:dateItemTypedateDate when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false0Notes accrued maturity date5false 4us-gaap_ConversionOfStockSharesConverted1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse27577882757788falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 false1Conversion of notes into common stockfalseConvertible Promissory Notes - Additional Information (Detail) (USD $)HundredThousandsNoRoundingUnKnownUnKnowntruefalsefalseNoteshttp://www.clovisoncology.com/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformation65 XML 23 R27.htm IDEA: XBRL DOCUMENT

Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended		50 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 2,108	$ 1,168	$ 3,872	$ 2,114	$ 10,218
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	1,103	592	1,957	1,032
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 1,005	$ 576	$ 1,915	$ 1,082

XML 24 R26.htm IDEA: XBRL DOCUMENT

Convertible Preferred Stock and Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended	6 Months Ended		50 Months Ended	1 Months Ended					12 Months Ended
	Nov. 30, 2011	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2013 Common Stock	Apr. 30, 2012 Common Stock	Nov. 30, 2011 Common Stock	May 31, 2009 Common Stock	Nov. 30, 2011 Convertible Preferred Stock	Dec. 31, 2009 Convertible Preferred Stock	May 31, 2009 Convertible Preferred Stock
Shareholders Equity [Line Items]
Common stock, shares issued					3,819,444	3,750,000	10,700,000	1,206,899
Common stock shares issued, per share								$ 0.0029
Sale of stock price per share					$ 72.00	$ 20.00	$ 13.00
Net proceeds from issuance of common stock, initial public offering							$ 129,400,000
Underwriting commission cost							6,900,000
Issuance costs							2,800,000			174,000
Proceeds from sale of common stock, net of issuance costs		259,146,000	69,976,000	458,481,000	259,100,000	70,000,000
Maximum issuable value of preferred stock											146,300,000
Cash proceeds on issuance of convertible preferred stock										$ 75,500,000
Conversion of convertible preferred stock into common stock	2,757,788								7,244,523
Rate of conversion of convertible stock into common stock							2.9

XML 25 R19.xml IDEA: Other Accrued Expenses (Tables) 2.4.0.8120 - Disclosure - Other Accrued Expenses (Tables)truefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Other accrued expenses are comprised of the following (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">June 30, 2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Accrued personnel costs </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,811</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,441</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Accrued corporate legal fees and professional services </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">350</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Accrued expenses – other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">198</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,224</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,702</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the components of accrued liabilities.No definition available.false0Other Accrued ExpensesfalseOther Accrued Expenses (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables11 XML 26 R31.htm IDEA: XBRL DOCUMENT

License Agreements - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	6 Months Ended		50 Months Ended		1 Months Ended		6 Months Ended		1 Months Ended				1 Months Ended			1 Months Ended
	Nov. 30, 2011	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Dec. 31, 2012	Nov. 30, 2011 License Agreements Licensor Pfizer	Nov. 30, 2010 License Agreement Terms License Agreements Licensor Clavis Pharma CO-101	Jun. 30, 2013 License Agreement Terms License Agreements Licensor Avila Therapeutics CO-1686	Jun. 30, 2013 License Agreement Terms License Agreements Licensor Pfizer Rucaparib	Apr. 30, 2012 License Agreement Terms License Agreements Licensor Astra Zeneca U K Ltd Rucaparib	Jul. 31, 2012 License Agreement Terms License Agreements Licensor Array Bio Pharma Inc License Agreements KIT	Nov. 30, 2009 Up-front license payment License Agreements Licensor Clavis Pharma CO-101	Jun. 30, 2011 Up-front license payment License Agreements Licensor Pfizer Rucaparib	Nov. 30, 2009 Up-front license payment License Agreement Terms License Agreements Licensor Clavis Pharma CO-101	May 31, 2010 Up-front license payment License Agreement Terms License Agreements Licensor Avila Therapeutics CO-1686	Jun. 30, 2011 Up-front license payment License Agreement Terms License Agreements Licensor Pfizer Rucaparib	Apr. 30, 2012 Up-front license payment License Agreement Terms License Agreements Licensor Astra Zeneca U K Ltd Rucaparib	Jan. 31, 2013 Up-front license payment License Agreement Terms License Agreements Licensor Gatekeeper CO-1686	Nov. 30, 2010 Payment On Territory Expansion License Agreement Terms License Agreements Licensor Clavis Pharma CO-101	Jan. 31, 2012 Regulatory Milestone Payment License Agreements Licensor Avila Therapeutics CO-1686
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front payment															$ 15,000,000	$ 2,000,000		$ 250,000	$ 250,000	$ 10,000,000
Acquired in process research and development costs		250,000	250,000	4,250,000	36,585,000								13,100,000								4,000,000
Future expected development and regulatory payment									115,000,000		700,000
Sales milestone payments									120,000,000
Convertible promissory note																	7,000,000
Interest rate on promissory note			5.00%		5.00%									5.00%
Principal balance and all accrued and unpaid interest on notes converted to common stock							7,200,000
Conversion of convertible preferred stock into common stock	2,757,788						551,222
Future expected development, regulatory and sales milestone payments										259,000,000		192,000,000
Prepayment of preclinical Activities			605,000		605,000	116,000							1,900,000
Maximum licensor reimbursement of development costs incurred								$ 3,000,000

XML 27 R9.xml IDEA: Other Accrued Expenses 2.4.0.8110 - Disclosure - Other Accrued Expensestruefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 4. Other Accrued Expenses Other accrued expenses are comprised of the following (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">June 30, 2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Accrued personnel costs </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,811</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,441</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Accrued corporate legal fees and professional services </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">350</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Accrued expenses – other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">198</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,224</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,702</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a),20,24) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20, 24 -Article 5 false0Other Accrued ExpensesfalseOther Accrued ExpensesUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock11 XML 28 R12.xml IDEA: Share-Based Compensation 2.4.0.8113 - Disclosure - Share-Based Compensationtruefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 7. Share-Based Compensation Share-based compensation expense for all equity based programs, including stock options and the employee stock purchase plan, for the three and six months ended June 30, 2013 and 2012, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,103</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">592</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,957</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,032</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,005</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">576</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,915</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,082</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total share-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,108</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,168</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,872</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,114</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The Company did not recognize a tax benefit related to share-based compensation expense during the three and six months ended June 30, 2013 and 2012, respectively, as the Company maintains net operating loss carryforwards and has established a valuation allowance against the entire net deferred tax asset as of June 30, 2013. No share-based compensation expense was capitalized on our Consolidated Balance Sheets as of June 30, 2013 and December 31, 2012. The following table summarizes the activity relating to the Company’s options to purchase common stock for the six month period ended June 30, 2013:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="56%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Option  Shares Outstanding</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted- Average Remaining Contractual Term (Years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,599,044</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14.05</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,046,158</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28.53</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(130,732</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.09</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(29,400</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16.75</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,485,070</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20.38</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.79</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">116,427,809</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Vested and expected to vest at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,261,717</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19.90</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.72</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">107,015,622</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Vested at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">721,162</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.84</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40,368,071</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table>     The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $66.98 as of June 30, 2013, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Weighted-average grant-date fair value per share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">43.22</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12.60</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Intrinsic value of options exercised </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,540,488</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">162,845</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Cash received from stock option exercises </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,101,935</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32,108</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Weighted-average grant-date fair value per share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17.61</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15.02</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Intrinsic value of options exercised </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,716,374</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">223,319</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Cash received from stock option exercises </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,188,312</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">42,149</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> As of June 30, 2013, the unrecognized share-based compensation expense related to nonvested options, adjusted for expected forfeitures was $23.7 million and the estimated weighted-average remaining vesting period was 2.8 years. </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 40 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 false0Share-Based CompensationfalseShare-Based CompensationUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock11 XML 29 R25.htm IDEA: XBRL DOCUMENT

Convertible Promissory Notes - Additional Information (Detail) (USD $) In Millions, except Share data, unless otherwise specified	1 Months Ended	6 Months Ended
	Nov. 30, 2011	Jun. 30, 2013	Jun. 30, 2011 Convertible Notes Payable Cash	Jun. 30, 2011 Convertible Notes Payable Developed Technology Rights	Jun. 30, 2011 Convertible Notes Payable Pfizer	May 31, 2011 Convertible Notes Payable Existing Investors Cash
Debt Instrument [Line Items]
Notes issued			$ 8.0	$ 7.0	$ 15.0	$ 20.0
Notes accrued interest rate		5.00%
Notes accrued maturity date		May 25, 2012
Conversion of notes into common stock	2,757,788

XML 30 R6.htm IDEA: XBRL DOCUMENT

Nature of Business and Basis of Presentation

6 Months Ended

Jun. 30, 2013

Nature of Business and Basis of Presentation

1. Nature of Business and Basis of Presentation

Basis of Presentation

Use of Estimates

Liquidity

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

+ Details

XML 31 R8.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value Measurement

6 Months Ended

Jun. 30, 2013

Financial Instruments and Fair Value Measurement

3. Financial Instruments and Fair Value Measurement

Cash, Cash Equivalents and Available for Sale Securities

Fair Value of Financial Instruments


Level 1:		Quoted prices in active markets for identical assets or liabilities. The Company’s Level 1 assets and liabilities consist of money market investments.

Level 2:		Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company does not have Level 2 assets or liabilities.

Level 3:		Unobservable inputs that are supported by little or no market activity. The Company does not have Level 3 assets or liabilities.

The following table identifies the Company’s assets that were measured at fair value on a recurring basis (in thousands):


	Balance		Level 1		Level 2		Level 3
June 30, 2013
Money market	$	147,985	$	147,985	$	—	$	—

Total assets at fair value	$	147,985	$	147,985	$	—	$	—

December 31, 2012
Money market	$	135,385	$	135,385	$	—	$	—

Total assets at fair value	$	135,385	$	135,385	$	—	$	—

There were no security transfers between Levels 1 and 2 during the six month period ended June 30, 2013.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References+ Details

XML 32 R11.xml IDEA: Convertible Preferred Stock and Stockholders' Equity 2.4.0.8112 - Disclosure - Convertible Preferred Stock and Stockholders' Equitytruefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_StockholdersEquityNoteDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 6. Convertible Preferred Stock and Stockholders’ Equity Common Stock In May 2009, the Company issued 1,206,899 shares of its common stock to the original founders at a purchase price of $.0029 per share. The shares were issued under restricted stock purchase agreements, which allowed the Company, at its discretion, to repurchase unvested shares if the founders terminated their employment with the Company. As of June 30, 2013, all common stock shares issued to the founders under the restricted stock purchase agreements were fully vested. In November 2011, the Company sold 10,700,000 shares of its common stock in an initial public offering at a price of $13.00 per share. The Company received net proceeds from the offering of $129.4 million, after deduction of $6.9 million of underwriting commissions and $2.8 million of offering expenses. In April 2012, the Company sold 3,750,000 shares of its common stock in a public offering at $20.00 per share. The net offering proceeds realized after deducting offering expenses and underwriters’ discounts and commissions was $70.0 million. In June 2013, the Company sold 3,819,444 shares of its common stock in a public offering at $72.00 per share. The net offering proceeds realized after deducting offering expenses and underwriters’ discounts and commissions was $259.1 million. The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders of the Company. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by the Company’s Board of Directors. Preferred Stock In May 2009, the Company entered into the Series A-1, A-2, B and C Preferred Stock Purchase Agreement with various investors (the “Preferred Stock Purchase Agreement”). The Preferred Stock Purchase Agreement provided for the issuance of up to $146.3 million of the Company’s convertible preferred stock, subject to various terms and conditions. During 2009, the Company issued shares of Series A-1, Series A-2 and Series B convertible preferred stock resulting in total aggregate cash proceeds to the Company of $75.5 million, net of $174,000 related stock issuance costs. In connection with the completion of the Company’s initial public offering in November 2011, all of the outstanding shares of convertible preferred stock were automatically converted into 7,244,523 shares of the Company’s common stock. The Series A-1, A-2 and B convertible preferred stock converted at a rate of 2.9 for 1 into common stock based upon the election of the convertible preferred stock holders immediately prior to the closing of the initial public offering. </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Article 4 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(d),(e)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Preferred Stock -URI http://asc.fasb.org/extlink&oid=6521494 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644 Reference 17: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644 Reference 18: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph d -Article 4 Reference 19: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656 false0Convertible Preferred Stock and Stockholders' EquityfalseConvertible Preferred Stock and Stockholders' EquityUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock11 XML 33 R11.htm IDEA: XBRL DOCUMENT

Convertible Preferred Stock and Stockholders' Equity

6 Months Ended

Jun. 30, 2013

Convertible Preferred Stock and Stockholders' Equity

6. Convertible Preferred Stock and Stockholders’ Equity

Common Stock

Preferred Stock

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

XML 34 R14.xml IDEA: Net Loss Per Share 2.4.0.8115 - Disclosure - Net Loss Per Sharetruefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_EarningsPerShareTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 9. Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, stock options are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="70%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three and Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom">  </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Common shares under option </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,343</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,718</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total potential dilutive shares </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,343</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,718</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for earnings per share.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.21) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false0Net Loss Per SharefalseNet Loss Per ShareUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock11 XML 35 R2.xml IDEA: Consolidated Statements of Operations And Comprehensive Loss 2.4.0.8103 - Statement - Consolidated Statements of Operations And Comprehensive LosstruefalseIn Thousands, except Per Share data, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE807381--1310-Q0005_STD_91_20130630_0http://www.sec.gov/CIK0001466301duration2013-04-01T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE807381--1310-Q0005_STD_91_20120630_0http://www.sec.gov/CIK0001466301duration2012-04-01T00:00:002012-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$eol_PE807381--1310-Q0005_STD_182_20120630_0http://www.sec.gov/CIK0001466301duration2012-01-01T00:00:002012-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDfalsefalse$eol_PE807381--1310-Q0005_STD_1533_20130630_0http://www.sec.gov/CIK0001466301duration2009-04-20T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4us-gaap_SalesRevenueGoodsNetus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  falsefalsefalse2falsefalsefalse00  falsefalsefalse3falsefalsefalse00  falsefalsefalse4falsefalsefalse00  falsefalsefalse5falsefalsefalse00  falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Revenues2true 4us-gaap_OperatingExpensesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Operating Expenses:3false 5us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse1581600015816falsefalsefalse2truefalsefalse1259000012590falsefalsefalse3truefalsefalse2793800027938falsefalsefalse4truefalsefalse2515200025152falsefalsefalse5truefalsefalse151643000151643falsefalsefalsexbrli:monetaryItemTypemonetaryThe costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Research and Development -URI http://asc.fasb.org/extlink&oid=6523717 false2Research and development4false 5us-gaap_GeneralAndAdministrativeExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse34920003492falsefalsefalse2truefalsefalse26800002680falsefalsefalse3truefalsefalse67100006710falsefalsefalse4truefalsefalse51050005105falsefalsefalse5truefalsefalse3071900030719falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false2General and administrative5false 5us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse250000250falsefalsefalse3truefalsefalse250000250falsefalsefalse4truefalsefalse42500004250falsefalsefalse5truefalsefalse3658500036585falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275 false2Acquired in-process research and development6false 4us-gaap_OperatingIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-19308000-19308falsefalsefalse2truefalsefalse-15520000-15520falsefalsefalse3truefalsefalse-34898000-34898falsefalsefalse4truefalsefalse-34507000-34507falsefalsefalse5truefalsefalse-218947000-218947falsefalsefalsexbrli:monetaryItemTypemonetaryThe net result for the period of deducting operating expenses from operating revenues.No definition available.true2Operating loss7false 4us-gaap_OtherNonoperatingIncomeExpenseus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-33000-33falsefalsefalse2truefalsefalse-172000-172falsefalsefalse3truefalsefalse-111000-111falsefalsefalse4truefalsefalse-176000-176falsefalsefalse5truefalsefalse-544000-544falsefalsefalsexbrli:monetaryItemTypemonetaryThe net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 9 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 false2Other income (expense), net8false 4us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-19341000-19341falsefalsefalse2truefalsefalse-15692000-15692falsefalsefalse3truefalsefalse-35009000-35009falsefalsefalse4truefalsefalse-34683000-34683falsefalsefalse5truefalsefalse-219491000-219491falsefalsefalsexbrli:monetaryItemTypemonetaryThis element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 10 -Article 5 true2Loss before income taxes9false 4us-gaap_IncomeTaxExpenseBenefitus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2truefalsefalse3500035falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse2700027falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Income Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6515339 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 false2Income taxes10false 4us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-19341000-19341falsefalsefalse2truefalsefalse-15657000-15657falsefalsefalse3truefalsefalse-35009000-35009falsefalsefalse4truefalsefalse-34656000-34656falsefalsefalse5truefalsefalse-219491000-219491falsefalsefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 true2Net loss11false 4us-gaap_EarningsPerShareBasicAndDilutedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-0.72-0.72USD$falsetruefalse2truefalsefalse-0.61-0.61USD$falsetruefalse3truefalsefalse-1.33-1.33USD$falsetruefalse4truefalsefalse-1.45-1.45USD$falsetruefalse5truefalsefalse-20.98-20.98USD$falsetruefalsenum:perShareItemTypedecimalThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.No definition available.false3Basic and diluted net loss per common share12false 4us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDilutedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse2671700026717falsefalsefalse2truefalsefalse2574400025744falsefalsefalse3truefalsefalse2637700026377falsefalsefalse4truefalsefalse2389200023892falsefalsefalse5truefalsefalse1046000010460falsefalsefalsexbrli:sharesItemTypesharesAverage number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).No definition available.false1Basic and diluted weighted average common shares outstanding13false 4us-gaap_ComprehensiveIncomeNetOfTaxus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-19338000-19338USD$falsetruefalse2truefalsefalse-15661000-15661USD$falsetruefalse3truefalsefalse-35015000-35015USD$falsetruefalse4truefalsefalse-34658000-34658USD$falsetruefalse5truefalsefalse-219444000-219444USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Comprehensive Income -URI http://asc.fasb.org/extlink&oid=16317811 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e557-108580 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 false2Comprehensive lossfalseConsolidated Statements of Operations And Comprehensive Loss (USD $)ThousandsThousandsNoRoundingUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/StatementOfIncomeAlternative513 XML 36 R9.htm IDEA: XBRL DOCUMENT

Other Accrued Expenses

6 Months Ended

Jun. 30, 2013

Other Accrued Expenses

4. Other Accrued Expenses

Other accrued expenses are comprised of the following (in thousands):


	June 30, 2013		December 31, 2012
Accrued personnel costs	$	1,811	$	2,441
Accrued corporate legal fees and professional services		350		63
Accrued expenses – other		63		198

Other accrued expenses	$	2,224	$	2,702

XML 37 R28.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense, tax benefit recognized	$ 0	$ 0	$ 0	$ 0
Capitalized share-based compensation expense			0		0
Pretax intrinsic value, closing stock price	66.98		66.98
Unrecognized share-based compensation expense	$ 23,700,000		$ 23,700,000
Weighted average remaining vesting period			2 years 9 months 18 days

XML 38 R32.htm IDEA: XBRL DOCUMENT

Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share (Detail) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive shares	2,343	1,718	2,343	1,718
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive shares	2,343	1,718	2,343	1,718

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

XML 39 R24.xml IDEA: Other Accrued Expenses (Detail) 2.4.0.8125 - Disclosure - Other Accrued Expenses (Detail)truefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE807381--1310-Q0005_STD_0_20130630_0http://www.sec.gov/CIK0001466301instant2013-06-30T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE807381--1310-Q0005_STD_0_20121231_0http://www.sec.gov/CIK0001466301instant2012-12-31T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3clvs_AccruedLiabilitiesLineItemsclvs_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Accrued Liabilities [Line Items]2false 4us-gaap_EmployeeRelatedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse18110001811USD$falsetruefalse2truefalsefalse24410002441USD$falsetruefalsexbrli:monetaryItemTypemonetaryTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Accrued personnel costs3false 4us-gaap_AccruedProfessionalFeesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse350000350falsefalsefalse2truefalsefalse6300063falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765 false2Accrued corporate legal fees and professional services4false 4us-gaap_OtherAccruedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse6300063falsefalsefalse2truefalsefalse198000198falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765 false2Accrued expenses - other5false 4us-gaap_AccruedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse22240002224USD$falsetruefalse2truefalsefalse27020002702USD$falsetruefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 true2Other accrued expensesfalseOther Accrued Expenses (Detail) (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/DisclosureOtherAccruedExpenses25 XML 40 R10.xml IDEA: Convertible Promissory Notes 2.4.0.8111 - Disclosure - Convertible Promissory Notestruefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_DebtDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 5. Convertible Promissory Notes In May 2011, the Company issued $20.0 million of 5% Convertible Promissory Notes to existing investors for cash. In June 2011, the Company issued $15.0 million of 5% Convertible Promissory Notes to Pfizer, which was comprised of a $7.0 million note issued to acquire the global rights to develop and market rucaparib and an $8.0 million note issued for cash (the “Notes”). The Notes accrued interest at an annual rate of 5% and had a maturity date of May 25, 2012. In connection with the completion of the Company’s initial public offering in November 2011, the principal balance and all accrued and unpaid interest due on the Notes was converted into 2,757,788 shares of the Company’s common stock. </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20, 22 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20,22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false0Convertible Promissory NotesfalseConvertible Promissory NotesUnKnownUnKnownUnKnownUnKnowntruefalsefalseNoteshttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock11 XML 41 R5.xml IDEA: Consolidated Statements of Cash Flows 2.4.0.8106 - Statement - Consolidated Statements of Cash FlowstruefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE807381--1310-Q0005_STD_182_20120630_0http://www.sec.gov/CIK0001466301duration2012-01-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE807381--1310-Q0005_STD_1533_20130630_0http://www.sec.gov/CIK0001466301duration2009-04-20T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 4us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Operating activities2false 5us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-35009000-35009USD$falsetruefalse2truefalsefalse-34656000-34656USD$falsetruefalse3truefalsefalse-219491000-219491USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 false2Net loss3true 5us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Adjustments to reconcile net loss to net cash used in operating activities:4false 6us-gaap_Depreciationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse123000123falsefalsefalse2truefalsefalse176000176falsefalsefalse3truefalsefalse750000750falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Depreciation5false 6us-gaap_ShareBasedCompensationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse38720003872falsefalsefalse2truefalsefalse21140002114falsefalsefalse3truefalsefalse1021800010218falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Share-based compensation expense6false 6us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestmentsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2truefalsefalse1000010falsefalsefalse3truefalsefalse471000471falsefalsefalsexbrli:monetaryItemTypemonetaryThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Amortization of premiums and discounts on available for sale securities7false 6us-gaap_GainLossOnDispositionOfAssetsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse11620001162falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760 false2Loss on disposal of equipment8false 6us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNetus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-34000-34falsefalsefalsexbrli:monetaryItemTypemonetaryThis item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563 false2Gain on sale of available for sale securities9false 6clvs_NoncashAcquiredInProcessResearchAndDevelopmentclvs_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse70000007000falsefalsefalsexbrli:monetaryItemTypemonetaryNon-cash acquired in-process research and development.No definition available.false2Non-cash acquired in-process research and development10true 6us-gaap_IncreaseDecreaseInOperatingCapitalAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Changes in operating assets and liabilities:11false 7clvs_IncreaseDecreaseInPrepaidAndAccruedResearchAndDevelopmentExpensesclvs_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-165000-165falsefalsefalse2truefalsefalse19220001922falsefalsefalse3truefalsefalse68790006879falsefalsefalsexbrli:monetaryItemTypemonetaryPrepaid and accrued research and development expenses.No definition available.false2Prepaid and accrued research and development expenses12false 7us-gaap_IncreaseDecreaseInOtherOperatingAssetsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse121000121falsefalsefalse2truefalsefalse531000531falsefalsefalse3truefalsefalse-96000-96falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Other operating assets13false 7us-gaap_IncreaseDecreaseInAccountsPayableus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-755000-755falsefalsefalse2truefalsefalse-1655000-1655falsefalsefalse3truefalsefalse15430001543falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Accounts payable14false 7us-gaap_IncreaseDecreaseInOtherAccruedLiabilitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-474000-474falsefalsefalse2truefalsefalse-888000-888falsefalsefalse3truefalsefalse21330002133falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in other expenses incurred but not yet paid.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Other accrued expenses15false 5us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-32287000-32287falsefalsefalse2truefalsefalse-32446000-32446falsefalsefalse3truefalsefalse-189465000-189465falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 true2Net cash used in operating activities16true 4us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Investing activities17false 5us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-66000-66falsefalsefalse2truefalsefalse-908000-908falsefalsefalse3truefalsefalse-2610000-2610falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 false2Purchases of property and equipment18false 5us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebtus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-27008000-27008falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562 false2Purchases of available for sale securities19false 5us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse20000002000falsefalsefalse3truefalsefalse2657100026571falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585 false2Maturities and sales of available for sale securities20false 5us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-66000-66falsefalsefalse2truefalsefalse10920001092falsefalsefalse3truefalsefalse-3047000-3047falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585 true2Net cash provided by (used in) investing activities21true 4us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Financing activities22false 5clvs_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCostclvs_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse7549900075499falsefalsefalsexbrli:monetaryItemTypemonetaryProceeds from sale of convertible preferred stock, net of issuance costs.No definition available.false2Proceeds from sale of convertible preferred stock, net of issuance costs23false 5us-gaap_ProceedsFromIssuanceOfCommonStockus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse259146000259146falsefalsefalse2truefalsefalse6997600069976falsefalsefalse3truefalsefalse458481000458481falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow from the additional capital contribution to the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 false2Proceeds from sale of common stock, net of issuance costs24false 5us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse13680001368falsefalsefalse2truefalsefalse4200042falsefalsefalse3truefalsefalse28340002834falsefalsefalsexbrli:monetaryItemTypemonetaryThe total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 false2Proceeds from exercise of stock options and employee stock purchase plan25false 5clvs_ProceedsFromIssuanceOfConvertiblePromissoryNotesNetOfIssuanceCostsclvs_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse2790200027902falsefalsefalsexbrli:monetaryItemTypemonetaryProceeds from issuance of convertible promissory notes, net of issuance costs.No definition available.false2Proceeds from issuance of convertible promissory notes, net of issuance costs26false 5us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse260514000260514falsefalsefalse2truefalsefalse7001800070018falsefalsefalse3truefalsefalse564716000564716falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585 true2Net cash provided by financing activities27false 4us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-18000-18falsefalsefalse2truefalsefalse30003falsefalsefalse3truefalsefalse3600036falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906 false2Effect of exchange rate changes on cash and cash equivalents28false 4us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse228143000228143falsefalsefalse2truefalsefalse3866700038667falsefalsefalse3truefalsefalse372240000372240falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906 true2Increase in cash and cash equivalents29false 4us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse144097000144097falsefalsefalse2truefalsefalse138236000138236falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585 false2Cash and cash equivalents at beginning of period30false 4us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse372240000372240falsefalsefalse2truefalsefalse176903000176903falsefalsefalse3truefalsefalse372240000372240falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585 false2Cash and cash equivalents at end of period31true 4us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Non-cash items:32false 5us-gaap_ConversionOfStockAmountIssued1us-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse7549900075499falsefalsefalsexbrli:monetaryItemTypemonetaryThe value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 false2Conversion of convertible preferred stock to common stock33false 5us-gaap_DebtConversionConvertedInstrumentAmount1us-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse3585100035851falsefalsefalsexbrli:monetaryItemTypemonetaryThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 false2Conversion of convertible promissory notes and accrued interest to common stock34false 5clvs_AssetsRecordedForWhichPaymentHasNotYetOccurredclvs_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-39000-39USD$falsetruefalse2truefalsefalse-684000-684USD$falsetruefalse3truefalsefalse2400024USD$falsetruefalsexbrli:monetaryItemTypemonetaryAssets recorded for which payment has not yet occurred.No definition available.false2Assets recorded for which payment (has)/has not yet occurredfalseConsolidated Statements of Cash Flows (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/StatementOfCashFlowsIndirect334 EXCEL 42 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\P,61A860Q.%\V8SAB7S1A.3-?8F8Q,%\Q,V0Y M8S=D-61C,C,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O'!E;G-E#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQI8V5N#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DYE=%],;W-S7U!E#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N M9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I7 M;W)K#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D]T:&5R7T%C8W)U961?17AP96YS M97-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D%S#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D9I;F%N8VEA;%]);G-T#I7;W)K#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D-O;G9E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G9E#I7;W)K'!E;G,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7 M;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H965T&-E;"!84"!O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\P,61A860Q.%\V8SAB7S1A.3-?8F8Q,%\Q,V0Y8S=D-61C,C,-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#%D86%D,3A?-F,X8E\T83DS7V)F M,3!?,3-D.6,W9#5D8S(S+U=O'0O:'1M;#L@8VAA2!);F9O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA2!296=I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1087)T7S`Q9&%A9#$X7S9C.&)?-&$Y,U]B9C$P7S$S9#EC-V0U9&,R,PT* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P,61A860Q.%\V8SAB7S1A M.3-?8F8Q,%\Q,V0Y8S=D-61C,C,O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\P,61A860Q.%\V8SAB7S1A.3-?8F8Q,%\Q,V0Y8S=D-61C,C,-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#%D86%D,3A?-F,X8E\T83DS M7V)F,3!?,3-D.6,W9#5D8S(S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!A;F0@97%U:7!M96YT+"!N M970\+W1D/@T*("`@("`@("`\=&0@8VQA6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA3H\+W-T3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAAF5D/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P+#`P,#QS<&%N/CPO'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M/B@V-BD\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!N;W1E65T(&]C8W5R'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/C$N($YA='5R92!O9B!"=7-I;F5S"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#;&]V:7,-"D]N8V]L;V=Y+"!) M;F,N("AT:&4@)B-X,C`Q0SM#;VUP86YY)B-X,C`Q1#LI+"!A(&-O2!F;V-UFEN9R!I;FYO M=F%T:79E(&%N=&DM8V%N8V5R(&%G96YT2!H87,@86YD(&EN=&5N9',-"G1O(&-O;G1I;G5E('1O(&QI M8V5N&-H86YG92!F M;W(@=&AE(')I9VAT('1O(&1E=F5L;W`@86YD#0IC;VUM97)C:6%L:7IE('1H M97-E(&-O;7!O=6YD2!G96YEF%T:6]N(&-O2!C=7)R96YT;'D- M"F]P97)A=&5S(&EN(&]N92!S96=M96YT+B!3:6YC92!I;F-E<'1I;VXL('1H M92!#;VUP86YY)B-X,C`Q.3MS#0IO<&5R871I;VYS(&AA=F4@8V]N2!O9B!D979E;&]P:6YG(&EN+6QI8V5NF%T:6]N#0IA8W1I=FET M:65S+B!4:&4@0V]M<&%N>2!H87,@;F5V97(@96%R;F5D(')E=F5N=64@9G)O M;2!T:&5S90T*86-T:79I=&EE2!I$$P.S,P+"`R,#$S+CPO9F]N=#X\+W`^#0H\ M<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!X.R!-05)'24XM0D]45$]-.B`P M<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI/D)A6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/E1H92!I;F9O2!O=VYE9"!S=6)S M:61I87)Y(&]F('1H90T*0V]M<&%N>2P@8V]M;65N8V5D(&]P97)A=&EO;G,N M($%L;"!F:6YA;F-I86P@:6YF;W)M871I;VX@<')E$$P.S,Q+"`R,#$P('=A2X@06QL#0IS:6=N:69I8V%N="!I;G1E M$$P M.TEN8RX@:6YC;'5D960@:&5R96EN(')E9FQE8W0@86QL(&%D:G5S=&UE;G1S M+`T*8V]N2!B92!E>'!E8W1E9"!F;W(@=&AE(&9U;&P@>65A M0T*86-C97!T960@:6X@=&AE(%5N M:71E9"!3=&%T97,@;V8@06UE$$P.V%N9"!R96=U;&%T:6]N0T*979A;'5A=&5S('-U8G-E<75E;G0@979E;G1S('5P('1O('1H92!T:6UE M(&]F(&9I;&EN9R!W:71H('1H92!314,N#0I4:&5S92!F:6YA;F-I86P@#L@34%21TE. M+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3Y56QE/3-$)TU!4D=)3BU43U`Z M(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T* M/&9O;G0@'!E2!D:69F97(-"F9R;VT@=&AO6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI M/DQI<75I9&ET>3PO:3X\+V(^/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU! M4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E.R!-05)'24XM0D]45$]- M.B`P<'@G/@T*/&9O;G0@2!C M;VYT:6YU97,@=&\@:6YC=7(@;&]S2!O9F9E7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@#MM87)G M:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z-"4G/@T*/&9O;G0@3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P,61A860Q.%\V8SAB7S1A.3-?8F8Q M,%\Q,V0Y8S=D-61C,C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,#%D86%D,3A?-F,X8E\T83DS7V)F,3!?,3-D.6,W9#5D8S(S+U=O'0O:'1M;#L@8VAA M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/C,N($9I;F%N8VEA;"!);G-T6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@34%21TE.+4)/5%1/33H@,'!X M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CX\8CX\:3Y#87-H+"!#87-H#0I%<75I=F%L96YT6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!#;VUP M86YY#0IC;VYS:61E2!L:7%U:60@:6YV97-T;65N=',@ M=VET:"!O2!I;B!C97)T:69I8V%T92!O9@T*9&5P;W-I M=',L(&-O;6UE$$P.V=O=F5R;FUE;G0@86=E;F-Y(&]B;&EG871I;VYS M+B!#87-H(&5Q=6EV86QE;G1S(&%R90T*#L@ M34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#%P>"<^#0HF(WA!,#L\ M+W`^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[(%1%6%0M24Y$14Y4 M.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/DUAF5D(&=A:6YS#0IA;F0@;&]S6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/CQB/CQI/D9A:7(@5F%L=64@ M;V8-"D9I;F%N8VEA;"!);G-T6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E M.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/ M33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X03`[/"]P/@T*/'1A8FQE M('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DQE=F5L)B-X03`[,3H\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E%U;W1E M9"!P6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/DQE=F5L)B-X03`[ M,CH\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]B6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DQE M=F5L)B-X03`[,SH\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/E5N;V)S97)V86)L92!I;G!U=',@ M=&AA="!A2!D;V5S(&YO="!H879E($QE=F5L(#,@87-S M971S(&]R#0IL:6%B:6QI=&EE#L@5$585"U)3D1% M3E0Z(#0E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@28C>#(P,3D[ M#L@1D].5"U325I%.B`Q,G!X)SX-"B8C>$$P.SPO<#X-"CQT86)L92!S M='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!B;W)D97(],T0P M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`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`P,#`@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]LF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`M M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY-;VYE>2!M87)K970\ M+V9O;G0^/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-#6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXQ-#6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/"]T"<^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO M<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO M=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T M9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D M/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X- M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^ M#0H\=&0^)B-X03`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`[)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^ M#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<#X-"CQP('-T>6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CX\8CY$96-E;6)E$$P.S,Q+`T*,C`Q,CPO8CX\+V9O;G0^/"]P/@T* M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`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`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^ M#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P/@T*/'`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`[)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO M=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z M(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX- M"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H97)E('=E$$P.S,P+"`R,#$S+CPO9F]N=#X\+W`^#0H\ M+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;G-E#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CXT+B!/=&AE'!E;G-E"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY/=&AE'!E;G-E6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%2 M1TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X03`[/"]P M/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,P+"8C>$$P M.S(P,3,\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D1E8V5M8F5R)B-X03`[,S$L)B-X03`[,C`Q,CPO M8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)U1% M6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY! M8V-R=65D('!E6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXQ+#@Q,3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`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`Q,SL-"F]T:&5R M/"]F;VYT/CPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV,SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`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`@ M$$P M.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X- M"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#(R-#PO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*/"]T"<^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P M,61A860Q.%\V8SAB7S1A.3-?8F8Q,%\Q,V0Y8S=D-61C,C,-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#%D86%D,3A?-F,X8E\T83DS7V)F,3!? M,3-D.6,W9#5D8S(S+U=O'0O:'1M;#L@8VAA2!.;W1E'0^/&1I=CX-"CQP('-T>6QE/3-$;6%R9VEN M+71O<#HQ.'!X.VUA6QE/3-$)V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@0T*3F]T97,\+V(^/"]F;VYT/CPO<#X-"CQP M('-T>6QE/3-$)VUA3I4 M:6UEF4],T0R/DEN($UA>2`R,#$Q+"!T:&4-"D-O M;7!A;GD@:7-S=65D("0R,"XP)B-X03`[;6EL;&EO;B!O9B`U)28C>$$P.T-O M;G9E0T*:7-S M=65D("0Q-2XP)B-X03`[;6EL;&EO;B!O9B`U)2!#;VYV97)T:6)L92!0#(P,40[*2X@5&AE#0I.;W1E0T*9&%T92!O9B!-87DF(WA!,#LR-2P@,C`Q,BX@26X@ M8V]N;F5C=&EO;B!W:71H('1H92!C;VUP;&5T:6]N(&]F('1H90T*0V]M<&%N M>28C>#(P,3D[7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@'0M:6YD96YT.C0E)SX-"CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@2!I2X@07,@;V8@ M2G5N928C>$$P.S,P+"`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`R,#`Y+"!T:&4-"D-O;7!A;GD@96YT97)E9"!I;G1O('1H92!3 M97)I97,F(WA!,#M!+3$L($$M,BP@0B!A;F0@0R!0#(P,4,[4')E9F5R$$P.VUI;&QI;VX@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@8V]N M=F5R=&EB;&4@<')E9F5R'0M:6YD96YT.C0E)SX-"CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@28C>#(P,3D[2!P'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/&1I=CX-"CQP('-T M>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P>"<^ M/&9O;G0@"<^#0H\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY3 M:&%R92UB87-E9`T*8V]M<&5N65E('-T;V-K('!U`T*;6]N=&AS(&5N9&5D($IU;F4F(WA!,#LS,"P@,C`Q M,R!A;F0@,C`Q,BP@6EN9R!#;VYS;VQI9&%T960@4W1A=&5M96YT6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%2 M1TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X03`[/"]P M/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P$$P.TUO M;G1H$$P.T5N9&5D)B-X03`[2G5N928C>$$P.S,P+#PO8CX\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0Q/CQB/C(P,3,\+V(^/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q M/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0Q/CQB/C(P,3(\+V(^/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L,3`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`S,CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE/3-$)U1% M6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY' M96YE6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L,#`U/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C4W-CPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXQ+#DQ-3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#`X,CPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`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`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF M(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^ M)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT M9#XF(WA!,#L\+W1D/@T*/"]T"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!D:60-"FYO="!R96-O M9VYI>F4@82!T87@@8F5N969I="!R96QA=&5D('1O('-H87)E+6)A2P@87,@=&AE($-O;7!A;GD@;6%I;G1A:6YS(&YE="!O<&5R M871I;F<@;&]S$$P.S,P+"`R,#$S M+B!.;PT*F5D(&]N(&]U<@T*0V]N6QE/3-$)TU!4D=)3BU43U`Z M(#$R<'@[(%1%6%0M24Y$14Y4.B`T)3L@34%21TE.+4)/5%1/33H@,'!X)SX- M"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!F;VQL;W=I;F<-"G1A8FQE('-U;6UA"!M M;VYT:"!P97)I;V0@96YD960-"DIU;F4F(WA!,#LS,"P@,C`Q,SH\+V9O;G0^ M/"]P/@T*/'`@"<^#0HF(WA!,#L\+W`^#0H\=&%B M;&4@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1EF4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`M,65M.R!-05)' M24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY"86QA;F-E(&%T#0I$96-E;6)E$$P.S,Q+"`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`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`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE XML 43 R4.xml IDEA: Consolidated Balance Sheets (Parenthetical) 2.4.0.8105 - Statement - Consolidated Balance Sheets (Parenthetical)truefalsefalse1false USDfalsefalse$eol_PE807381--1310-Q0005_STD_0_20130630_0http://www.sec.gov/CIK0001466301instant2013-06-30T00:00:000001-01-01T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0USDUSD$2false USDfalsefalse$eol_PE807381--1310-Q0005_STD_0_20121231_0http://www.sec.gov/CIK0001466301instant2012-12-31T00:00:000001-01-01T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0USDUSD$1false 4us-gaap_PreferredStockParOrStatedValuePerShareus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse0.0010.001USD$falsetruefalse2truefalsefalse0.0010.001USD$falsetruefalsenum:perShareItemTypedecimalFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false3Preferred stock, par value2false 4us-gaap_PreferredStockSharesAuthorizedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse1000000010000000falsefalsefalse2truefalsefalse1000000010000000falsefalsefalsexbrli:sharesItemTypesharesThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false1Preferred stock, shares authorized3false 4us-gaap_PreferredStockSharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00falsefalsefalse2truefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false1Preferred stock, shares issued4false 4us-gaap_PreferredStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00falsefalsefalse2truefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false1Preferred stock, shares outstanding5false 4us-gaap_CommonStockParOrStatedValuePerShareus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse0.0010.001USD$falsetruefalse2truefalsefalse0.0010.001USD$falsetruefalsenum:perShareItemTypedecimalFace amount or stated value per share of common stock.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false3Common stock, par value6false 4us-gaap_CommonStockSharesAuthorizedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse100000000100000000falsefalsefalse2truefalsefalse100000000100000000falsefalsefalsexbrli:sharesItemTypesharesThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Common stock, shares authorized7false 4us-gaap_CommonStockSharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse3016981530169815falsefalsefalse2truefalsefalse2620719026207190falsefalsefalsexbrli:sharesItemTypesharesTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Common stock, shares issued8false 4us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse3016981530169815falsefalsefalse2truefalsefalse2620719026207190falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1Common stock, shares outstandingfalseConsolidated Balance Sheets (Parenthetical) (USD $)UnKnownNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical28 XML 44 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 HtmlAndXml 62 151 1 false 26 0 false 4 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.clovisoncology.com/taxonomy/role/DocumentDocumentandEntityInformation Document and Entity Information R1.xml false false R2.htm 103 - Statement - Consolidated Statements of Operations And Comprehensive Loss Sheet http://www.clovisoncology.com/taxonomy/role/StatementOfIncomeAlternative Consolidated Statements of Operations And Comprehensive Loss R2.xml true false R3.htm 104 - Statement - Consolidated Balance Sheets Sheet http://www.clovisoncology.com/taxonomy/role/StatementOfFinancialPositionClassified Consolidated Balance Sheets R3.xml false false R4.htm 105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.clovisoncology.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Consolidated Balance Sheets (Parenthetical) R4.xml false false R5.htm 106 - Statement - Consolidated Statements of Cash Flows Sheet http://www.clovisoncology.com/taxonomy/role/StatementOfCashFlowsIndirect Consolidated Statements of Cash Flows R5.xml false false R6.htm 107 - Disclosure - Nature of Business and Basis of Presentation Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Nature of Business and Basis of Presentation R6.xml false false R7.htm 108 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies R7.xml false false R8.htm 109 - Disclosure - Financial Instruments and Fair Value Measurement Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Financial Instruments and Fair Value Measurement R8.xml false false R9.htm 110 - Disclosure - Other Accrued Expenses Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Other Accrued Expenses R9.xml false false R10.htm 111 - Disclosure - Convertible Promissory Notes Notes http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Convertible Promissory Notes R10.xml false false R11.htm 112 - Disclosure - Convertible Preferred Stock and Stockholders' Equity Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Convertible Preferred Stock and Stockholders' Equity R11.xml false false R12.htm 113 - Disclosure - Share-Based Compensation Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Share-Based Compensation R12.xml false false R13.htm 114 - Disclosure - License Agreements Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementsTextBlock License Agreements R13.xml false false R14.htm 115 - Disclosure - Net Loss Per Share Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Loss Per Share R14.xml false false R15.htm 116 - Disclosure - Commitments and Contingencies Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies R15.xml false false R16.htm 117 - Disclosure - Subsequent Events Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events R16.xml false false R17.htm 118 - Disclosure - Nature of Business and Basis of Presentation (Policies) Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies Nature of Business and Basis of Presentation (Policies) R17.xml false false R18.htm 119 - Disclosure - Financial Instruments and Fair Value Measurement (Tables) Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Financial Instruments and Fair Value Measurement (Tables) R18.xml false false R19.htm 120 - Disclosure - Other Accrued Expenses (Tables) Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Other Accrued Expenses (Tables) R19.xml false false R20.htm 121 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Share-Based Compensation (Tables) R20.xml false false R21.htm 122 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net Loss Per Share (Tables) R21.xml false false R22.htm 123 - Disclosure - Assets Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureAssetsMeasuredAtFairValueOnRecurringBasis Assets Measured at Fair Value on Recurring Basis (Detail) R22.xml false false R23.htm 124 - Disclosure - Financial Instruments and Fair Value Measurement - Additional Information (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementAdditionalInformation Financial Instruments and Fair Value Measurement - Additional Information (Detail) R23.xml false false R24.htm 125 - Disclosure - Other Accrued Expenses (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureOtherAccruedExpenses Other Accrued Expenses (Detail) R24.xml false false R25.htm 126 - Disclosure - Convertible Promissory Notes - Additional Information (Detail) Notes http://www.clovisoncology.com/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformation Convertible Promissory Notes - Additional Information (Detail) R25.xml false false R26.htm 127 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Additional Information (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformation Convertible Preferred Stock and Stockholders' Equity - Additional Information (Detail) R26.xml false false R27.htm 128 - Disclosure - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureShareBasedCompensationExpenseRecognizedInAccompanyingStatementsOfOperations Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) R27.xml false false R28.htm 129 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformation Share-Based Compensation - Additional Information (Detail) R28.xml false false R29.htm 130 - Disclosure - Summary of Stock Options Activity (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureSummaryOfStockOptionsActivity Summary of Stock Options Activity (Detail) R29.xml false false R30.htm 131 - Disclosure - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAward Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) R30.xml false false R31.htm 132 - Disclosure - License Agreements - Additional Information (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformation License Agreements - Additional Information (Detail) R31.xml false false R32.htm 133 - Disclosure - Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureSharesOutstandingExcludedFromCalculationOfDilutedNetLossPerShare Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share (Detail) R32.xml false false R33.htm 134 - Disclosure - Commitments And Contingencies - Additional Information (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments And Contingencies - Additional Information (Detail) R33.xml false false All Reports Book All Reports Element clvs_InLicensingArrangementCostsUpFrontPayment had a mix of decimals attribute values: -5 0. Element us-gaap_PrepaidExpenseCurrent had a mix of decimals attribute values: -5 -3. Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -5 -3. Element us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff had a mix of decimals attribute values: -5 -3. 'Monetary' elements on report '127 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - Consolidated Statements of Operations And Comprehensive Loss Process Flow-Through: 104 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Jun. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 105 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 106 - Statement - Consolidated Statements of Cash Flows clvs-20130630.xml clvs-20130630.xsd clvs-20130630_cal.xml clvs-20130630_def.xml clvs-20130630_lab.xml clvs-20130630_pre.xml true true XML 45 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 372,240	$ 144,097
Prepaid research and development expenses	605	116
Other current assets	598	659
Total current assets	373,443	144,872
Property and equipment, net	1,030	1,084
Other assets	751	38
Total assets	375,224	145,994
Current liabilities:
Accounts payable	1,589	2,297
Accrued research and development expenses	8,199	7,161
Other accrued expenses	2,224	2,702
Total current liabilities	12,012	12,160
Non-current liabilities	211	338
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2013 and December 31, 2012
Common stock, $0.001 par value per share, 100,000,000 shares authorized at June 30, 2013 and December 31, 2012; 30,169,815 and 26,207,190 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively	30	26
Additional paid-in capital	582,415	317,899
Accumulated other comprehensive income	47	53
Deficit accumulated during development stage	(219,491)	(184,482)
Total stockholders' equity	363,001	133,496
Total liabilities and stockholders' equity	$ 375,224	$ 145,994

XML 46 R14.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

6 Months Ended

Jun. 30, 2013

Net Loss Per Share

9. Net Loss Per Share


	Three and Six Months Ended June 30,
	2013		2012
Common shares under option		2,343		1,718

Total potential dilutive shares		2,343		1,718

- Definition

The entire disclosure for earnings per share.

+ References+ Details

XML 47 R20.xml IDEA: Share-Based Compensation (Tables) 2.4.0.8121 - Disclosure - Share-Based Compensation (Tables)truefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Share-based compensation expense for all equity based programs, including stock options and the employee stock purchase plan, for the three and six months ended June 30, 2013 and 2012, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="68%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,103</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">592</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,957</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,032</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,005</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">576</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,915</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,082</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total share-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,108</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,168</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,872</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,114</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Share-Based Compensation Expense Recognized in Accompanying Statements of Operations2false 4us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> The following table summarizes the activity relating to the Company’s options to purchase common stock for the six month period ended June 30, 2013:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="56%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Option  Shares Outstanding</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Weighted- Average Remaining Contractual Term (Years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,599,044</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14.05</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,046,158</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28.53</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(130,732</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.09</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(29,400</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16.75</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,485,070</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20.38</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.79</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">116,427,809</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Vested and expected to vest at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,261,717</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19.90</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.72</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">107,015,622</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Vested at June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">721,162</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.84</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40,368,071</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Summary of Stock Options Activity3false 4us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $66.98 as of June 30, 2013, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Weighted-average grant-date fair value per share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">43.22</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12.60</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Intrinsic value of options exercised </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,540,488</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">162,845</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Cash received from stock option exercises </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,101,935</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32,108</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Weighted-average grant-date fair value per share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17.61</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15.02</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> Intrinsic value of options exercised </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,716,374</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">223,319</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Cash received from stock option exercises </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,188,312</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">42,149</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Schedule of Share-Based Compensation Arrangements by Share-Based Payment AwardfalseShare-Based Compensation (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables13 XML 48 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	6 Months Ended		50 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Operating activities
Net loss	$ (35,009)	$ (34,656)	$ (219,491)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	123	176	750
Share-based compensation expense	3,872	2,114	10,218
Amortization of premiums and discounts on available for sale securities		10	471
Loss on disposal of equipment			1,162
Gain on sale of available for sale securities			(34)
Non-cash acquired in-process research and development			7,000
Changes in operating assets and liabilities:
Prepaid and accrued research and development expenses	(165)	1,922	6,879
Other operating assets	121	531	(96)
Accounts payable	(755)	(1,655)	1,543
Other accrued expenses	(474)	(888)	2,133
Net cash used in operating activities	(32,287)	(32,446)	(189,465)
Investing activities
Purchases of property and equipment	(66)	(908)	(2,610)
Purchases of available for sale securities			(27,008)
Maturities and sales of available for sale securities		2,000	26,571
Net cash provided by (used in) investing activities	(66)	1,092	(3,047)
Financing activities
Proceeds from sale of convertible preferred stock, net of issuance costs			75,499
Proceeds from sale of common stock, net of issuance costs	259,146	69,976	458,481
Proceeds from exercise of stock options and employee stock purchase plan	1,368	42	2,834
Proceeds from issuance of convertible promissory notes, net of issuance costs			27,902
Net cash provided by financing activities	260,514	70,018	564,716
Effect of exchange rate changes on cash and cash equivalents	(18)	3	36
Increase in cash and cash equivalents	228,143	38,667	372,240
Cash and cash equivalents at beginning of period	144,097	138,236
Cash and cash equivalents at end of period	372,240	176,903	372,240
Non-cash items:
Conversion of convertible preferred stock to common stock			75,499
Conversion of convertible promissory notes and accrued interest to common stock			35,851
Assets recorded for which payment (has)/has not yet occurred	$ (39)	$ (684)	$ 24

XML 49 R2.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations And Comprehensive Loss (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended		50 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Revenues
Operating Expenses:
Research and development	15,816	12,590	27,938	25,152	151,643
General and administrative	3,492	2,680	6,710	5,105	30,719
Acquired in-process research and development		250	250	4,250	36,585
Operating loss	(19,308)	(15,520)	(34,898)	(34,507)	(218,947)
Other income (expense), net	(33)	(172)	(111)	(176)	(544)
Loss before income taxes	(19,341)	(15,692)	(35,009)	(34,683)	(219,491)
Income taxes		35		27
Net loss	(19,341)	(15,657)	(35,009)	(34,656)	(219,491)
Basic and diluted net loss per common share	$ (0.72)	$ (0.61)	$ (1.33)	$ (1.45)	$ (20.98)
Basic and diluted weighted average common shares outstanding	26,717	25,744	26,377	23,892	10,460
Comprehensive loss	$ (19,338)	$ (15,661)	$ (35,015)	$ (34,658)	$ (219,444)

XML 50 R7.xml IDEA: Summary of Significant Accounting Policies 2.4.0.8108 - Disclosure - Summary of Significant Accounting Policiestruefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_SignificantAccountingPoliciesTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 2. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2 of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for all significant accounting policies of the reporting entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790 false0Summary of Significant Accounting PoliciesfalseSummary of Significant Accounting PoliciesUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock11 XML 51 R17.xml IDEA: Nature of Business and Basis of Presentation (Policies) 2.4.0.8118 - Disclosure - Nature of Business and Basis of Presentation (Policies)truefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4clvs_BasisOfPresentationPolicyTextBlockclvs_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Basis of Presentation The information reported within the Company’s financial statements from April 20, 2009 to December 31, 2010 was based solely on the accounts of Clovis Oncology, Inc. Effective January 1, 2011, Clovis Oncology UK Limited, a wholly owned subsidiary of the Company, commenced operations. All financial information presented after December 31, 2010 was consolidated and includes the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Changes in or reclassifications out of accumulated other comprehensive loss are not disclosed in our notes to the unaudited financial statements due to the insignificance of the activity. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial information prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. The Company evaluates subsequent events up to the time of filing with the SEC. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2012 for a broader discussion of our business and the opportunities and risks inherent in such business. </div>falsefalsefalsenonnum:textBlockItemTypenaBasis of presentation.No definition available.false0Basis of Presentation2false 4us-gaap_UseOfEstimatesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Use of Estimates The preparation of these unaudited consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, other comprehensive loss and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to clinical trial accruals and share-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. </div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592 false0Use of Estimates3false 4us-gaap_LiquidityDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Liquidity The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through public and private equity financings, and management expects operating losses and negative cash flows to continue for at least the next several years. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless or until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through cash and investments on hand and additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. </div>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.No definition available.false0LiquidityfalseNature of Business and Basis of Presentation (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies13 XML 52 R16.xml IDEA: Subsequent Events 2.4.0.8117 - Disclosure - Subsequent Eventstruefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_SubsequentEventsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 11. Subsequent Events The Company evaluated events up to the filing date of these interim financial statements and determined that no subsequent activity required disclosure. </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.No definition available.false0Subsequent EventsfalseSubsequent EventsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock11 XML 53 R27.xml IDEA: Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) 2.4.0.8128 - Disclosure - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail)truefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE807381--1310-Q0005_STD_91_20130630_0http://www.sec.gov/CIK0001466301duration2013-04-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE807381--1310-Q0005_STD_91_20120630_0http://www.sec.gov/CIK0001466301duration2012-04-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$eol_PE807381--1310-Q0005_STD_182_20120630_0http://www.sec.gov/CIK0001466301duration2012-01-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDfalsefalse$eol_PE807381--1310-Q0005_STD_1533_20130630_0http://www.sec.gov/CIK0001466301duration2009-04-20T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Share-based Compensation Arrangement by Share-based Payment Award [Line Items]2false 4us-gaap_ShareBasedCompensationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse21080002108USD$falsetruefalse2truefalsefalse11680001168USD$falsetruefalse3truefalsefalse38720003872USD$falsetruefalse4truefalsefalse21140002114USD$falsetruefalse5truefalsefalse1021800010218USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Share-based compensation expense3false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6false USDtruefalse$eol_PE807381--1310-Q0005_STD_91_20130630_0_712080x713040http://www.sec.gov/CIK0001466301duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseResearch and Development Expenseus-gaap_IncomeStatementLocationAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_IncomeStatementLocationAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Research and Development Expense4true 3us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Share-based Compensation Arrangement by Share-based Payment Award [Line Items]5false 4us-gaap_ShareBasedCompensationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse11030001103USD$falsefalsefalse2truefalsefalse592000592USD$falsefalsefalse3truefalsefalse19570001957USD$falsefalsefalse4truefalsefalse10320001032USD$falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Share-based compensation expense6false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse10false USDtruefalse$eol_PE807381--1310-Q0005_STD_91_20130630_0_712080x707836http://www.sec.gov/CIK0001466301duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseGeneral and Administrative Expenseus-gaap_IncomeStatementLocationAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_GeneralAndAdministrativeExpenseMemberus-gaap_IncomeStatementLocationAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0General and Administrative Expense7true 3us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Share-based Compensation Arrangement by Share-based Payment Award [Line Items]8false 4us-gaap_ShareBasedCompensationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse10050001005USD$falsetruefalse2truefalsefalse576000576USD$falsetruefalse3truefalsefalse19150001915USD$falsetruefalse4truefalsefalse10820001082USD$falsetruefalse5falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 false2Share-based compensation expensefalseShare-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/DisclosureShareBasedCompensationExpenseRecognizedInAccompanyingStatementsOfOperations58 XML 54 R18.xml IDEA: Financial Instruments and Fair Value Measurement (Tables) 2.4.0.8119 - Disclosure - Financial Instruments and Fair Value Measurement (Tables)truefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> The following table identifies the Company’s assets that were measured at fair value on a recurring basis (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="70%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Balance</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> June 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> Money market </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Total assets at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">147,985</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Money market </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total assets at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">135,385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19190-110258 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false0Assets Measured at Fair Value on Recurring BasisfalseFinancial Instruments and Fair Value Measurement (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables11 XML 55 R3.xml IDEA: Consolidated Balance Sheets 2.4.0.8104 - Statement - Consolidated Balance SheetstruefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE807381--1310-Q0005_STD_0_20130630_0http://www.sec.gov/CIK0001466301instant2013-06-30T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE807381--1310-Q0005_STD_0_20121231_0http://www.sec.gov/CIK0001466301instant2012-12-31T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 5us-gaap_AssetsCurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Current assets:2false 6us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse372240000372240USD$falsetruefalse2truefalsefalse144097000144097USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585 false2Cash and cash equivalents3false 6us-gaap_PrepaidExpenseCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse605000605falsefalsefalse2truefalsefalse116000116falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Assets -URI http://asc.fasb.org/extlink&oid=6509628 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 05 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6386993&loc=d3e5879-108316 false2Prepaid research and development expenses4false 6us-gaap_OtherAssetsCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse598000598falsefalsefalse2truefalsefalse659000659falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 8 -Article 5 false2Other current assets5false 6us-gaap_AssetsCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse373443000373443falsefalsefalse2truefalsefalse144872000144872falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 9 -Article 5 true2Total current assets6false 5us-gaap_PropertyPlantAndEquipmentNetus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse10300001030falsefalsefalse2truefalsefalse10840001084falsefalsefalsexbrli:monetaryItemTypemonetaryAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7 false2Property and equipment, net7false 5us-gaap_OtherAssetsNoncurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse751000751falsefalsefalse2truefalsefalse3800038falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 17 -Article 5 false2Other assets8false 5us-gaap_Assetsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse375224000375224falsefalsefalse2truefalsefalse145994000145994falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 true2Total assets9true 5us-gaap_LiabilitiesCurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Current liabilities:10false 6us-gaap_AccountsPayableCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse15890001589falsefalsefalse2truefalsefalse22970002297falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Accounts payable11false 6clvs_AccruedResearchAndDevelopmentExpensesclvs_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse81990008199falsefalsefalse2truefalsefalse71610007161falsefalsefalsexbrli:monetaryItemTypemonetaryAccrued research and development expensesNo definition available.false2Accrued research and development expenses12false 6us-gaap_AccruedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse22240002224falsefalsefalse2truefalsefalse27020002702falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Other accrued expenses13false 6us-gaap_LiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse1201200012012falsefalsefalse2truefalsefalse1216000012160falsefalsefalsexbrli:monetaryItemTypemonetaryTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 21 -Article 5 true2Total current liabilities14false 5us-gaap_LiabilitiesNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse211000211falsefalsefalse2truefalsefalse338000338falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of obligation due after one year or beyond the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22-26) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22, 23, 24, 25, 26, 27 -Article 5 false2Non-current liabilities15false 5us-gaap_CommitmentsAndContingenciesus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  falsefalsefalse2falsefalsefalse00  falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 25 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 7 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 17 -Article 9 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.(a),19) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 false2Commitments and contingencies (Note 10)16true 5us-gaap_StockholdersEquityAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Stockholders' equity:17false 6us-gaap_PreferredStockValueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00  falsefalsefalse2falsefalsefalse00  falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false2Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2013 and December 31, 201218false 6us-gaap_CommonStockValueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse3000030falsefalsefalse2truefalsefalse2600026falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false2Common stock, $0.001 par value per share, 100,000,000 shares authorized at June 30, 2013 and December 31, 2012; 30,169,815 and 26,207,190 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively19false 6us-gaap_AdditionalPaidInCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse582415000582415falsefalsefalse2truefalsefalse317899000317899falsefalsefalsexbrli:monetaryItemTypemonetaryExcess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Additional paid-in capital20false 6us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse4700047falsefalsefalse2truefalsefalse5300053falsefalsefalsexbrli:monetaryItemTypemonetaryAccumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669686-108580 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e681-108580 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 false2Accumulated other comprehensive income21false 6us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-219491000-219491falsefalsefalse2truefalsefalse-184482000-184482falsefalsefalsexbrli:monetaryItemTypemonetaryCumulative net losses reported during the development stage.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 210 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921 false2Deficit accumulated during development stage22false 6us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse363001000363001falsefalsefalse2truefalsefalse133496000133496falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 true2Total stockholders' equity23false 5us-gaap_LiabilitiesAndStockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse375224000375224USD$falsetruefalse2truefalsefalse145994000145994USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.32) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 32 -Article 5 true2Total liabilities and stockholders' equityfalseConsolidated Balance Sheets (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/StatementOfFinancialPositionClassified223 XML 56 R29.htm IDEA: XBRL DOCUMENT

Summary of Stock Options Activity (Detail) (USD $)	6 Months Ended
Summary of Stock Options Activity (Detail) (USD $)	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Option Shares Outstanding	1,599,044
Granted, Option Shares Outstanding	1,046,158
Exercised, Option Shares Outstanding	(130,732)
Forfeited, Option Shares Outstanding	(29,400)
Ending Balance, Option Shares Outstanding	2,485,070
Vested and expected to vest, Option Shares Outstanding	2,261,717
Vested, Option Shares Outstanding	721,162
Beginning Balance, Weighted Average Exercise Price	$ 14.05
Granted, Weighted Average Exercise Price	$ 28.53
Exercised, Weighted Average Exercise Price	$ 9.09
Forfeited, Weighted Average Exercise Price	$ 16.75
Ending Balance, Weighted Average Exercise Price	$ 20.38
Vested and expected to vest, Weighted Average Exercise Price	$ 19.90
Vested, Weighted Average Exercise Price	$ 11.00
Outstanding, Weighted Average Remaining Contractual Term (Years)	8 years 9 months 15 days
Vested and expected to vest, Weighted Average Remaining Contractual Term (Years)	8 years 8 months 19 days
Vested, Weighted Average Remaining Contractual Term (Years)	7 years 10 months 2 days
Outstanding, Aggregate Intrinsic Value	$ 116,427,809
Vested and expected to vest, Aggregate Intrinsic Value	107,015,622
Vested, Aggregate Intrinsic Value	$ 40,368,071

XML 57 R23.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value Measurement - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Security transfers between Levels 1 and 2	$ 0

XML 58 R31.xml IDEA: License Agreements - Additional Information (Detail) 2.4.0.8132 - Disclosure - License Agreements - Additional Information (Detail)truefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_30_20111130_0http://www.sec.gov/CIK0001466301duration2011-11-01T00:00:002011-11-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares02false USDfalsefalse$eol_PE807381--1310-Q0005_STD_91_20120630_0http://www.sec.gov/CIK0001466301duration2012-04-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170pureStandardhttp://www.xbrl.org/2003/instancepure0USDUSD$4false USDfalsefalse$eol_PE807381--1310-Q0005_STD_182_20120630_0http://www.sec.gov/CIK0001466301duration2012-01-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDfalsefalse$eol_PE807381--1310-Q0005_STD_1533_20130630_0http://www.sec.gov/CIK0001466301duration2009-04-20T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170pureStandardhttp://www.xbrl.org/2003/instancepure0USDUSD$6false USDfalsefalse$eol_PE807381--1310-Q0005_STD_0_20121231_0http://www.sec.gov/CIK0001466301instant2012-12-31T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false USDtruefalse$eol_PE807381--1310-Q0005_STD_30_20111130_0_806085x812964http://www.sec.gov/CIK0001466301duration2011-11-01T00:00:002011-11-30T00:00:00falsefalseLicense Agreements Licensor Pfizerclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorPfizerMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8false USDtruefalse$eol_PE807381--1310-Q0005_STD_30_20101130_0_774639x767051_806085x742042_842551x712753http://www.sec.gov/CIK0001466301duration2010-11-01T00:00:002010-11-30T00:00:00falsefalseLicense Agreement Termsclvs_LicenseAgreementLicenseTermsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LicenseAgreementTermsMemberclvs_LicenseAgreementLicenseTermsAxisexplicitMemberfalsefalseLicense Agreements Licensor Clavis Pharmaclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorClavisPharmaMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMemberfalsefalseCO-101clvs_LicenseAgreementsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsCoOneZeroOneMemberclvs_LicenseAgreementsTypeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9false USDtruefalse$eol_PE807381--1310-Q0005_STD_181_20130630_0_774639x786515_806085x744360_842551x712753http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseLicense Agreement Termsclvs_LicenseAgreementLicenseTermsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LicenseAgreementTermsMemberclvs_LicenseAgreementLicenseTermsAxisexplicitMemberfalsefalseLicense Agreements Licensor Avila Therapeuticsclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorAvilaTherapeuticsMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMemberfalsefalseCO-1686clvs_LicenseAgreementsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsCoOneSixEightSixMemberclvs_LicenseAgreementsTypeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10false USDtruefalse$eol_PE807381--1310-Q0005_STD_181_20130630_0_774639x837520_806085x812964_842551x712753http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseLicense Agreement Termsclvs_LicenseAgreementLicenseTermsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LicenseAgreementTermsMemberclvs_LicenseAgreementLicenseTermsAxisexplicitMemberfalsefalseLicense Agreements Licensor Pfizerclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorPfizerMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMemberfalsefalseRucaparibclvs_LicenseAgreementsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsRucaparibMemberclvs_LicenseAgreementsTypeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11false USDtruefalse$eol_PE807381--1310-Q0005_STD_30_20120430_0_774639x837520_806085x810873_842551x712753http://www.sec.gov/CIK0001466301duration2012-04-01T00:00:002012-04-30T00:00:00falsefalseLicense Agreement Termsclvs_LicenseAgreementLicenseTermsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LicenseAgreementTermsMemberclvs_LicenseAgreementLicenseTermsAxisexplicitMemberfalsefalseLicense Agreements Licensor Astra Zeneca U K Ltdclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorAstraZenecaUKLtdMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMemberfalsefalseRucaparibclvs_LicenseAgreementsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsRucaparibMemberclvs_LicenseAgreementsTypeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12false USDtruefalse$eol_PE807381--1310-Q0005_STD_31_20120731_0_774639x735415_806085x756559_842551x712753http://www.sec.gov/CIK0001466301duration2012-07-01T00:00:002012-07-31T00:00:00falsefalseLicense Agreement Termsclvs_LicenseAgreementLicenseTermsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LicenseAgreementTermsMemberclvs_LicenseAgreementLicenseTermsAxisexplicitMemberfalsefalseLicense Agreements Licensor Array Bio Pharma Incclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorArrayBioPharmaIncMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMemberfalsefalseLicense Agreements KITclvs_LicenseAgreementsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsKITMemberclvs_LicenseAgreementsTypeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$13false USDtruefalse$eol_PE807381--1310-Q0005_STD_30_20091130_0_774639x767051_790417x831248_806085x742042http://www.sec.gov/CIK0001466301duration2009-11-01T00:00:002009-11-30T00:00:00falsefalseUp-front license paymentclvs_LicenseAgreementsPaymentTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_UpFrontLicensePaymentMemberclvs_LicenseAgreementsPaymentTypeAxisexplicitMemberfalsefalseLicense Agreements Licensor Clavis Pharmaclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorClavisPharmaMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMemberfalsefalseCO-101clvs_LicenseAgreementsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsCoOneZeroOneMemberclvs_LicenseAgreementsTypeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$14false truefalseeol_PE807381--1310-Q0005_STD_0_20110630_0_774639x837520_790417x831248_806085x812964http://www.sec.gov/CIK0001466301instant2011-06-30T00:00:000001-01-01T00:00:00falsefalseUp-front license paymentclvs_LicenseAgreementsPaymentTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_UpFrontLicensePaymentMemberclvs_LicenseAgreementsPaymentTypeAxisexplicitMemberfalsefalseLicense Agreements Licensor Pfizerclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorPfizerMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMemberfalsefalseRucaparibclvs_LicenseAgreementsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsRucaparibMemberclvs_LicenseAgreementsTypeAxisexplicitMemberpureStandardhttp://www.xbrl.org/2003/instancepure015false USDtruefalse$eol_PE807381--1310-Q0005_STD_30_20091130_0_774639x767051_790417x831248_806085x742042_842551x712753http://www.sec.gov/CIK0001466301duration2009-11-01T00:00:002009-11-30T00:00:00falsefalseUp-front license paymentclvs_LicenseAgreementsPaymentTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_UpFrontLicensePaymentMemberclvs_LicenseAgreementsPaymentTypeAxisexplicitMemberfalsefalseLicense Agreement Termsclvs_LicenseAgreementLicenseTermsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LicenseAgreementTermsMemberclvs_LicenseAgreementLicenseTermsAxisexplicitMemberfalsefalseLicense Agreements Licensor Clavis Pharmaclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorClavisPharmaMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMemberfalsefalseCO-101clvs_LicenseAgreementsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsCoOneZeroOneMemberclvs_LicenseAgreementsTypeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$16false USDtruefalse$eol_PE807381--1310-Q0005_STD_31_20100531_0_774639x786515_790417x831248_806085x744360_842551x712753http://www.sec.gov/CIK0001466301duration2010-05-01T00:00:002010-05-31T00:00:00falsefalseUp-front license paymentclvs_LicenseAgreementsPaymentTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_UpFrontLicensePaymentMemberclvs_LicenseAgreementsPaymentTypeAxisexplicitMemberfalsefalseLicense Agreement Termsclvs_LicenseAgreementLicenseTermsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LicenseAgreementTermsMemberclvs_LicenseAgreementLicenseTermsAxisexplicitMemberfalsefalseLicense Agreements Licensor Avila Therapeuticsclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorAvilaTherapeuticsMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMemberfalsefalseCO-1686clvs_LicenseAgreementsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsCoOneSixEightSixMemberclvs_LicenseAgreementsTypeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$17false USDtruefalse$eol_PE807381--1310-Q0005_STD_0_20110630_0_774639x837520_790417x831248_806085x812964_842551x712753http://www.sec.gov/CIK0001466301instant2011-06-30T00:00:000001-01-01T00:00:00falsefalseUp-front license paymentclvs_LicenseAgreementsPaymentTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_UpFrontLicensePaymentMemberclvs_LicenseAgreementsPaymentTypeAxisexplicitMemberfalsefalseLicense Agreement Termsclvs_LicenseAgreementLicenseTermsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LicenseAgreementTermsMemberclvs_LicenseAgreementLicenseTermsAxisexplicitMemberfalsefalseLicense Agreements Licensor Pfizerclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorPfizerMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMemberfalsefalseRucaparibclvs_LicenseAgreementsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsRucaparibMemberclvs_LicenseAgreementsTypeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$18false USDtruefalse$eol_PE807381--1310-Q0005_STD_30_20120430_0_774639x837520_790417x831248_806085x810873_842551x712753http://www.sec.gov/CIK0001466301duration2012-04-01T00:00:002012-04-30T00:00:00falsefalseUp-front license paymentclvs_LicenseAgreementsPaymentTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_UpFrontLicensePaymentMemberclvs_LicenseAgreementsPaymentTypeAxisexplicitMemberfalsefalseLicense Agreement Termsclvs_LicenseAgreementLicenseTermsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LicenseAgreementTermsMemberclvs_LicenseAgreementLicenseTermsAxisexplicitMemberfalsefalseLicense Agreements Licensor Astra Zeneca U K Ltdclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorAstraZenecaUKLtdMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMemberfalsefalseRucaparibclvs_LicenseAgreementsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsRucaparibMemberclvs_LicenseAgreementsTypeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$19false USDtruefalse$eol_PE807381--1310-Q0005_STD_31_20130131_0_774639x786515_790417x831248_806085x823211_842551x712753http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-01-31T00:00:00falsefalseUp-front license paymentclvs_LicenseAgreementsPaymentTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_UpFrontLicensePaymentMemberclvs_LicenseAgreementsPaymentTypeAxisexplicitMemberfalsefalseLicense Agreement Termsclvs_LicenseAgreementLicenseTermsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LicenseAgreementTermsMemberclvs_LicenseAgreementLicenseTermsAxisexplicitMemberfalsefalseLicense Agreements Licensor Gatekeeperclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorGatekeeperMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMemberfalsefalseCO-1686clvs_LicenseAgreementsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsCoOneSixEightSixMemberclvs_LicenseAgreementsTypeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$20false USDtruefalse$eol_PE807381--1310-Q0005_STD_30_20101130_0_774639x767051_790417x812357_806085x742042_842551x712753http://www.sec.gov/CIK0001466301duration2010-11-01T00:00:002010-11-30T00:00:00falsefalsePayment On Territory Expansionclvs_LicenseAgreementsPaymentTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_PaymentOnTerritoryExpansionMemberclvs_LicenseAgreementsPaymentTypeAxisexplicitMemberfalsefalseLicense Agreement Termsclvs_LicenseAgreementLicenseTermsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_LicenseAgreementTermsMemberclvs_LicenseAgreementLicenseTermsAxisexplicitMemberfalsefalseLicense Agreements Licensor Clavis Pharmaclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorClavisPharmaMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMemberfalsefalseCO-101clvs_LicenseAgreementsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsCoOneZeroOneMemberclvs_LicenseAgreementsTypeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$21false USDtruefalse$eol_PE807381--1310-Q0005_STD_31_20120131_0_774639x786515_790417x817072_806085x744360http://www.sec.gov/CIK0001466301duration2012-01-01T00:00:002012-01-31T00:00:00falsefalseRegulatory Milestone Paymentclvs_LicenseAgreementsPaymentTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_RegulatoryMilestonePaymentMemberclvs_LicenseAgreementsPaymentTypeAxisexplicitMemberfalsefalseLicense Agreements Licensor Avila Therapeuticsclvs_LicenseAgreementsLicensorsNameAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsLicensorAvilaTherapeuticsMemberclvs_LicenseAgreementsLicensorsNameAxisexplicitMemberfalsefalseCO-1686clvs_LicenseAgreementsTypeAxisxbrldihttp://xbrl.org/2006/xbrldiclvs_LicenseAgreementsCoOneSixEightSixMemberclvs_LicenseAgreementsTypeAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Research and Development Arrangement, Contract to Perform for Others [Line Items]2false 4clvs_InLicensingArrangementCostsUpFrontPaymentclvs_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15truefalsefalse1500000015000000USD$falsetruefalse16truefalsefalse20000002000000USD$falsetruefalse17falsefalsefalse00falsefalsefalse18truefalsefalse250000250000USD$falsetruefalse19truefalsefalse250000250000USD$falsetruefalse20truefalsefalse1000000010000000USD$falsetruefalse21falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of costs incurred under in-licensing arrangements for up-front paymentsNo definition available.false2Up-front payment3false 4us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse250000250000falsefalsefalse3truefalsefalse250000250000falsefalsefalse4truefalsefalse42500004250000falsefalsefalse5truefalsefalse3658500036585000falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13truefalsefalse1310000013100000falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21truefalsefalse40000004000000falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275 false2Acquired in process research and development costs4false 4clvs_FutureExpectedDevelopmentAndRegulatoryPaymentclvs_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9truefalsefalse115000000115000000falsefalsefalse10falsefalsefalse00falsefalsefalse11truefalsefalse700000700000falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFuture expected development and regulatory payment.No definition available.false2Future expected development and regulatory payment5false 4clvs_SalesMilestonePaymentsUnderInLicensingAgreementsclvs_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9truefalsefalse120000000120000000falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetarySales milestone payments under in-licensing agreements.No definition available.false2Sales milestone payments6false 4us-gaap_ConvertibleNotesPayableus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17truefalsefalse70000007000000falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryIncluding the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.16) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.16(a)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 16 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20, 22 -Article 5 false2Convertible promissory note7false 4us-gaap_DebtInstrumentInterestRateStatedPercentageus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3truetruefalse0.050.05falsefalsefalse4falsetruefalse00falsefalsefalse5truetruefalse0.050.05falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10falsetruefalse00falsefalsefalse11falsetruefalse00falsefalsefalse12falsetruefalse00falsefalsefalse13falsetruefalse00falsefalsefalse14truetruefalse0.050.05falsefalsefalse15falsetruefalse00falsefalsefalse16falsetruefalse00falsefalsefalse17falsetruefalse00falsefalsefalse18falsetruefalse00falsefalsefalse19falsetruefalse00falsefalsefalse20falsetruefalse00falsefalsefalse21falsetruefalse00falsefalsefalsenum:percentItemTypepureContractual interest rate for funds borrowed, under the debt agreement.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false0Interest rate on promissory note8false 4clvs_PrincipalBalanceAndAccruedUnpaidInterestclvs_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse72000007200000falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryPrincipal balance and all accrued and unpaid interest due on convertible promissory note.No definition available.false2Principal balance and all accrued and unpaid interest on notes converted to common stock9false 4us-gaap_ConversionOfStockSharesConverted1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse27577882757788falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse551222551222falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 false1Conversion of convertible preferred stock into common stock10false 4clvs_FutureExpectedDevelopmentRegulatoryAndSalesMilestonePaymentsclvs_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse259000000259000000falsefalsefalse11falsefalsefalse00falsefalsefalse12truefalsefalse192000000192000000falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryFuture expected development, regulatory and sales milestone payments.No definition available.false2Future expected development, regulatory and sales milestone payments11false 4us-gaap_PrepaidExpenseCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse605000605000falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse605000605000falsefalsefalse6truefalsefalse116000116000falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13truefalsefalse19000001900000falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Assets -URI http://asc.fasb.org/extlink&oid=6509628 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 05 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6386993&loc=d3e5879-108316 false2Prepayment of preclinical Activities12false 4clvs_MaximumLicensorDevelopmentCostsReimbursableclvs_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8truefalsefalse30000003000000USD$falsetruefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryMaximum amount of development costs to be reimbursed by Licensor per in-licensing agreement.No definition available.false2Maximum licensor reimbursement of development costs incurredfalseLicense Agreements - Additional Information (Detail) (USD $)NoRoundingNoRoundingUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformation2112 XML 59 R30.xml IDEA: Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) 2.4.0.8131 - Disclosure - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail)truefalsefalse1false USDfalsefalse$eol_PE807381--1310-Q0005_STD_91_20130630_0http://www.sec.gov/CIK0001466301duration2013-04-01T00:00:002013-06-30T00:00:00iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE807381--1310-Q0005_STD_91_20120630_0http://www.sec.gov/CIK0001466301duration2012-04-01T00:00:002012-06-30T00:00:00iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$eol_PE807381--1310-Q0005_STD_182_20120630_0http://www.sec.gov/CIK0001466301duration2012-01-01T00:00:002012-06-30T00:00:00iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Share-based Compensation Arrangement by Share-based Payment Award [Line Items]2false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse43.2243.22USD$falsetruefalse2truefalsefalse12.6012.60USD$falsetruefalse3truefalsefalse17.6117.61USD$falsetruefalse4truefalsefalse15.0215.02USD$falsetruefalsenum:perShareItemTypedecimalThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false3Weighted-average grant-date fair value per share3false 4us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValueus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse55404885540488USD$falsetruefalse2truefalsefalse162845162845USD$falsetruefalse3truefalsefalse57163745716374USD$falsetruefalse4truefalsefalse223319223319USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false2Intrinsic value of options exercised4false 4us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptionsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse11019351101935USD$falsetruefalse2truefalsefalse3210832108USD$falsetruefalse3truefalsefalse11883121188312USD$falsetruefalse4truefalsefalse4214942149USD$falsetruefalsexbrli:monetaryItemTypemonetaryAggregate proceeds received by the entity during the annual period from exercises of stock or unit options and conversion of similar instruments granted under equity-based payment arrangements.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (j) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false2Cash received from stock option exercisesfalseSchedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) (USD $)NoRoundingUnKnownNoRoundingUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/DisclosureScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAward44 XML 60 R13.htm IDEA: XBRL DOCUMENT

License Agreements

6 Months Ended

Jun. 30, 2013

License Agreements

8. License Agreements

CO-1686

Rucaparib

CO-101

Drug Discovery Collaboration Agreement

XML 61 R21.xml IDEA: Net Loss Per Share (Tables) 2.4.0.8122 - Disclosure - Net Loss Per Share (Tables)truefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="70%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center">Three and Six Months Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom">  </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Common shares under option </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,343</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,718</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total potential dilutive shares </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,343</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,718</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 false0Shares Outstanding Excluded from Calculation of Diluted Net Loss Per SharefalseNet Loss Per Share (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables11 XML 62 R30.htm IDEA: XBRL DOCUMENT

Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value per share	$ 43.22	$ 12.60	$ 17.61	$ 15.02
Intrinsic value of options exercised	$ 5,540,488	$ 162,845	$ 5,716,374	$ 223,319
Cash received from stock option exercises	$ 1,101,935	$ 32,108	$ 1,188,312	$ 42,149

ZIP 63 0001193125-13-323794-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-13-323794-xbrl.zip M4$L#!!0````(`'-O!T.3<,E@>FT``*O;!``1`!P`8VQV90F'P;X3!Y(+`G3490\?!C,BF%ZJ%H_[W>.ITNLNCAL9#^/?P/:"QKB-\AW9[=GJTA^T&Z2Y,<6D^F M0;*0K#B6;OE=N73+IYM*1G M4+:\X%?C'>V!E7]R_I[;\P\J[;^JHC4V3?-<7%TUC?*4*-C8)4S9XOG9>=3T M9&B*S__\_.DN?&23`-41@*H\!,'T^,V,L7"8ER M%IX]I$_G<*&A>1@_52D-X_0)9`=MC=.'A5`:?I>LJ_*:5,5BRO)&L<25AB_B MLHR*JFA+!K3S\F*E:=385"^;1JNF>3'-FN'R*UP,7,,+JEUDB^9[EA>;:)IE M&8S@;?J-;!X^-M_$KS1\4Y0\L;QHOJ6\UG!3,ILTJ^*HR,YYCYQ# M"Y9%X?,-,`;WWY,FJ';?K,BVZKQY#E<',%HE28S7^"(76GW+QI(8/!?\J1\& M>329QES%Q6=!%F9IS-H-4W''8\;&'P9<<=%*,\_F^>@5H[B]@3@O82V'W<5- MQJ9!-/+F4Y;DS!'=7TAAFA1L7MQR\5@:#V\\*ALJQ0AA%&;JN5:R%<]&1'?5)!E$@P M"O\W8QQ.63;,^1?EZW"5#;3`EFZYFH4LA;J($*(AVW54Y)G4]"QL4]ES.?=X MB`&M>K:.]05(%:"3PJC+BNA+#%?9F`$'H[LB#?\I;L@O\WS&1K]-TZ1LR.?4 M(S.QB?SRRM_`;E'7I=3%R*>>AXAF$V#!TY#O&XKG8LORW1?LRIGY@OP5"(^D M`Z#61]`.]N$QK@]Z[9L8.MB1#41-ER#%-G0/ M>[YLR-#!0XT/86WP494QD&DJ/Y^W0U$BYF;UXG,PCR:S">_X`)3B]R">L>MQ M53<.M7:RIN+UGI8U+O4O_=608DWX=4-33X"\:/22;P8EF(Z#H!Q;%TY!J^HZN6#%^@E?.AS*V#7)L0MV$]$2-Z:1VW,W(Z M#@"[,E0''VD_*,"8R@!:TU32&06$4\`=!:TG'!!3I=Q0$-P9!QKG`%Q#XQ@4 M7`)LL&'%;5"PNP)^C,"TA'`A>#C8>UR14GK/W#`H10UP%J5(HLSZ/(]7P+7!:+&LK22I1V5-O&RR[$6]W,J[1@^4VP MX#/4J6D94J)H&@:M4@SM=1-R*[)6$_*&'FW!72,GR!^M9,3_\?YG%CT%,5"8 M6X439-D")BLQ31WL>PJJ6D!6-Z,J3=/!\8`07,<09_BJBDQP+Q&6'>RZ'I"M MZ1PR#!T3[(>AF[):1=T&4%U!:KY;.5L?['S64;=S/EW9MA70*H@C*7A=BN9?L M'=G$3`? M65^#;'0]Y0W7B?V#\70Q&UE@0N![O#E\992_*A3=).\UP:>IN!;U-'"[9?"] MB2L#L9IC(-O3/5,S35/1G-(6$A%\JK06?)Z>EY-UQM5L\H5E'8U3D]BV9CL. MTJD-4;Y#=40=DR#;)(Y"3%!JV7XAFE`-HN.34%VB/BZIO\,X@LY+1.(MA%_O M4_[1LAOY]-A3KL'Z&PK&NG(\JMMRL6LRN0FRZZPT2I6`M@,3L>D[M)QAL%E& MZ'C;++,-U/Y9M9>.`]X[H38Y#2?2KO\;4XS&,_IGYA'MWMOHVN//6K/B,2,5M$/^K4"_1T.DD`U#U`+1?BO4V^Z67[I[MT':UN&GG_*^8Z,$ M+@+&FXLNWXRNKN>3GGIN8.,41<<&-KJ<+9IF8-K*S9,7UBD^]9MSJ;D5616&,XFLYA/:]?%(\OX`,C8(XR!Z(E= M)F$Z89_2/+]BQ?7X/ICW#S;/.Q*C@OE`3%5"O,DT3A>,W3+Q@&_:\U0W;(-@ M'>F*ZR,BJSZBAJ,B7:6>BDU+=@@=ELN_%.,*!WMA5%$+GH`W&#;?!61E\%&O M)IIW(Z@I_6@4<<,=Q#=!-+I,G&`:%4'<0^6F@X\:58A8F%M3\&;Y-T8V7Z9: MK3/TUVZ)A4=JUH=P@_`;`'EGWV3IF.6YH,-G/=99P*EJ/JQ"^@&WY!'RQF6^E5[O@JI$G_ M]MG+FUD6/H+O^^+'W;))$"7@Q7V&GY/9I%P2+Z\71PAT#ZC[-+%+=:(CR[`M M@"]C9'FNBGSL``V\>(#H0T44N>CU4/=06%N=PJLT"7O;\3SBJ7D'C:)OC4Y. M,""/,CFJ/"K9EJIJ6%A>0PUAR'=A3\'/X94-M6&[#TB3;Y?GK.BUGD*,:6BX MP:>K27[T`O5..A+\5;GJQ+4H.2^A^T&4"6UVHSR,TWR6@5?/R3A&GJ`]4E_1 M?C:B:RB.XCSW4UQ_:(:NGV2X$],:!9=:[9"Z8Y$+MCV5,4LN8< MS54J=HJPD4C'Y/$Y3#%>EIF;#B):JN&KSY7#RFJ49NL.J&C/K;2*=,$>9Z-B:X@6[8,1'330+:JZ@@K)M8MCR>!Y7((\9A2-F2LZKZB:9E'.7#:.PJA82^"5-?KU M._I'CLJ--B_6KWHP;X=ZLBJF_@]BGM?$.E$,*IO'&\1;*=CJ-??6JR2#CYI) MM[G,VWHW69?J.GR$19"&?AM=FCV5@ MV4.?%L.XH]@T7W8KM@)RI*VXZLM.JZ-MQ74\F;B&9B$J.Q;HAV(C:JL.,GUB MF3!(5%,UGKGN"%2<(JC"6%'Q*VUAJYU39;J,\B,:J*+J_=@Y MI6R@/F(QD2)V3BDZ7YHQ=Q69GG[GU*EQOF'G5#]W#FT2=K(*2N7Y6(/*3JS_ MESN'7JNGK6HBGXD&YF5".MLY=))]*Z]1T%=ZL4KO]JV^W<4HX^7;AJPTZ=\^60R3Q-=/\UH7*'6#EFV&W%EV'IB%6R'72PJ)*E1.ZP2K8#5+31^C15R9[D@,4.IA`.D,@U M+_M[J+WLPFB)#="$T*IW=.S:RS=7!'9`!9@T73.W34X[C'=O$6E"\ZFA-`SM MS4*S4U1$=>'Z\H.'L8[?5!%UJEFXJX(AL12I'F5.[H:*KJID5B>4]YN83J@0 M1PT?QV\#YX9/G.#\/$4C-K(7O^5L=)E<3_DKR/A6CK"(GLJ@6JQXS."SY<6# M-HYA357?6EC9KIA(K"$@3$VB5ZEY&]0J;;6ZB7)M_WHLEI#65I#L((]";K6B M>';0AO#M=&VNB34P9+JRG((IY/MQ/LSMPUN^X91+CCA\QW4]"#)%W ME.EN1G8CJ])RF809"[@77OX+AHB[J"_6Z,`@LTLVP&S4DN/MT&PPL%S$]+-T MTF1S;39.L^5BYWTP9[DW+[(@S<#\!-GBLF`3D6F".[,TCLNM3.)4\FYI:VE5 M#&Y4-C?'G9"&VMH+:&1^"_YS,F._I.DH/R@UTY*HW8L4+9F2-]8HA#8!R'2E M4"4;RQ"@E]T--A1IA&Q&H5MA;&3TZPO^AQ@E4$SC!OZRFH1K$KT4=6V>'7S)H?,N"F-=7_1)$R;*RHY?6GR?^:QG&@X%5 MB5E=N$X@7)FFN:@*N![W>`;D8YN?>U^A82>,IK?_Y.*Z6`\JCU@J2T=Q+R'S M57%#([4:CMU`-D+-GH]LLWF&K@B^N7;.1$GX),V*Z.^@[',>=HO*#W"+;S(V MB6:3_%(<2B(O4JF5)F>:CT_[D&C MM1.9VD*J$M&.NEN,URM]FF;M\U6U]B/42N3ARONUI0\VX6EF(,4,C82>3KQ2O$D9-?CM2+&7B+G.[")1@FM^K![P;1Q M7I3H:UJJ0E\=17X=BU\2QRV..-!5R6T_6:C,/@E1R M,6+1Q7T6"*.^F'Q)#]BLBBFN`*W7S4%#UZ+(!J*F2Y!B&[J'/5\V M9)>?%2IZ<_#1^?3[W<_G&^*\2.G!!%4L;MF#R*(DQ54P.22P.9ZPF`M[_?OE MG71]Y5Q_NO[EKQ^ERROGK)2^25513UWR"J*KZ MX&9[&K*H:B';M[%E&M13#%R^Z&<,*L=*02NBU&GVHYAE#D2@#V".OPG+,(&` M?6,Q3P#`^!,"K3-8^Z-0S4(M, MFT+?+Z;'4^F6DHKS1M"O54FY()OBE>DL#RPJT-ZUG$K)*))UI,I5:2MRU379 M@099$%^"FSO_+_9M=)F?N`9V@_`W+.!U):X)]R+[<@?!B\8!]P:*Z7S\S#CGJ[LC\U'<@@Y\W@I'S4D9_#^39\6&YOMVZI;C8L?D= MV*$*(J8&NF7;!C(X^&D4/?WP4/ST_AW_8RKEQ2)F'P:? MK=M?+J_0_?7-A83I=/Z3M/S$OKZ_O_Y\(_.U9U?5K]$_)=G=O@GY]'JVOESJW/^ M3<]_3/?(K7.Q[[T_[]'EE>M=W5](Y-^VXBB?\SHD]X],XMH4)`OI,_\NX0>I1T\PO"$ZD<9Q^C7G8H3ET@:3QFDF!8`' M8KH"!&&`;@[,,3X"XO?O%F!5\S/)RL6U%3>KN\6C!$?+[_Q1XKYF6=\$U]Z_ MFV;I."I6^*,<;`&,U1&7>S;E;>"I^2SDD=)X%L/5YQ#IQ_?O@BG<_A3$)>0P MG4SX>.0E8V5:,!T+)J'1:!9"G,AW'XR`M27T('R,V!,G)`!\\&!^0U96N4*3 M$5#+9S*`D,^FTS03^-^_6X+\(9A,?_K7.0Q/\R<^7>1>[+@!);%GRIW.J9<%].NL!P!X>'P#5D[IH>9N?MC1 MLFSLQ3)+\ZRG^R=`#J\*#$,%VT*#_;!O6D."F&<@NV`537%4\NYB/#R@T6%V(;5B9T"LR0;=+S&[^@'UKD"Q=5!SKSTM< MEOGG.]]+Y[]4G];*_^?4VWCD-F]J M$J5IM%CWHNY^Y2!?GZ;?GS?H$S\VH$TSBZT1E7^YB?D&>ST^Q^(CS43=/R^SRFM)P)K,7RP[7_ MH_SP!?J9)^5GV!+2RK/_F8659G1%>LPN?3WI'VUR7\[9:+;!/*0=B8=0O9X0 M[HLFO'8^ZXQ,;F#&$2C(?PP&H]%X?+6U]S1:5GY8:_8-DTE6Z6*MVW\;C>$K M^.:5VVF>:)/;3+!9`%T.EA/;7SYN^;XELSW:^-X.A!?W6_!KC'Z;5XY"DW1# MWWL`8707N\M?KOB_AR/$F0B5!N*L2K;:K1O.]V58MV$^>':^W+0\+NKV>;L\Q>4^F>-EMX&09I9B"!G\5 MKH!VB^MBH7V%]A4X"^U;:^VK@USWHFP2T#=1(R_M[@SU;S,HM\'*/S.7(HK=J=IY@;?:;S0#A:3L;I]T^R- M!O+`,L:R,>IVY:[FZ'+/[NJ#D:9J8R5/;/K6_1_GBVH.[V4OO.V\'YZ]/V;N MPEAWM)ZB._+`9C?^JGVY-]!,V>F.\;H(<]`=/YF[L'#C&S^4P2#\R%(7\L]\ M'7WR.>0?'%7!"]DE39BV,3G%^6]TY2.4@H%:#'(@V/F3^77 MC](`PV3TA\].2.9AXRA.6/H`CT3#(-"Y7HZB"&JW6\4H5'/G*'8`0(J^VZUO M,YAQ+)$[S"4F=R[&Y!>L6C$+(+KDG;VM]1`:*,B`S;@\09L-\":()F#G,[.& M33!//\C#V/%?-"5Q-G67;NQ/"(^-MUOONAV%;&N^H`5YCXV7^0.#3YR+UE\, M/WU@&00%:5V>/\\B^*Q&F0O_83))F.'P6/"=$8FGE\`P8'3\0%6[Y>4_`P>4 ML]=,"8'0&"RPI$.,J\)P6:2=Q4B!=@$M0J2[\QY`DK"]4![Y+T+]&([]/;JE M[+;."M\!'N'47\(+0%@\+\&I%@3K.?)4"#PX4$X7H[!1'M_E%.'PYL4S\,&( M:))MVI+=[1:>T3QJO&W8F$+!G:AX[&7?A($=HG%7KL".6^PK)Y/R$\6K[ZAM M#R]JA_I`=8R>(8]&8U4V!HXC]X>F(9NV;=G66.LJROA\WL0#]CN`C_(SXS$+^"S#YLWA@F)[)[\5[/D^ M\JVZ*Y+LWZH_ELQ?.WX6G%T_SEY[8MZJPXK'YZVZ1,]2R9SO\1!6\D&LKC-8 M7;V;FQC/?KP9NW\&YO/#Q)^^58?L&I,3\EK-\LKZA4&=,I\-Y6-KLH] M1@^G+(+A^4X3?G118HZ.8EP'JJQL_R6-UG=$1$Z;T M5VN4_\"Z(M03*N.H*D,Q+$DU:YC-]V?O%Z; M%(Y`H4^.*6W>J[HBV?J6?=Y;"IP/0HL<&%>GHSA"B9Q:Y#9O1F>]`$AO/(+=; MVW8(1&P0CKY!T"PLY6+73?^(#<(3IH73<2YDUW?1"Q@V""?.`6@XS*==Q8HM M*:HI65KM0!8;!+%!N`"#NV[CK5G\H-@RB/#!*=2/K:F2:M5.]8B]P5-NQ\ZI MTX`:;C2>R?+M="_DA.(EKF)#D72K*RFV6C>,Q=9`;`TNP-2NVWA?7%+XI943 M#WQ1,CO&VH`[DM6K7]E9P@/>D?Q\TFQB\CM-!VXR_Q9'M[Y'O?[JG]#^Y_!K M<45MCJM/$ZQ9XX<9?/>UO*?TH&2NTE;6'Q!7-4VK;ZFJK%OJ4#;&NBX[?=N1 M566@#H=EK\X.:% M=-V48"7AQVOEUK7.Z4ON-]V_SJEQFLJ?1^U65/X\P>VF#;[#M-G\(6XN;1[A MQX?9`]9GW-7+`ZN.&UOG_]46-#N/=>YM[3._4+^@MX MGQV#T3I6[6(P9YU=^OG>MA"V0_GFJ-VB#:])XN<.36R>A4[8Y5 MNQ1-`>^SX34[2NW\],*1*UAYFR/75BU)M\6A@<9"K&FZI*NUKS9TYG:7<.2> M5"-+:K<+7%X[K2P@?G9RA":I1KVEV-,'+`Z<1[Z9I#Z&W=^_T+PJ>TD.GW*N MF`/-ZO9LV=3@-4,S3+FG.:IL=T?J8#CH#OM]99^4<[6[W;/]6BB#W+V@=\C8 M#]UPZKL!^1PF:9PQXK9;6+0*:488T<@7ZB+)\$<&W@YWQ%,YU]9QIX-_^(5" MD@C^O]T:_9WYL#!8S:\C'.YU$,R",;>G22;K)* M[\$@-X@!,R,/^"9G?^X0P`ZR$$@3`&D]1/YPO+P9(P+5%BZ M;#BP#I:PH``\7!_,*L]/W>03`VWF?&**!@HRS$1>BC*QP7+77CD%="A#7JXY$S7-;%M]71PZ*. MH(\8OXD6E+S'RHEA0C]T"`J[:82U$Z'+JD!#LH*L@J5/V:D@G'.&I]C*X6^2 ML-UBTR,5$OI)>3@*96"RI%.4+`3'FLL8G.V"IO/(Z[1;G^]+U`H;3^@J"K$I M2E8P23;#:>`F";3#$`(DYD!"&-RZZ:*3<+("``"RZ,X),`Y,6?" M\N0A&P&,.]E8`$`7>&GA_D7QM\7FVJ$__)2W^R%GEW8+/@)! MET!1:&&!W.EZMVZ8P@*+LF1M7N0LL^ZK;-C'(8`PPD0/,#98Y^Z4R8`)3>_P MM&/>"$C:U,>^4!1$>?^+TF#F!Q29^.(J+:"W-&"2R@]!4.7VS<)=(2VRA-%A MW4+%CBBDY,?]N:`&&3*JHNR=(K-_AHRV^XW\"6?7(_L$$5Z^C'Y#YBCIKVX! MN[8^E/_*(C1RV%)EDAT7U&VA8[@$Y_H6[#6^*%&)M5O%L@2EQA=2ONG9U)/W M25>TP,R.2A,D-P-Q!6[L-BI&Q1;E\5Q>F+,H]"]7W9V<5CY1S2`X'Z;3FL1T M7R<)C6^9V,K%;<48><`RG#/>XWU4SF?@D)Q^5"R"=A%L%YP M>\,TV2P#]O3_,C55$O`@&'D8I/\G/:$*T7>OODA>&WJ2%\<\P M>K`TUJR99,M\2SI!)U*:9B7]`*STK#Q@[C5Y*\?;#(R= MZ`ZLF':+6T7%5I%RDW>KCLHIP>U?V!R3W,SSF/>M8NN!(>FB80Q[--S)\BW. M>V;>@@$+*BWYT$P[$.VO?3.EE;WM0/TTF=*BVX-U*S)_WR(!-;_0\#$/A$C^ M/1+MN?94!>U/1?O*CDB`<'H03GD$H68966L2/E9&_FF/\CEL;D[RF)B1F-&Q M'COK9/0O%7_HV8N&&F;RJ88M.5UQYEX`+`"N)\"E/\\X""F.AKS`6^"]<_]2 MXSLHRAWI%@(<_`J*%_:VY6%!-T$W0;=ZT:UF;I_O45HFSN2YQ'GQ?[&9$[:^ M`%@`+`!NGG$O\+XLO!NTF;N0"P4%Y03E!.7.A')G'8##-R?XQY!.Z6)"XTKT M7N71^T>34S=OV(Z+VP[(6E)P`6`%^4*2_POBR\&[1U:T8\ M4%!.4$Y0KBZ4._.R4#'E=9VP4E91B79=NC19UP[]C=<`55FM6XUX&:ORQ,K7 M^C]XT>MV:TEC/_((Q>LWR8.3_`0/\C]>Y/;A)0N/WH.P>67"D$[2LASM%U[> M>#7D5:4/#RR]I^BV:?ZI_VE>_8II M#[)BRII9N3!BYP!WW/W08UOK_"X#[VOX1U%>JX_5M0Y_'41?509#RU!E8SRP M94/K:[*C.%W9[@]ZAMG7^U9?W>LZ"%'?[`D*B?IF#:[X=5G=BOIFHKY9LVDO MZIN=36DM4=_L#$`0]1#'SGF*DY,"X`%P#4&N!E! M5H'W9>'=H*!Z$_(L!=T$W03=SI]N-7/[B`QI8>L+VT\`+`"^*.->X'U9>#=H M,]>,G$M!.4$Y0;FZ4.ZL`W#XY@3_$/7-+BXR+&9T_C.JF4=(Q/./["$09Z@% MP`+@&@/<#)>`P/NR\&Z0"Z@)<4)!-T$W0;?SI]M9NWY$]%Y8]L+2$P`+@"_* ME!=X7Q;>#=JZ-2,>*"@G*"%M"OL]YT M&F?4^\UW)W[@ISY-OF/7AR^*-1IH^EC1!O)X:#NR,1B9/D6QK+>JB?4UG=.8N)Q.[1;]L:1A`H^[,19$6RQC/Z$>B6:L.-:Z>-9% MU+2RK;UK6EG=O6M:J>IIRCP=MU]1Y^DM2JT\J!-2?GBJ7LCK"2@PV8K)U@RP M#5Q.69:H9HDPN?XF2QHG41C2H-V:1DF:/*IOQ#[]98XWJ:NJ>P]`N-UJ`J\F M&4;MX#WKR$\AG*91O(QBK"`!D&."PP7(K[*X MG6[=4&Y0&*P)F5&";@<(1YS;OF*'2[ZA^O;$FV)-,^HF@P6\SX?75K2ZP=L@ M%=N,V+6@W$'4[--1_^?'[3?C_?!TE(5I\LU=X5.]T'OX?GDSV.&#_[VN/C0' MJB./C;XN&WU;DQUK:,NZWNN9RL`9C2QKKQNQNMN#XZ\514$>HC(ZA-L8O<+& M&%5MC!V1J:D M+(B4A>9'@43*PB6@7+^`;DWM+I&R(#AAGZ0IZO=[84;2!\:?^IZI>_:I9NFU# MMR5]7C:U>^4<4J#8/`H\&B>COS,_7?T>I?28"1T#7=$5>^3(CC&R9,,>:G+7 M-L:R-=;'JF/WG.%(?2JA8^'&-WXH@TGV$9,$\H^8SF@(6AKQ1B(P*7STQ,]` MRB!\6&'2)Q-3N@"J)%*[=3?WIW,P;X+H#I[$?)I\6A(.!(?MP3*,:>I' MH82CCFG14+N5`5LFK`<^"K_(R,FGDM)X`9-+>F\W:IT MV"$]1JH'^0,$U[&$8]PD(>^TW(\!BU[;K9A.J7\+)`YIBC&F*:5>0F9QM&"C M6S?*6M*6XE0\ZF53Y#/VC-5QBB?P,T/S+H:!0ALX"9^%L'A( MZYW6Z;9;E:?7O17[U#/&L@<4#I#'-6EC/7`@=T9XX)RB(N>K;!T54>?_V;NRYK:-9?VN M*OT'E"L/217`8`=XGNZ0W=7R>U0UP+3OF`M+1/7)\WWO[4+BO-JZ0A!C,@H`58 M='!9(Z#Y)%/1*G-[GI4+@VA@%N+K^&XK5Z8I+YG23\*4JFP'$;PB3])OT:+^ M`?W'55>XO2XD%?L!/Z)8>#&?X&2SK':#>AI8^9YFJDJ?3GFP'@="X#N-D@*<,W+6@(O*]_3NFME!34EEV[/JJP<__<#UU7-6`&H,Y7`";AGW MQ=!9"V/N410+DM_O#-OM6/5>&W:\<>R697/;1 M,P4B3K&`9QQF=[4]$`)2KA-=)<_I.&OD4]&>H-D!=\NSR8-(V2RLG>"*$U2\ M>*H*'\[,&(LLR3&$<`4E&O>/;0`SEG]-3K:XMNCS5DZTPGUHM`OB41O5=).# M:RJ;1P]A`50(<]#Y&$6(Z\MC[:FF;:N.:56!R],"7JM\?MRVJ002ZCZ:PNT" M5B^%?'JJ"X.WF^!CX\$T:(4KUO0FS$JCB*MD,S9NDONI$UC9KF@^9Y,(W@;D M`#<7=0`77TSLB&B`M`)G$Y!UF4]/2^6&_J+G)I)6\D_(D#[N%WD!OE2(.^VE M:1A/28_U'^M+KD(*8'L/8!T_+$B1_`P7YMF[^`H6G4Q6,F+TQP'0H((\W4-> M+\H2VS2\Z]\^#:[!N[E>S_.9ZVF^GCWL=W5=L[O]D69;GJ_UG<#7>KKG#4>V M9P8#T<1D>!W7:%#U98`<4Y@`^)_BK1FIR94$? MV3P$>8RG`7`I#<=Y$?Y5C`T M#7.D8_+1>//VRO_#?V]T!RN\.`ER++-I&*9X408\IO?O/V4[&CA#TQZ.0%Z' M/WW-=WU+"PQW9'B6;74-_91Z\+H=N"17?DFR3+G"_`;195,=#W]^$, MHD@7259Y"@W:DW_';TCXN1:]D9Q"//R]86*9I55NKA.=!AX0@VF.XO&LF)"C MPJUS_1J*3R?B>]0&8C[=`F!1.^$E`6+&2DE30MZ?Q]%*-TR7;7\BMS>8N^>[OK]EOV\NOCO%>V MNS9;*]T#M59^ODM9XWL5G,7ZAT_1E_J']_">NT;\-H00N7'M>MOL$Y["RS9D M[E!URB:1M=<'G0+>3;K[A$Z@728[?_>%?92J@+/^3UE=: M7\EG:7U;;7W/H[M$4FXO%OCK?3E;/SAN:"UY1\4\O-B'?X2F6S+ZH_@P.OS" MTC'A2AZBZ^;=KZ.U#YI=N]]W^D&@N7X?)XKZKN8'75OK=^W`M+NCH:[WK^$- M;]["*SS+7"ESV&E3*T0!KD>WT3B,<]'>A,\`GVJ,.*Q[_W+;[07>T.]UM;X] M##1[Z(ZT7M]U-0^N=TTG&#E6?X=FFX/6%)I8WCF'IU-I58-0EQ6MV M[6:WWP$VO8+T#*0OPYM/.`J:&BR'XE/J*$WF`7V[I_=^N%VU`KTY,N^E&B<= MVQOV=%O7K)$W`#(2!;L];>3:0].Q3]#"ANVUAV@QD6CS^(QLG<`+^!IX13P(L"=V_(?`'A@U_&FB!88TTN]?SM?[0 M-[4@L*V![?FV8>X$H_UB!3%$08UJJJA*LB)BV7M!^@DK2!E5'8KBR46:3--P MCC7XI/ZHGA3-8A;%:54_G^+&1[LFB+Y<7<_JD*+3A MYKXYNIB:BQI5#+-'%7L^J'5`\+W4RV@+2#/C6I?T>JW-J2;DPT)4XO`]H&2E M[`YH@24*5/049@*;.SO/VH2N^1)0W/9Q2A/D:_?V6EF'<80ZC!956[Q>GKV6 M^ICSE@Y9%7-^A#]F5[TGG2AV\\L9FDX MXXY%.)E'<93EF&:^9V?J6YQ*[9.N.VV39,GGW;T-SY5^I8RKY6-G6F0=V1Y\L8>NOZ6"1[ M=_@>X$KVGBU[+=7W6N?32_;NH)R-ULUV.Z.0[3Q:Y23E).4DY=I"N1T;6P_6 MQK/<+?1;AF_(\F@>8B??WGH]3W.L'NJ4-[``N,`+#Z@Y. M":47_Q'A/X`>U-=2D82X$U66J[KZ1#%[$VZI/,ZL[>U+L7R)$5'A!R%OZL,MS'O[%%%9)"Z''9EDQ%UU,-/4DY+BD MU*694@LGXLU3HQKAY\,-+,]4958/3E2KV36JDN"$89XFJ!N)"&T6WU;.+IA4 M6.Y91_F`\ZN4))XFV*UT$V81CC1KK)R!(BAHQ3B8H4HKG'X8POI9'54#8E-<1DMG)"`UZX\GYL;;V+P9PM;4Y4DY7_!=<*^L&]WE0-1COBS$;MGU6@;1!=.8NJ!J@>B MC:-T7,P1\':,9.P1J+>80L&'Q$PB1."_O!#0M4G6Y#ZVNM6OWK77=EGQ+"NE M#^DT!/U%Y*R;SU#+Q9,KCK@K5%W595RWI1UR7J1A!*-!=S34^K[I(W:^H_4" MS]."0<\W3"LP]<#<2:V9AU5K1D?Y-<0V6SQX?42;9ID8_(3@WG0>FP1MA8H+ M9LD]HDM_B#'W.7U4E7?QN$/C;)2ZD3SX::VW?/#3#ZH2@C"DH)7X62U1FQO5 MJZ@'IXPZ(U$_B(MY:^0`=,.#&"!%`]MJ>V_J*H[APPDRY5PM/,IPCNL.R:B> M_+,T-@^QR$,XIU&R`*4R#\>LH.DABFC"5&Z3<8%Z!N=6C5$U@\I2%;%H`JN. M>6IUCD`/X/7\S:?(Q,D]5`*L`5.!1RZ*.7SU#-P6[(Y%C4'+!X6$ M473&QW-Q-M)F<6IC1C@#V$5+G"`A;?"G`^Q&4.T[[#6O6F+I>?@X<>4Z19BP M@]5KENR1]/`XYZI3#"ZB*_DNX'TT?0;E:'X3Q16,=['00$WBL"/> M[TXV*)KAL*685;_D5BQY#&=H^)"AMP4=T"R(-73Z%`X3"!:T>RQP6TNPYJ0'O'M M@$N(Z)>.4G%$NO0U&^!WW\I?[LT0Y<7:W:H74YW M%,.)FPL)J?Q>5!5/09UL]+Y17"XOUNT+&0Z4A*V()SI9+>Z3@M>$\Y:2F`^? M$.@N)";<@BHK!G1(CCM:B_\-XR),'^O'&VHY8G;E5N6W_RB_1',T(6A:'^X2 M5%#)`TI_5MR`]$8"0Z>IR]2-YA$\4-#Y-44:%*WG+)3S+[]"@J40AYLF@M3( M^#J:Q&B>.;H2AP!OW@>M\/*B"9I#UG%<^?@S\J6Y>DI#B`CUWPQ@P`SSS MD[!;'=A$R13CYL\CR MTD`)!4PSN&*N?&,D.H8!J/O)MVC0ATMS%\CW$('*0;^9!GR'N3U M-HQ2G$B9DRXMTGIC8&&33%B[,O#`P;W+J!(T^NX6(20J>R\&<-`$-BX9G9H( M`?D&W%)AH#2>@9TDCO%GXA@9C$3'$/[P&3:P%7)V-H6=N)LD+T-.SC;<1-S` M/L(AV$]RK1[D`;?7`L0G(`J9),/PB#X`R%0T7XK$<`5D`":TBWO6&$I"%V'D MA]$B3?9D8JI312X<:*T@9E)'"5B:AU&\=+R0R+=)DN.6<&Q+%5P+:5@9#K.^ MTR7MQ_,/XE(R;[11[C8U0*9`NL;1`MR>VK>AHPE^1(U$LN2?XJ9[X+4`#51D M[6^=3QWEYU[O2FV>,!SM2!X#!3"U,QEH6? M,CZ!LP3E(2(-2[\SJ.;FTD(^#8.&_"U-Q*Z3#ZA(V'\+GI$@J:#1EQS2!>P+ M[NX6O#>@337@$!]\>?&9/->-@I7=)<5LHO`8OU0I?Q8QG])7/@?H^NSD#^Y3 MR#;J#U@@'7IX1,J6Q``/P4:LKH;A:(!VD?P!/;X"VL4Q=)2;-`DQ48'"6!"A M23$4$0;$\OOPN38KI73FP%Q\"[L)]B.Z)P%836B.>BD"Z>=A$@D0\ M$,Z66!PEA6*,9!I)1NH[S&`NG&=W`FR:F'_<&#\0:1I8!+)D!:=-%A"UE!-O6) MN?"8+0)Y2N$]H`.7,R'DL5(FA+^1K6R;+[^(9VC%@=SH$X@P MY&IF$V/&\R&8LF%5M@RSI<#/CO*^E@.1CR2RDY2)7-L&02-9X($BSD<7H18H M1S(PO`^Q>I$0186&,Y*`3MA-CC\*V2P'%U>B"<$/8W\M/:3,-)4K"&OTS(S[ M;=3SR*;P>+"E>8R3E)-2$W(%G($_A(ISQV\O^_Z^\O0,6!HC"D\6PSB/-?98 M][LCQ[4U>S#H:7;/U35_V'4TTS+]7F_4UP( M!YM]!1JUQ&K>-BBY_/L56.QCC9#NFH.>/W0"K:>[`1!4[VH])_"T_M`%DG:[ M7=,).&1UMZ-W=X"-W2MQ#CG<^^<4W<$3P^DUWKPU=-LU'/]00[MIVRMTK8+: M(<6T^__H:O=ZENMY@38PNH9F]WL]K=L=#K5@8!J6,S`"FZX82!P>$D1 MB.&()KMZ>D?`!U_/5TS6DQ0B.3$AVU<&=9'(5C5R>BO)A,;`8PH.XJ29"BGS M7F7$-VDFH'9&\-XFC2LFZCDE5;\FY`J`Z.N.QSYF@M_U^RAX6J]P(4?_:';MZV^Y8TL,3'>_*/[WO`; M$^-?=LO+Y*Y=A@^WS<=]Y'$NU:>M::$#:!)SY/FCP=#4X&=P!,R!H?E.X&B> M:[KZT!X.G,%NY1L'CAX]4"84XO=Y[U23=JV('B5@M@3,EH#9\K7?]&L)KRL! MLR7/)&#VN4J'A`\^/$+P&PI\:^+\!(P6P)FGV*+O03,/FOV2L#L,V:N!,P^ M<_9*P&P)F+TW!AY7DB5@]BO@LP3,?@U]$C#[K-DK`;//FKT2,/NXKN!Y0/!*RDG*2L`J``>6 M(0NB[`ZQ5!0!KX@`#]BJ0@!/X10?*3`#6)Q'A`.6*Q-VRP@R`HE"V"M/PQ4J MOR:7%U_#-N$P;[R'GAIQDIBC`RTUW_0Y(IORZ8ZQ/'ORM?SCZ79>1-0\#&RPO1O%/,$5/S;X[DU&RTG'%VB[;.;5B=`B$AJ;NJ$'`"Z,Q[K*SL@5LJ25T*TPY0IFN7%]28^E1?_DVJ_/CM2GGU_46.$%>H-)YXY6F6J9^/%)18(=I+L5V`DKS4 MZTKPDY=Z'X&LM$Z>I62W3[(_,@Q8GM:>>WTAQ!!Y&A(8X4N]\C-KXJ9^_P>B MS/T@3]<)G*[>=)HB9."+B?L[$#X$B1Z_U`M_AV#^F)J\97U<95(!`;>WYPO6 MMWP6W^A/I83/Z795W6[=-Z$C:.I6?>@S[(ZLJ'_FPX]R65MW=,#^G7]>]D4H MBVPB3<9AJ[YM5S6<5U($]`HY;/H=1[9\'UW3GM^.6E9$7"8"I3TYI+;YWK!T MU3MV(_,/THKLF:\(62Z-R+%5[OGMZ*0#D%&2WK)(AB`'-AEF5[5U75J,\V*K MX78\F;,ZNH(]OQV=40/!.?22?I5N)R$T>^>N7.]Y?*Q9=3YN1Z+>L5[)IX17?8#]CB?306=[B@W#56W34_WVY?S. M*#@XCWY%&1[(]1XTS?O/@X'?:;@?M73R&=F\*Q5G_EU>;(H0%!D@'#Q`,%U# M]8Q7@G?]BER+;J?[2J*^5WV`(4"0P$/G>XIU3]4-1W7-UC%9!@@R0'@%#G?; MUMNR[P=ER"`_'QS#_'@FXE:VSO3(V.!K:\?`XTGKL!7_"9#MCS``Z_!LWW#&2^ M[9M[*?3$L$3YN+R(2OP-9%K!E"CF<)R$'AC>)/=,2=DB91F+PBAT]<('P2PE%^Y[J=KL^Q*;>A)JK*PUTTOE,> MDF*&<)RPA!O&8H0<9=$]O.+FD1;"01LO+^Z2V82E&5PY08!.\7NE_/5#E-_! M:C6X19LG,7M42K1'5O:.75[`'Z.T^@.'SLSO(!!$:,UO0,-L`8RCY^X,X^CM M#N-H'P?8\*"OE<"&36@B]T!01)\1$;C>R?L$(8'KGX<(O%K_N*9*:+,WU;9? M,GR7\K$"7740^:CR<<=A\JLFO'DZI^O4<\H57F'(<025*>*?:!/ROFY#\#JX MX[5@*4=,?]+9D-F+;\M>6)WV?=.4['UVBMGLN*U+,9]T\=R[E;`0PB$1'.'T MAO.&W#BJ*#NJ8^NJ[&:JF^WKHFZ97Y7$&9W=YV.WKH\O4SD2E'>E,CU#%>U M/%D3?;8L-DU+M8S6@ZFU8B M]^4FU/>>+F_&XN4B!I663&.X:\+#18W73X^3^8+%6S&:I-!,;! ME<"SHCD]_&$EPKV\2,MAI`2;@_\78^_Q<6;'5QYQ=.?3]=$_3J)[_.E?/Q:9 M-@W#Q?\,H@S+PV%='VZ#QG8_\DT&299G-+2ZCQ2Y"A_G6'S^F7W)^S-0_&\O M+Q3E7^7#Z$(B7?-1O12"\RG#&_N/]27B6;V',)WP0=D9[_GMQ9.AH-OG!'\E MYHJ@6)6!OQ@$6PUH;0Q.Q8&F!K`NSF&1']GMO]^P9'9]-?1US_(-33,L0]?^ M3]=UY_K3Y\&UX1O7*`JZ:^G7^ALEFOS[332Y-AW#MASOVO7[CM,;!EK@VB/- M'OJ^YIM=2^MYOA4,3<,R1[^J^UN^/+"!E=ZCU`]/1#-/UC5'@>$Y_"*34 MW[Q%4162^I0.\3=_#?JGZF\F4G*&WE$:I/I_]JZMMVUD2;\+T'\@@NQB`HA> MWB\9G`#4+<<[2>2UG1WLO@0T1=D\H4@-+W:\OWZKJIMDDY)MR1=%'@3S,(Y- M-KNJJZN^NG0U;M)^K\4MVE)W!.P>.I5@O=CD(_SA-+WUX^*6-,NG*"#%-0U# M)*"FB.89/6'Z^SHC@]O'3VZE*Q\]90R[@H:,$E#`09@5(/)2S$GT+[.0MA9J MXAPD$'Z,%A$]+GU)BU!R!OT>'4,IKJ)L+JW\K("59`=,HB2(RWG(CM:P_8A. M^CR\#N-T1?\D([O>4,+?..26S/!BL&L@'7K+)2BG#8_R7LA4)"701#F^:*,[Y[M:I6E M`%-(`)M91__'/T]G>NJ/PCIDZ;P,@!QI7(9\4E+BH\%DYW]PBGZC.O,!'122 M%B4]LH*EA8G"]RJ.P\-X@NH*9"4IXELP\EQ6!HR3?A"D&29OX6])*OG+M,2W M6D><,/D[KXYA;>(L&X9^CP89E`/E#XBQ50/LLZLPQ.G6.3>?N^WP?<>+I M!34CJ8MQ=T-\]I-R@?8F0S9XE01)KTW9'">@)"^RTL]N69.1@;CT4DOU^%V] M("U%+H!HU&P@?>,SC2.CQKF5\G*UBJ,P(YC(CO+1!D`TR.0=9:L`/QN^!@/- M(QP('\[*P(N(*SUAAKC+^11]4&>`4V$< MST`,3"0,_+Q@>I/&N0`@O6*BSPX%DJVA[R#"E?X"K@+[8+L!WHE@HXN: M'30-5TY,)5'9!1L$WH.=C2P#$%3K<\S#O>IEWA=Z[P;`VA*N! M>.H%?Y51%IYD*;@#Q>T)*)T"(2/\EHG#H^%;F43LK2A/#4VUOWT]&[\!H0_` M18GS?[R1]36(IYJF-;145=8M=2P;4UV7W:'MRJHR4L?CB:':I@403[7>?+`L M^'##C.T):C/B.`FR$-8+]"?]_SB9@6AD,WC71WYZ>8[:]Q"9H+[Y`-A7;;%A M.W+66)`NPT]IGD^S=,GDJ(1G^4M@DX8A[@?VW+G_(\PG/\`](/,'FNZX")?Y MES1!'O&-?DR*+M^O\-B*XTY-RY"-\=B3#<]29&?BFK*F:X[G35U%&QG?]&\V ML$TW%<7M,NZEF-#Q<7T`?*>@;I,R_)BF\_Q+^.QL^I%'[Y,H_L>;(BO#Q_() M1O^/]M1)E(#&M)(FQHP)CVLPZ6:[:` M]3]$@QG/'*`6B!] MH@U-Y,18=D?J1'9T6_=+Q2'*D_'F@X::0&#E M^B9T7N;D,8AGVY0$;AT_/&G M4?D(F(-?.^65)8@`>)8KG"W.L,*$I\3VB75LSY@,`A:1OMNYY@'=Z18*TXGA\G;.>?IX4?UV6:_TU5FHJ;#Z:M M6KIM/*3*GY<5#X%%0%641('AZ7C=`=BV:3X`$CN4=&*O61J$X9P"3<=Y M7F*6AXHGEFE"._<0"=B$71^B91NOBR,CV+]Q.2?;P#P1$"4<'EV/ MPPPE(D]L5W>V<+&VHO$19L^+XS2@GV:+T[H*B6U!*KX9^:NHP,1I./W7*VT$7/Q`7&\""^SM\/,?TX6YRP1JKLO32.@MOG M+WE2+$\=*D-'MBW#D@U5U61G/#5DUW*F^FBD>/9(/:22ISK#3SRBPDF139T< M_E,JG_95.A0EBS1;UC4OJS2CZLJHN+JGK$-:L/B''\-'`8VR+#"6N_=[WBJ+ MXB:3K%$F67$Q:7UG#8="-9JLIC1/XS#&E#BK7_$YTL#<\R@&9RN79@F>`;B\ M'4@@R4<2@\=8"/"??H*5"57Z^H?T*5I&0.M`\J6;JS3&;]XD M.('R(H_F$0Q4%QIP'@Q8H0[L,JQGK7RY(PETM<`1@:,2;T:,!:[^H@BSAU@0 MB`4R6#+!*Z[RJN"A8898IT!/8AY^,QTTPWXOC\"(+*+`3["2"V;#*W.`\52) MD[,R6T#$N1\PU5A7^_1[80S\2FAB42),%)YCI0IEXH-6H3=*!>Z6[@`T7 M:"4YL7,)BY(BK#!:Q+"TU"B9E0U7E4WX^8@5^:9)3`N5(--CK$HJ,ZKI$-_@ M79HC7I^5KJ*$US/`IO"9`T`%44F(6`77'N05#\K"X$0$-8JN">OW5FD>(>U8 MU)67,5N31BA861>>!EG$Z4W>5+&0`<_A_4HRA/JT$;EW.4X3ZUC"(/;SG%:, MC9F65!`'4E`N2ZI.`U(P7$N%V'4&3(HQ_T/4I(4T9Z42;-F0"/@ERE/*6/'` MJLV;8C/TX39@J0A\I`H=L((S$"H47/C*V62TN3X2]CN>P:3)HR() M_RIQBV!:'Q:M7%73*<"^('6+B.J?>.%H2`/W>^=4E;A1L/(KZIA^@9+@5RKE M7V7"*KRJ<8"O?,U:FG'CB$@GEVW4'S!!VO0P!!4Z-F*`F\!+P%3$TBD9/*R_ MFH(<"(9#D?^HA1#E#\MJ\?6[RQ#I<5^ZR%(?2Y]0&$MB-"F&$D:XX(FF^C1# MNL*O(XJLUBF+\N]Y796)D\U+)*%Z==L2JBUQG`#Z>`UT70B7/S_8,Q03\)[B MR2-S-)0-S09GR7.F\EA5)A-'=<#YM`\)[#E'564XH)J:+X=9TTX3&LUDU7*L M5X$]CQ/IWI?_W0<+^WMG"/;+]D"?P70@?FI5;G:JX`'AI5D\O\$RSK4R;J9L MO.LH]A''9/XJ+(LH0)A!J.2W!OJ.?J?'FE^,?W^'FA`W>WH=9H.JY'6MJAN^ MAPJ>16EQ@T<748%J'A!(6?BL='59`[MP!5,E/'.9I3=83PIF-LT0H:.9@1?1 M]%0UL6AZI<\8DR%--.#$(*#T>1@&2TY'88QO(9S-0/$P$]JBCC_1H@\L+Q,K M&D\X,.!S4!JC_IYGY27@'3#SJ*&1)Z#9.3.$/ZI$=&6`+$,$1,CV`!G@*8 MO[P`A`.LD=`6BDL+`'X,SS)FT94#JTOQ ME%C""_+UE9P17'Q>L@WR'=+;H(QN-]C\!U4Z:?#S4^_+V71V"AH[29.P5N/W M'3#]-#D_GYS*9R?>Z/C+Q_<<1[/^@>^E93B/RN5]NOEWZ<]_'I]/:(!)\_JF MEH2CV:?9Z7LIN[SX31G`?^_@W=GIN/DV/27?A!??HT)&!"+G199^#V5JMO<\ M9NAY;!"H7QY[X`J8%AY`?K\W35/FR8]10XH5$ZA\IV/OG52[#DS,*(',3B'1 MMKL!SP;?_0W6Z1V*6LP=0J9E+Q$Z9BX3&Z>JG80Y7V83Y_HYV/&UK6 M%N\!%G3HUI0[Z&8&H3GC)U+&[08]`LJ,G<9K3_&79GM=FDWOR%$;9"/P`2^; MA:`VH^R/(%/?PQ",;[]W"`L.KTO(4\TL<#W#D#4-L1MM2#;9;DYI\G)ZVIU/#>510>,XM+*[2 M.0/S`((H!GDDG70B.<"Z!O#'E:/I;SZ)=@\4E=YJ)@B9HA#XI$Y9;?0I#%G# M3FDSZL0[]G;0J\<"W,FY'N+-'`3OAU3`IH-U+5P*7!&E`Z;/CZ[6P/.%U(6S MIBYH>_[2%X_1%W4LXK0ZA7E?-.(9EF]SP.+7XCU6V9<`Y5C*[$GAE),%C)LQ ME5ZD-6X3+$07,JV=@:_T.;[.AFLCUD[(X7N2WI`3)9S_):<0GP-WOWX0-964 M8W9`6J;@BY9QV`[(K-+X5OK-&Y_(,$B:A^\PVQ.#NLW`GZ6P^8EW>E(ITZ+M M>7.R$&?S^#%@G\H(X.@Y^;\LT1D!]"J78#?NMP[]WAJ7M[0.%SBGO*3CUC`P M7Q5?>FMO`G0!=NL!)QP#+Z#*,5&`"!:#ZM41;?/?T,01L(NJ,Y#HV0\H4P2H MCT[D2U]7--QR%8>M$]L;D\D1!L"Q,T%Y`73"LXN0$GC4D>*:PNV-2&*:AO(O M\`+/6S(0C#E"=FJ!_ETF*S^:-Y/$Z5%H@_OV[(97^TBK'16>?T4.5()NFNI` MTS36\XA6(Z#*KWZ/NKJM'='>%+E::XZQ+N@!UO/@Z+7HXI,#!-.531U4:X>6 MDX4!"?*(81WJ""&&=H1C\VUOH-I0..^%_K,>5X.27FB4=IA@C6R^%M3<;/5$-<"0-+5@ MP^`G3;,.GN1A1=Q+60_!M^CW-D>V7\ZW:`?B,5XAA(_N"UA(;Q6AZ,[Q@88.( MX>R7K-P(Q@.#R.N%&D,.BYQ%9+%8II6:\GEYY`M)MY/+W)_1-Y!6IYLWNJ9W"@R35HIS,A@!^X5MXI98-9*1EY39J0!:[30F M5;DJ*_2B<0?D.,*\VEL*?&E6P(;.\"_OZ.!MS:RQ-4)EH<9JTK6V)JXK[ZNZ M6.H=#ULSNL9SACP[B/+&Q`S$GPF%S^'P9;@,HL*_B!(*PX`OXV-M9!3`)J)2 M#/R1*GOO^8"2Y\Q,+<&'P10UZH9YA.$8K'FGTLEKJG?%WG?9-9XY M!757W&`W2/(Z;E(^43",H/*&8D&)4"9=U)]O,P'+2(*07A)W$4]CP]XB10@& MCM6AWV'B?J4)#G]KU`":JB+&O'SN%H%8'/L757%:777Y"V&_FJ6E)$(L%L+< ME42@`'Y5.GG++A6ME[X;)\HR'T881BE'W919J*(CS2!8KP:Q MFJH"`4TMJ*(H9[4NF`)F@:!JK%:P_N/QV?D`2S0W8BH\=0)ZKU*E38O1 M5CZW#;@;!Z,3),9#)B6/7M=1X#9%`)0N,W\Y((U?M4]FS][K4^#7*H@JI#_R M>N@J?"$\)PF/89RC>90EMD5EG8?A]UPHAZO'Z*ANCFO6O]!U13:6I-"Z,_R& M4^@$>E17$RJ-Q%"/M"'2T^_=4Z;3*;Q9*WKD]2N=^,_VVJA3FW]WN;U0DS_U MHXP:"["NEI]P]K,$3W?2C^U@+[G.__Z//0MD:6J5FR:XPUV=!50QXZ MABX/1Q-[.G4,9VKHK)I?X33O3([`BO46!"?HCT78_9\WJ[KW7/I!GO)5@3FJ MQ7HM/`^5`L<8DT]YD^YIFOV)S@3O;/%//_^2%O\3%K.`^]L'R!X=&Y;I;L.> MW4AZR494WVQ54QSEAZW8CFX]B@ECR[`]U8:MH^'^<6Q5]MSI6!X9BFM.-7=D MF".0$(6Z!ZANI^7E-IVI7HAD^(7QN'7?BF0-2<:-X9KVSB1[21'-H[A$1=X< M@6--*5@3(7R7V_S98N)G>!L(MK6BT9^F19%#NJ/]P.8:CL@AECY^@#FF84\\ MX*RL3VW8%",7]*GK>O+4,B:::6BZ,;11'C1D#ORKW3OA60@7M`=U\?U<6=.J M^33O,L",%S;Y:*Y">#3/;,/2W1^V8YFJ^S*`]%R4^E:=2V-V(DR`0U>@0X^Y*OG'>Y6TD\-[W9BP#:,:U["YA8;5^:I M?'1TV]24BH^.JKF6L3,?K?5K?<:&IIFZ*8^<\4B&+SFR-YDX\G@RA?VN>XZM MF4S14S]3=SL^;L&/K=KR-9W3GZTMGX:\U5X:'VC?5`/Q@6886W7FVY+0-M,Z M]T=]*3&8QWNNS,H"G4ALI((G;0-$9*B!=P-3=S!K*Y.Q51GPR%GB+)6X$?@XRTW>F.^(S(IV[0U7GF^;?WH\1PR]VN8`?)(\,4&H[= M3\\^;D[9FTVPWGQPE4[?K(.Y.F5O7,"K4TS];W-URI/YMN7>H:M3#,O1NXQ[ M'5>G;,.F9[@ZQ7C1JU/VM=;4:-=N0\>?<'7*OLAE5Z<8EMG6C?NZ.F5?9+*K M4TRE'3IZN:M3]D67RU=OS=6YBR(,%]/9"P`X6<&+BV<+2K66[$:UDRQ<1N4R M9SW+=W:A]V7,<$D[5Q`\CKB??;?,;@Q[9+-9XV]^M\R^-ISQYH/Q-[A<9F^( M$W,U(("OZW*9?7$'+Y+;,WN;?Q4AW+:J.QUW"US-[T)@`[5>F$9O\&=\L\%>ML&7/5T$JKAKN' MFV5J[Y[K(@Z8#E&S.F"+-7M##&-M]ONY/&=OZ@9\^G;HYN]S=-A2FBC1= M5]WGRV+\Y)MS]J;),<"B6@=T=<[>MAU0;KFN_1INSMF7"J;;A%13V\)_?,3- M.2)O,6@,`W[V"TQ]W%0P5EI5\O!$^I[G!IQ] M48Y7O'3VS"NX`6=O2D5':/=3[K_9:ZWQWO89I85=37MMU<9[VXX8P;(FD+FJZ+N3_%-K;/93;LR8\X)%-[35,(Z1 M^4%1^G%=3SNK>IC#S@L#/R^8][`]NS2'%7EJ\,.Z0Z2ZZMC!6\<\>PA`#IZ4 MO>Z)JG[E*V&&>#U#W7Z6?%6$6WU9O@:)AN.^GD`F; M_D0S[B/SH0D?2HH(M@8V]E#55HFT92NF^LUV%5#W/_`N8L-I"J8UQ=`>52*M MVE-7]\`/F.H3\*RGK@8:QAC]?WO7UMLVKH3_RJ+O:G@1);'(%M!U3]!;T*8O M^U*XL=IX-[%S;*=-SJ\_0TJ^R+=0MDA3CH``<61*T5PX,QS.?'1B#[,L"*(T M\M&BO%S6X^C?3RI]^Z)`?;%2EP='?KW/!-9'[>+S/1G;0"6Z$IO)K!*]6HBN MS`@#S,-H)_/`G`.QQV)>4<"*#F;>A][CX.[AKKAQ-%Y2;'G?YQ*4HUX:9Q?[ MCL4P*E9PM,*O&K2O%A,)W,F)=)9R55*L:N(9'"6NRRI`KXZ_M!L%Q*]`P-9DB&L`AC[H$& M(,9I;0:$09($08*=+$A3QV61ZX0D94Z6^21-O&)ZS)"]^:!'"*6 MLGD_>1`H,(4K+6[ZF/^67]583FYA!(6?VHR`2>6%"0N!_``"1"#4B9*8.BD/ M>!KB*$#I@A%8%EQ5PF\FZWQY=QIF@GJ]D"=$6*;-UA-9>V@Z?D4 MST4!C7LID7$_S8!Q6\`*(MKIN+LCK[>3Q"5_(C,[O\4"8_AS<7IA:W2"BMSX MLH_808\A`UEI<*MM%Y3:V60$0H\&":$U+:/DE&7,YSGJ(!Y7F2EODILY_J% MY&IL4-<"=580X2N6M4"5.!/^`N*F!OR%[WG,3>+(":-,M(MZL-"D?NS@R.=) MD/DQ0O'<7T`8T8"[:&ZS3(T1ZIJAS@PB*\,4[.2&O3.]BY4Y-RK=L1M7>@%& M@4_KQM[KR8K8<]TT2ZG#$A(!VV+N$2X#G,))YR3,&)HKD.SZLR]5RJ:FK1W M<>\@?FWJT59DF-S8]Y<-T!X-VGJMT`)$X1`K%*?(37QPS`&*8?U"@2M!1&.' M9RXLXEQ*.?475BC`<,VUS`H]QX@:VJ',#+E=S5?S4XULX1O)^>%BRL'E-5B$ M>7;%1SZI@B3LQ=0L\).,<^:$"84I%R3P*<:9$X5AP$(N>$KF&N:N6G:-*3\S MT`DS5OL55E/F+B%0,(\QWH!U0V#=((B*G#2`%;@+#M6)(@Q*'"(:)A[GF"PM M0?F\C*`AY`1M[K4$G]BEK57W2BC!N`'WZL/L9V'JQ#Z"J(1[F1-X<>!DC*9I M$G@XXWXC[E6;I\`R!8U8P;F#/`5Q$Y[B"'QEZ%+'3;W8"2$V<^!#@*(L\\$> M+I2+("_@?#]/H5>/T(P;S^M18]`P64+`;Q((:I&7.A!K^$[DN1'8P)3X*/8Y MCA<3LSHM]]2DAE)#'BOV,$A5@58RA8Y47DQ>R?FX=S^82@3-?MWM>>IYTC<6W-36X<<$ M[^IV^-6GVRP0#L>Z<7`*5`3"P`A6=.ZD<7"VL74?_)'(35(WH]Q)$18YC83" MM";$\4C@0V`1N!%")0P.>>T]6TESFC`X!^FQ4DT.;1T*3I-*J#K51;4C>NWA M/4%PK,`]4>!;,X91P)Y@YJUTH;4$]D2)2PV@GA"-J"?&)%V`GE3E;!STQ!BU M14L.\[PJ$)(9S!-C5$I\#"9;30Q`GA@CBQ>R6P$!WH%X8AK0HR8G]HSVR4GC M>1C3)G>1T#*#YM$8((,Q%E%@D1=4>604C^%P2M4J_F4R!GO5`%JEW/\HO?0' MFQG%=1LPA1*,@IJFYBBM],;FA.BDIVL=O<]WTMO5/6Y*A<3"%"XM0X^:;QXW MTDAL3`%E'5V!":ZAC[A1BVVP24VJ&EMIGC71H[:98/TM:C(*9-SZ#K4U_NAO M4*.Z&]3,IL#7S]5I+@6.BQ2XY^/JHNH%I,!W'E?4;`J\*/R@K\D+18(_2(_5 M9KV$J=%X!(ZF%'@S2J@ZU8L4N$_:GP(_Y*PQ16[)%#BG[AID>GM2X,]PJ8$4 M.-:>`C<@:9$"IU7+<:0,N`%BBPPXI_08J-_&J&0%D2O'/NC-@!L@BV^T2=9E MP`\X0U0I`XX-9,`;SM8:4`[1>^RN+`B/D*T]A%*UU;ZL3<>H5=G:0X[555MB MR!0VC*#,0+[6QFRF?A:+%!-SD;O],65 M'X-\_,?D^@9LXI^O;J;3^S=G9[]__WX]R:]?_QS].HLOWD%,![2Z'CP35VS4WN_"7Q1N=GVU\T;?G9S-*2IZ=59AV?K_`SRKHGO;&,I_W5G#? M0:XC.+2X.A^8@\%<#/,VTB#,34%\VYO,6L&K MYF!K^[,^0X"XDBQAF$99-H)N8)70)0!"`7^0SW&UR[^O\O'=2GRV.E(.>4;H M^[W#9(98._G8N\N+M]@],/PUN.U=W8"?NL\AR+S6]%YE"OWJZ7[YK4J@B')T M.4;/"ZS\Y[7OX]&G8?YE\)B*BBSXK=$Y(P,4RK03T4=L@J,9^00?T+I/UOGH.<.TNJVY)2M4A5#M,Z&>O#J'73 M3U,\,Q[WGJ+!Z/*F-[[KP3+].)/@W<65WN6]K[:`]77K?5VD1OOUOF4Q]`(% M<17]\.3-OW*B0J/YWX'T:I6JVQ9(%]M$Q]U-VA?@V2K!GI+O%@GRO_-A?MW[ M^N[]M'\<`_;YX;IWWQL/OEN1GW>/H?SJV/#=5&CS5+!^+?DRYV(71;1/>)L/ MH[%*>`V9ILL?@_\]F]PZ1*;8P2IAO1QF1*;=A#P%X75[QRT7I5U5$M9PI_YA MJE9-@A,*VF'Z_AI,BLSS$9-O?^=C\4OK#K:2[J,CZ;[Z.I@XC:=B=Q2*"%.S@@7?> M.]GF.8M*;BV,.4F)=LN8DY&I7II__`\\4UCTI_?"GE=MPWS0Q1`"@(D< M@9NU"(.A./=G6H%LF5W3)RF"")9%=SYKF=SDP:&R$J\JJ@^C8?[TH3?^-Y]F M#\/^P;%^IS+;5>:E*(G]B)*V02]=99)=(;/+]VFFV97.Y$N-IIAEOW#'>TO'>[1^?Q/ZQ]26: MFC:P*^L(V^95"V92I\4O5HNQRVD@`C,7<_C+"S`7>\QPKUUZ.P^?!\/!-'\O M3@.\&`)K?HI681E(3R*(F?^1E?"K`76YP9CWK_+KF^'H=O3SZ;.H(6AL^?7E M9C267B;)OR\I[H:NYH^C:2XTO`>?3T%]<(!`81BC;BO4Y[(W%B4%5R-Q-O:X M=SU]Z-TNG8:XW&(G+9S8^!S?CXK#LSMM.5!;4$`X!6.#2=`*;1%GCX;#OOB5 M_O=A\*MW*\S_BK3@RTXQ]E6,$IA[NV)\$P$6_!4@S%UNEYI(.W$!,IE,(71: MB1I2^%@&UL550)``,)BP)2"8L"4G5X"P`! M!"4.```$.0$``.U=;6_;.!+^OL#^!YT7..P!YS@OUVX;-+MPW@H#:1TXZ5YQ M7Q:,1-G$2J27E)+X?OT-*=F28U&6+,F4DOM2UP[)F6A:G-'$*G9[UO=_WAW<5HU/OMUQ]_^/2W?M^:3*Q+1BGV/+RP MOMO8PQP%V+I'SXPR?V%=(,\./11`:]8-H7\^(('_:"N+S`_<.&)\.@,S)8%FP]^,/5E3X]%F0M0I/)\OB1X/O7V[N[!GV49]0 M$2!JKU64C655/?KX\>-`_34J+;A"78MQ<-IL)CCLYX@_MS#O?BW&R_*!0TX.J`"90\X^[`+10TAB[(V#(QT,OP)P"B4>$_>Y3=;.]36AH&P$ M>;=,$"F8"P$05R"G>K\YS6^3R2WB.-=E:D$A6"&`V(CKWYL%TC,KCWV)$;4 M(1S;074PFTU6YOJ2".!`A!P/A<"!^(*1_.(,@VM$^._("_&83K`=<@XSSSD2 M1.PZPG>@5".\E2*,P%9S96/$D#HKVC$[\O>AXRA5D64KV[7Z&*A1&&-0>SZT M;1YBY^IYCJG`U;LUL]$:F;Y@%/RA@#QX^)8SGPC!^.(K"[!HIL/*TFL**G8Q MAW%R%S#[3U`8]3ECG@,>V-5?(4R1>X"_(P\UBN1N!N;Z7/JKTN,#Y5(48CT# ML\&FE/P7.R,*&ABYA&!%5K93C-WQ7+K$4*>ZIM?)2^,B:D8[RM"J$V+H^X@O MQJ[2P/%C4S4:-0;H@MQ\]PRG%$M!G-+4BF[G$IQF$@%XER`7_U;'NA@YUKF%92 M"_.Q>TF\,,#.5QS<,"%N,5=5ZQFL51BH=6KS?1(LO1^89`+@!X-CU-PT7I)@ M/2L!Y2CB.C(4W+O5JK,Y MD'I*QC`VI-_;Z#6--V?QO8_IHB3YQN?-\$'@OT+X[]5CL\-83RG&:"=1'YD. MLH85RF+JR,WDZ%=)JX'=_(B1P0M.]L%>[G:]8@!8`&FMD?5D>@;CZRH04U4Y M&"X2#RH1(Q3]*4+S@52-`?8"L?RE'V6^',7Y&#_%/__Q&5/,D2>]6,`Z][))\])NE M37#^%0=)9VCX72]C@LM8+V0O;^$UJZ01CN6^.F@H6^ M@<&ZQ(_88W.UC223088VK.4X=A37]S-$[V>2@(Q4+.XP^$JN'\;TX" ML/]CU]4@KYU,>V05]UZT>P-]NL0SHK>@+.>%0K`S>;1KM+;$MP6,Y7(\%UW9)@YIZ51-RKD1&3O M7YW(,CR'OGZO*!'7R2[B M,KTBSTM`-^")O=AIN@BYS!K7.%F:PB8\R,W]L*VL:\J7XWXS*"9_63:?:P5? M+L1*5#0DX=`/U3Z!&J%R_X#C&3`$QBL9]#`?CEV8[?1R+]6*$:2K/*E;1&!N MND!S$H#!T"#2E#;"N3IJH&,T^J,YOK:,R+4R)KB4YTUDW!P^Y&;K(_)4)#VX M0)S+E&:5LZ'AOEA=(ZB8[S.J=I)S`;PL9H+7E*V#*7**K^3:`*9P@2_!9[9) MD#(?EZ$\./.RA@9=#0V;D$=J>LH\AJ!!N[6:82SYAJ#RG%P[OW+!6I3E5%EC MT=,BYC:CH&%^MTHYNZP)KM=/".69U:R2ACB>@WL2>Y#YJI%=U@S7,KP6+&X] MF1)+'6F^E$D&_U#+?$X5$Q@*6^T\.VUB1;_N3*87\2_L2R?#Q7IT^4K7R;BN M'JS&_G8R%)LY[:7!%G3P->''CH/7S`"::&/'P6:Y09I`8;N1%ET!I,%G>=HK M\*#2;P5\ID$[ZM"8W@5_5JD$_"^=!)\ST'7Q:LWF6IJ/W4%=;%AGKCB3<=VAN;L8WLVH90*V0]-W,;#:#8<$U@MO-F\D,;7ECI:2$BER@Z M9.^3T`*DB)GB\R9N")F`.QC1;M!H,I9HP@7&IZV,*(W\>F^*QFYM7 MD%_'T*&2-96.;B9++1,U2+;7:P>:]-6#J750852Z^BU"MTHGS%6]@I5K2>G: MI!5'5)/;&,JG>U5OU-#1)VFL;CEX3.!2G2^^"9G#&_MP,JU7W2$GE^89&>*: MOJS8:(OD$#E(-H;,)3486/LJ!-$(R%"^9*` MNHYD&?#39W9LJ5?+:-*1T5P/K`)4RW(9!Q+K:7-?R-;N?=Y@(].%J:'5]FAA M='7H-^I@#E8:1@AYE+=M9=\8*X>3@&+16:;T);JE-+@NFJ:E*,TG\/T%!=*" M+F`%J+6M!>13IC4C:5V9W:-+[;*Z$==RCWHZK0RD4K$Q%U:##6$X98I594=_PZF6=3GQ1+./B)I#J4 MG[(O2=7FA"92[E`^S/Y']=9%3V(=.Y0\64]P4#T1]!=.<_:53AWR@>N7RGJ>02?//M0O%%THHY,')NH7 MSZYY5IIC<=VTY!7DMR6G1'.@[LV):9>T-LTQO3Z-[?7,72E44K&V M5#)[V\$V+&O[?MO[LI.QH%)"V#8P.QGX*26!;8.@6FS'\.REW[UI[XRKW4?. MO-FAO3BR@X6Q#P'N&IM2&::(O'I_CNA";4NNG@1V4SYO>_&T6/[24O#%V$UO M]<9KBT4[.+1GV`F]Y4;VIFPYEPDI2AW.%QO/#0Z?$'=:`63C<<`6:T75)^_; M`*+TT_7FF-[C:_)O`>3J8?O>+:1[UW?,7]%6%K< M.[J7P]O(:_$WO]O(?=5WN5\AIA:/BYSGK]O(KOXAZTYQVV*%*/F"=!LAZ-^" MUG+[:2"Y>(#1"U_^!U!+`P04````"`!S;P=#!(_?'H8D``!,O0(`%0`<`&-L M=G,M,C`Q,S`V,S!?9&5F+GAM;%54"0`#"8L"4@F+`E)U>`L``00E#@``!#D! M``#M/6MSVSB2W[=J_X/.6W5U5W6.XV1G;B8UV2WYE76M8_ED969WOTS1)"1Q MAR(U(.E8^?77`"F1D@`2($$!E)$/L2WAT=T`^HW&3W]]602#9X1C/PH_GIR_ M>7LR0*$;>7XX^WCRY?%T^'AY>WORU[_\\0\__8G":+$:7*&I'_H)##:X\\/?GIP8_<^`_.\-X*-_7(SO!N_>G`\& M\R19?C@[^_KUZQODS1Q\&H6!'Z(W;K0X&YR>KJ?[.0/LP^#[-^\`MM(WXR@- MO0^#'TH?76+DT)D]`.G#X-W;\_>G;W\X??O=Y/S'#V]_^/#N^W^56T?+%?9G M\V3P7^Y_0^.WWYV2'H/QF_&;$H[_.7B,PAA:+Y9.N!H,@V`P)KWBP1C%"#\C M[TT^:)#C.P"*AO''DQ**+T\X>!/AV1E,\_YLW?#DCW\89(T_O,3^5H>O[]?- MS\_^\?GNT9VCA7/JAW'BA.Y61S(8J^OYCS_^>$:_+;<&.+QDT[P,UG=GV9=9 MZ]C_$-,Y[R*7TE0`G0&W!?GK=-WLE'QT>O[N]/WYFY?8._D+F?`G'`5HC*8# M"O&'9+5$'T]B?[$,T$G^V1RCZ<<3-WB.Z3J]_?[]6]+_3U>1FRY0F*Q_.J%W M'29^LKH-IQ%>4.A/!F3\+^/;+33<('KVXPAV>Q#-5G3K)?D^/B/MSX2&/FN+ MP!AZ_OJ8P)XE4Q\3#T-O,G8-#/A]Z'MTJI&UKOJ8.`(7$&,&VQT/7Q2GR MKE^6*(Q1^V5E#JH0Z,LH!.4I\9\"]("CA1_'$5[=1PF*NUDPV?FZ0A5-$89S M\IA$[F^P8>C/>11XH*]=_YZ"B#P`^@UA4$B2QSFPZPNBW1+]$#87G2'?9\`V MHEGH?T/>;0@[,%,@@8ML>&<\FHZ61'^&/NUWNDI8.B=1-[M#9BZ5**:+A8-7 MHRG=@:,EI>'0!3T+]F![I"I'5XD&*/Q>&B"8B4U'C)UPENV6BU71YL%94?GP MU<%-53W%0"@DRIWODO,SG&&43=K-SA6<1O6YC$=I0DQ*8NU?O[A!ZB'O!L3* MI1.X:4#G'$VO_"!-D'>/DKLHCA\0IEW5'-8V`"@5;8N%GZRU'Q`R"<"#0#'J M3HQ+3JC&$J"*PB3::'TE]H]G#L@'.AF`$T>![V4'+O1`TL;$^LU6@]&YP&N" M7I*+`/A40PH=$,"^4?0!!B#[PWC*;@#MFL*//J@T4S"4@>^#3I/20[2>O;N= M*#AMU]AO;+1B"3I$NGHVK;A.'+`&U!\+D3F[QCO?7S%H-V1".)"Y*7OG.T]^ M`'("'83Y-H7#4/ITM&/:0=,UK:[04W*(O<*;IW-IL&?^D[:'P%A\YL[7N/![ M3$QG%X=\1$U4'5-NSV3M;MM5#%5UUA>.S@$ M]6YC=7:')'\F;3AVM+_KYNL:WPKC^Q#B0G+ZSN5F^A2CWU/X]?JYVV/,GRG' MT<&N*)J<7(-U%@-),OB.8N\$P\N(:4SG"[0X@EA23"WNG8(XQR&P&[Z MA$XWE)&#E#5`#J^W2;LB65=;,,,A0Z%'LC"R3\E0':3!4#@`$CC/6],')($H MPDR:44QCY+Z91<]G'O+/"-\BOYQFN5OG>8[0G^"C7XFOPF3_>_/.H?G,L4D5>,&6+83_!,Y^#KTKH#5,4#C-NT>RO6:97.#Q/4C[P8^ MBQE@\ML>&DY"(S$HBY:'@[&T[>&TH5L0;U6`,IL?#MIL'?F;D]WN_HQ4/KKUV!X,/5-DHI/Z/ MO7`>']BJ3H>"_"I7:#@P7I4UENZAN?$#A"_AW,TBS%_E[5:'@FV,9GX,NRM, M[IT%]VCL-NL>NCLT+IRA@0+3]_0:>0GL; MXFW(0/5;#Y-K@6(&3-YGBJ.%@#!:3QFQ>-T@PA["'T_.W[Y]\Q;^06NJV'X@ MEBKR/IXD.$7%AV#.@L9Y'5"3#S1F-"._G`R6(%TPK,3'DWH\91@`H4WQ\-BGM:RR9 M^O@&P?.W1X)@M>%6X*M)P6&Z2G>Q9IKL:S3WK(-BD^I:PSUG^BY"'(MF>^76 MAJLL/C^=;?N(#^`WKKR`V-@6FSKQ$R5P&I_.'&>9&60H2.+U)[N66?[QKR26 MCM&C2W)IMCL!LY)1?2W"'PX2Q#FH-%7:]C\;DT MI^LG%"(0W"1CRUO`@2!J"MFE^>T9#EWK>NG`)-ND)$^>IM'3X'(*BU]<[KE` M("3RS0S[&,77+P`WL!,_=/"*RHQ[)7=0LBNBPR=RF%W>JO/; M:X6^EM*LEEH@)K=RXDE-'*5?.C^ MGOH8>13JR=P))W,1#CA_0:2($/*&S\#,9N@^)99]?NFU9(N+*?@-!SM. M0_>0SA=A_8&@IH01%JX9\P(TC:A1:WH5&)L7KU&X_FV4AH)$FJ(]>R'G>O%1 MIL@NTS["B+,D09B:@LG!63G\*LZ+R>'9ADB6S3*3`[.2Z-78<";'9N4P[=2G M9G*+-,#N_*(58;6#`YQBN':E/+R^0@L!P%*N-@YL=^ MJTU]90%@O0'3JHJG&MP5.Z4-\EP0CCN"TUB'FV6_`$,MZ)SV#XWFUXZ2S]Q-E- M\ZYKK05R6MN6!VCVI3ZX:F)M.XWTP5G#.;;::(=2B*B[;75`3@A(A=G0(VR8*A3\ M=*'*+C9MZ'C2AH0U%4-T$VEM1$3_.+A;G>VG*+O4.;;WQN?\SMQ@=CURU0RI MP-'6L3$WUESIQ=J*8HDYCK3G1JG$F:/0%#B:ODL% M<&0I\P6"1[!QN;CIRHYX??FZLBZ3\O)5F?C%6IJ;$*((=Z:4/# M_$*H'N=^KVI=X&Y>)23%^YWC)BXH8&Y.;KU37EQ+3A^1D.62KL=2D+=O;$FKS&7<-X.-)J1:77=ISK$U)V]2SF#)*!3.. MTH]43N!I!\YY#(XU#^3N[ MQN;:/SA$9YRCQ'`#+"%.P/8F9$TD9Z:$PNSTH/#-)G#]OC& M+6]0U<,(#&[C.!6'/F]M!.3\>OU"75Y;K.@. MS?TS:K(_OQ&*G`.JR:=O2MQ)KPN39,'>!-'7^!;6!2,WT50D!".ZKHL()_XW M6AMK-"6/FM.,DF'H`<-?^.D"P'Q&<991Q;$:&@ZFIS#$O]-\_DDT1J!JNGZ` MMFI%32*R0@\85A26_&+U)2:5/3<5XH9NXC]G8=Z:>_M=3*6FM`D-PA.0X.!X M-Q'^9>Z[\P=G18#]FQ/?1\D_43)R:=+@KF.AR0A:5OK9\0/"/@`Z4J/Q$0$P ME)B?,)!^C)R`2+A/P'GS8!AO'>4'LL49NL4J>U@.SA%&#HGH93^ED.,,H0M' M(A!(FB[\FK%(=..$-C4+]&(9L5<'"0&L*H>):>=YER^3<*@94L\^C\:%I9 MSZJZCZ87A;8$PFVXDV/-P:2^GQG8;'3+//VI1H9(#&`(?O1&VE[:M#AZG/X& M85>8!U5'2["S$GMB?Z[\\B-Y*:!I&<7V@]J8?K85P")AF9D,);"&&S08R&Q\ M6?7!6^/.'-0@.A2&0,MUKQK(;'S;K[OHH`;10=Z#U6`@L_%MO^ZB@VJB0Z?O M-W*D?^Y?V'L$B2V=6:)><@0M>4N9:S.>1#F4?*\@L=UY>4R2HQB!*;>DC"B2 M_`$TE>QR$?+H^R#$0P3B&XVFI<@9-P>MKI^2T\2;AGJ`?-@IVW%X>H=CW8[Q M_J*:,0^%6;3PXSC"J_LH0?$>&$PS0<&HYNS"+&C[)?00!BX-)\1_1N0R8?[, M!_+(31XP;JB0(<*D`? MF=&T9',REX>7UB#.]<]B%;[%`T M:II[TH=4M$/1L";:TH>4MH-MMP:)(-I3Y0R@7R/CO@^7Z0^U\62B;WVX@:\J M3V4[8[4ZWZ,/%=NZH(MX_D@?ZKJII%"C#,8^E'Z3#]9OR*$@`%M0R%SEJAF% M9,/I!27,U9U44V(OR:4@@KD*4"?;@94[LB'&^V.X7VK`[5*!Q6V>M+#ABNU= MZ<7"FRM;VQ%*(BI2$,-<&=HE,90YYPM"FGOS]3#'KS;>4Y#*W.NS:O9`M&$6F:1@G[\**,&A*U39WKPVLU MS=/B=BA53K+J0[T.-8AWXS7M0Q4091NG59:B]DHBMB20VF(-3;95/TK2ML"^ M4F[)EJKM'?:5-D,?7D<3PU[N`.@QX*8!?PN@I1OB9P'D;+M-D;5UG";87*]J=/G3`/"^=3V=IUWBZ M5J7E%5"O#!'CBGI]>\W0;W[]FP]F,7;GJSN2O2*&2E5GK7C1K1-38,X_;VF; M/&08/;1BD!\0Z@[<)[/841,:XU5@:1^@V-#^$)3>\RPYJ4787.E0A@J)*QV/E6=YVL4M8QXI49^>PG8 MDTSJB5D")A%$;`-U20\SMH@$IY8Q]YA48=GU^C.$]%X>T!K`V3P76UR<(UH* M:\6+]Z%OPVF$%]G%?1L'L7&05QP'X91RV@&',KQ12!)KZ:^3K]$$.V$\13C. M[JGNH-5P$*-]9-;79'U-"I:AZ?G2KF98OY-5O::N::7KK8O]%Z2 MH@#<\I7\]FK>7MH;GJ<=U3;O"!Z6'E+95,OK3ADL#SB:HCBFF_X&"2XMKY.6 M=TH6RR!:(31&`7EC4GB7UO<[EA2NXPIOH M&,H01^+P:U?K%*-UAT\5XUMWWO5':#I9WVI4-=WCJ+501!0B:VR8:&SP MJTHH=NLJ?Y^3G\A8T4'7*Y65R5BE!D:\')G5:]F4SA-^/'*OGSYLZ(:FVS@O MS%6]`)5]=+V"641>;AP7,=W!MPE M!M"/7UV(AM=:/^3K4AY70%,AX+_*NS#:JD'8EHQ$GD3Y,Y#*H['_FR> M5&?GUO7JLX>"XTV[!NE,+GIF-SXCS"9095,MX4NBHZ$[_YE<0D^<<$9D2.:> MOUA]=OX=X=H+)!(C&(9A`=V]LT#52?V2H[P:3*4O,'!?$LT/PP2Z,K8;IY'Z MN9G$X3;3/+^]/E)ZO0Q3DSTB173(5?K4"888DRH3-,F'S\%$>AJ(4:4$%NM[ ME%BIXD@/4_\;+?@9X664%6/BRW1^8QTT'@.?P+X+I@;;E<#^M)+TK8:T-)#? ME:I>"XMP,D%X00P*CFBM;FL$U)4:"Z]U;R$O[Q4M:?/U'LNRY[_=23/<>WYX MDAB1/,_-0JQQ'NV^9++G[3C"`'!KTI3=HR:'?5LC6NU+-3D"W!KU;6>ER<'? M!J@*1&#,CP$+.&G-#0&KPJY&;^S/!>4:/'D^)^WWBU4OI)!;),?ZST>#M91; M.\?^NZ/!ODI7S9']W@1UN_+FKGQ@0G`#L'WAVCFXX`7>@Y+%"%-$Y$Y.L\C' MMK96$^C4_[YI]<&ICJ*P95Y/-G]SU$S?P'7AGPUNW/"R_O>>C^V%.C'Y)!%N MDE#'>N84ZY((IA_=1O&LXHDT?G"I#R^0JPBN[&JL^_CKJGXOQ@$J0RN5MK2) MO*[BE+=%M"\GN29VL^_PXB;I%MB*O6=@3@9]^5E4\L0E^3F/`D`G)@<9)+@Q M6?5$I\_=C95!-D9#+7G=S>'5%#LNO0%;DWV^V\[>`E!X"V#[4(K>`V#V,@J3 MC,[DV5?D?5E&8;$0LMA5C-3G3&,3<_4XN5*?G1=_D6:/_<+R9"^E3+=7B94V M)=1/3Y9:]JAJSA-V'B=F;L_*+EIP8#S#?$L4"B=X2)\"WQU-@*DK-/N>^6CK@7*RX?^:KF'<'#K6O":ZHG<\PA M#UK[+N]*4*F!%OC6KWV5]=.J;$)N>SW0YRP9>5]ES4?`V&$`)S%_`%,5?R=O9X8PP4I_6=V#)RMKF^JQ_OGVV M;?COV41]>)M4%+D:HT/_0Z1'%FQ@5]H1D*@;1S)7VAUAHJ4,<609O\EYE_*; M0DZ(F)QXV6C-2ZJ4R9F637"3,.JTIURJW-*5.H;^D)'B1:[T/LA&%XS'MMZ2 MUY_EH'`KBSG+3`X#JUQEKH=#?\*56@+(),F?GQ\1RI*^_X((IM:S%G$S]?BJ M@"AZ`IXA[?<%1',YZIQ;6[N:84QK7U7!5(YV>#;)Y-":VT!W\84#!B^H$Z02 M.4U7R(N2DX>N9J'_C20-#UT89NF$*U`O-T0"Y$=P5FB?%A7,S8HD-O>A?D(A M$",8AM[06\#JQ0DAS3/*R5D9F1;KJP,KDH.W0)LUOR,SD3/)]VQ7]3`(@\HD MD^H^1X&%K8U3KH6!0%"0E,S\G@,AE\BY%>FI)9[CSI&7!F!!L%E\*0,WOE@5 M;7++>OC5P5Y5_3UUXVN+)>[!7!57W&]L#MPE6O-(O6>%".$H-;!>!55`2I55 MMQIFVA-M5272?4E"%A*#.Z5&ZGF[R1[^QI@+ZJ/Z(P!'%K04OJZL7$CWV*G2 M*4V$&*9V7PRWII`ZL;_EEE)'Z2.,I7=,>XX"*AME-]!Y9,P%F/4;0H\(/_LN M#]H@R)G`:%KXN[)T`!I.O'26?N($Y-/*"OU=S:;SZ;5*7.XC>M4:`"6[/9Y$ M`'?Y>X+/?93\$R6[F-Y$./^(M./=.SDP$$=%9^J2'BTSO^R!R;LUM[%4G3@O M%Z`>3_V$Q%L9SN\V9*L?W%Z[,=$-:)UFO7<^M;X8L0='%HJGZ54EUO80.&'\ M@!'H1K=A@GVP:%R:J'()NA&-D4%3UFV%+F>R]GD/;%$S[7-K>[X:VU.5?F1R M1K@!%&QB6?;!#:V6I)T*7OV>;:-W:'O+TN0,^IX2F.,BD.2\`]C9%?I*2'/(Z3^IVR M8^'ICY.V&IAW2Z#ZR-.E4>8Q6%[JB$$`'M$Y*0E`(R2``#S'27T=$N`X]/1Z MY,R1`,>LU4NC;(@$:`*@D>>$ZV/-\5]OL8T?J(MSH1:(7M*9X9[406E9,'I) MZVW'I@XR2T!@7`W8K/8.@E) MOKX,MC;2\_4FJ'620?!ZT]$.YW0RN;AJ+VG,".V87,W5;!H+>_),KAZKF<0J M[6B3:]0:3F9)%YS)I7$-I[2T$TY[!5YS:=UQ`$;_`RM'1GGAY(>"\J]2MSYT M"EM!;O->;#";W"ICB\4JO$ICQXP4FM(J6'.HL3FTFZE3$-4:0`=+C]H0_9TU MAU2K+P)$%[.,]%Z=5!!=,K;8VJ43S\?(1?XS\DA9@;6*N7U1E!-45CF#+;^T M"Y"]@VKOH+ZN.ZA[_C5Z/?\@"1II6N8?KE%0CH&\?'79)7%@J;>V1S MCVSNDWP&Z88R&,XPR+FE,M7*! MUT^9RE)]/QV*9.EAT_LH03%LS0K#C-=:!^17Z"FY#6,0?V1_`,]`0,UD#*R9 M/AM!ZG/!%DJ`9W.0D1B@SVX(3@W=FY3$T==.NM*#.\/0&Z-9&I"15CFGVH&H MP0#=PES,!Y,_.@&*/_OP7Q*%:/T"N10*(N,IP>@VS!@=\447LH)6G?RR!&8> M)A4K(-ZY_XXK#OUVQ43^-XE'Q0PXQ/IT#AGSF(OV,AHZZ:$#,3D*T:/_ MMNH,D^B#!A7ZL+/WH` ME6CAW(:N!(QU8W0,.7FK[5\H1*[SY>]WB=<$_& M30#GC-$MY)>!`T9$MLH-@&9T[Q;>3Z!+_H;0$N$&T.YU[A;6AZG_K1&<6QV[ MA3&^=Q9(5+8S>AT`.G$)RNQG/(2=2?E<7YW`2,(KO-NG<\@D:+??RVCH.EO7 M<>HZ2P?[3Q*L9;=/-Y!);;6.]YCD\G6^JQK#T^K!^N8>H5V(J%U2^2A\50\E M-/WLO/B+=+'FH247`S73Q\A?/*4X9KC,EH[OY:^@7*88[[M1JMNJH2CV0]=?.L&%$SBAB\@CSZZ+4^1] M")2` M(1/O16-V-HJ2H0VB21RC9.C^GOH8>13,R=P))W,_)#& M6WZ!XYV@<#2=RM&G^31JWHMC>G#I@S5E'^I&DK%VNO08>A/S6FQ4L>4W[TJ)N*--PIRQDETA_NL[$U#G M)T!(AA/*V0V5^GIQ[457TD>#C:;>:7#NE M*<("CF63+[HW1;O>IZK_IGD3EB9^I'O/Q)J@VD^V5;&/A?+<3*X\I`AC1@:B MR:5GVF.]%[F7+=+0+W1+Z9$%HIJD,/?*HLKX%OO28OOHP1'?6E1-?LE<_EY< M-^QJBZH/8_;A*-6'JNO=GJ_*V\=]J)A^6(DF=#VT#Q70N]I5G%S)/I0J[V0G M2:7M:B\RWJ#>CZKT,',+_F@FBF!`)"?3.TNFRJRIG$SO+9EJ\FUR0OW9$HKM MPL_I\YTH??26F*6J7:E<\?6+&Z1>5N7GT@E>Y1=DM(;]8L0=@7%P[Q(P]I.">JJ>67'=:[W:P@>=>\Q7N=D2X:+J1N*G?5A1B MJ[R/R&_?YPI4)M834GW?IB4#$;MSHV02/6DD!Y2$9<=&/3O1;JA6YZ082C&H7+"J"7,0\2GKQ-7J5`(\%WY"W6+#T".N-4`4A2[!IGV)9.XXU0DTT0A]2[,Z=N'2R,[X&Q^4N"F>PHHOBJSI'6,/!S,![\S3E M9_A_D2XR+2_[/D&[YZ#Y.+KDI10O-5![V7/V83>`T8Q257-["1&Y\+2F`",%R#_?VL>A[9J8W?JD_)59FM7 MRJ?1$N=90U2G/C,::H6W,JZTW<@J>RT?$N3ND:WPP<[*'+'F)D80]6Q(N](F M[O=D'E-EAMM1*Q4/,`"Q@)3X)R^,Q-5GSL?K!B/ MT$58C:GL8E62CE62`\+YA3R<>1TG_@)`X=%TIY%5G:SJ=$#525AD:=>$E&F) MNZ>R#WXG,//R"%T\D;AF%PZ MP*!X4L>?L(06'<8*;2NTK="V0OL00EN8M5DY;J(2_M5(^L9LUPK\(Q+XQV72'YGP*RHN M["TE7;?:2+CX`%:X6^%NA?O1"'<9UF'EN8GRG#Q'8HB!S@.%S0!YK:V!;:2. M866PE<%6!G MOR6HUZ)N"3+'\FXYJK70K6)C+70K^E^-Z&_-AJU"<(0*0=N0N!JUH`"PC$+I MP<7X8K6'Q/"K@ST9-4'%+%9M,%)MV$0`-\^,(/SLNXBSY`&%A=;V&B,WFH7^ MMW4%67I@Q',-5,^GEWIL\$M/ML1#-_&?8:DE4S(:#VR54*N$6B7T:)30#AFU M=O6T`R(UY\?'4XY*N9YH*UB9:,?L/Y%N0Y#=J-RX!29^B/#PR;X_';6[^;D7XW*W:MV+5BMPNSMX)U M6L';*\%K;YT:+,"4O?,M?CM5U416X%N!;P7^T0C\+EB1U11,U!0J7D\VY!*L M)(1LMBHYB+7PC520K,"W`M\*_"X$OBR3M<+<1&'^F#[%Z/<4?KU^MF%K*\], MDF>'A)-[##@@<]M;:6REL0[SF[^!K>#E"]Z?SL@43TZ,X(__!U!+`P04```` M"`!S;P=#P1Q:X2M'``#2ZP,`%0`<`&-L=G,M,C`Q,S`V,S!?;&%B+GAM;%54 M"0`#"8L"4@F+`E)U>`L``00E#@``!#D!``#E?6MSW#AZ[O=4Y3_@.*EDMTJR MF^S[9#S6;JU!3%1DO,L,D>DBVK]]@=@($;KKS@^8_OOGXYO_AR=7/S M[C_^_1__X0__Y_P_#?+O1AY"00/#IO81!N]N#6>8)^#&Z] MX-V\CNTI_>0AWP>H'L"C]ZBJ"3H*>!BMDS@_`'EGC\]'B M?#1]M)8_C!8_V-/_*3\=;O>1]_R2@-^YOTX>I]*M1/_04HFD'\QW(O]]&#U_0&K& M'[('W_WC/P#Z\`]OL5=YX=LX>]SZ\-\_W7YQ7^#&.?>".'$"M_(B%M;TJK5< M+C^0O]*G8^^'F$BY#5T2)0$#`?,)_*_S[+%S_*MSRSX?6^_?XM6[?\<*_Q"% M/GR`:T!L^"'9;^$?W\7>9NO#=^GO7B*X;K;"CZ(/^/T/`7Q&WW*%-2RQ!FN& M-?Q3^FN2:.\`?O+KPPW3H65%%GWI`S72Q__`B5HQ$[XE,%C!568H?IT3+B*= M1)H(Q6)#MR+0QS$/HT;'B:RU$S\1@;OX_-EQMA]P*GZ`?A)GOSFGZ6RE0?ZG M]->_7+@N0D*"H'H?^I[KP?CB*4XBQTTR;<3'/[X3>.%#;C]^I>)!!.-P%[FP M4TCHY^EHQ2_^$WYIXZ-7,/_`X/SKEW?`6_WQG;?ZQ9Y:D_%T_LO<&H^FXU^L M7ZQW_U[(`IDP\',F[O_]@=HAU[4$\1*\'=X_NY]_%U$U_YS(S>Q$/[8XF#[Q MP0T1U6R3\\IG7$?A1BB7,OVA<$P^Z$-/?._LG2!?!1T0,E\B:7_D?O;,T];CK:J)HTMK6;%H!90Q230"I`JDN4%(& M"FW@9ZP/$(5Z83MH>`BF[Y(7&.7QN'[;PB"&L0%8[@N%!J#WBJ(!+'"UBR(8 MM+2?]8?U83BU0#0'%_9DP8!H*LD(Z/7QRJYXM:6"#,)4+;$XD"E[KPD1$<2C MA(M-&"7>W\B(X6Z-04O,1)"^C^#&VVWBF^`5QLD&61NSOVP?86H1U<-"P=RT M44?.RA%']8"R(G"W!KDJTDYFRD!)FUQ4-HV)],5F0H)3#DFX!MLL"`Z*R"J/ M#_JC\^IX/F&L=1B!V$$_Q-#=1:1AT8SW(V!3XX.^4=?%%]7VO;4193RO&/6- M1H@V.LOQ?%X`N]ZQU=V:2O"MU%5U4@\AIZMZO%MAXOC#NS7KYI9*]N""J$X0 M[$ATXP#7?XT)LD>S\8C@&O^F0<6M%\";!&[J+7WKXY)1O0K='28\PHH=;1', ME)F]G$Q_&;/`_3.6!XC`88:J3<0EU34F;PWN&I.\I/IG]_5O:+B+8@NC72@B M`X']$?>PQ+X0?50_R(D=@EDRGDRG/(`36=JQW=TC-JX']*@KI+N[Q88SVRU- M2*X`AX/B(@@:N^SW4;B&,5YD=?Q/4+#?SGI)?>>=88GPM-%X,:HBIBP08(E& M].-EN%E!D!M&VY`LV_OP&7FZQI[B@?:V[#]>X/9<(WK%+7G:T#7FQ4QFDXGW M`2!_7M"0_"-\A7ZXQ:U6-J7/X<.6%S4UIWRKQ#)N,1F/ELMJXQJE23)WJ4=-,RS19?OH#ZRRB18#:KW!%@B7IN9[M]GY M>/:6S&3@#4H1?$%&>:_P)G###;P-X_@S3.[6C\X;NWGI)$5M`]_%--&F<#Y= M%I/QF0)`)X,J*@#5`;`2@+3@67JD1ULW8+!@V/5@A"08;B48'M&AN1_0)^%K M'8/.4=2"[=7*2TB_Y=[Q5C?!E;/U$H>9&XRG56*UV03A[JFUG*68S`4!+`EA M$*2R-.%.@F-VS;$MDG3N!:[EY.'?%1#-@5+![!U-ETL[ M98?L=8#?5XOCX\RWQ#%!N]^8?&P%-DJ&V89!HNV%)/Y.-OW M65(+"KT@4PRP9E!2C8>^F7*`M`.B'E#]FMI`P+5>6SY44J&1M MX9F^W&Q;NZL^I#Q7NZ[GV%-[7LY9_8M;_=VP^=!3F\#[(<695L'G0OM1@3]W&A1,@N?=T88N;M@S[P5WM6"[%U_5E=6=Z1 M]$8+:[)LRG9#./P8KPB57U527^\N`5Y2,3%@",-_:OZ5^$7`2L,8NOV+!^A$E MDIJ'\&J-C)SC-D07WJH3X=FJ,/K+B^>^W#M[O*GA/YWX"\@,XG\Y_JT7%:9[A`V&+9\#N4#K__T)03 M^D[R].*`XDA/]YAJZ29D]8V0A5\O-2T5AH&,MY2ERH@=DB@#6E)_WT59O:^"HD%I;Q-,P MH+6SPK7!%;5Z0Z'23>D74RG=EDLG]N*[]3T^'IDV_J3\[9Y535;T+=7=DW:3 M1`LZC!;V@G9)B,RTV%LN57&/0[)?5N'7W1J4I=+JS7N-96Z'\->N?,>R5&V] M!''(Y3T#P:#HZ`W@0P@7P0K_Y_JWG8=&BOC0PD5RY431'HVPR,B+T9B(O:NP MS1'.R!)=^=!$#T>TROQ+X!7?^2.%&BUOEIJ_-/\-D+\!:6@4/0.H$DWWF; MZ[S.'ELGNBIWTL2#9!`+L[>!U+/P?+58QV(^Q5;19FD]'BQ(!8)4@U0ERI807W4T M[S]0&C'2D"--YR10'MZOKG6K@BS$U*GBZ(#JHH^?X.8)1IQ421]0#&FJ570N MW;(7RQ(X?Z9O:\17#_/S+J]N>%0SHI[H)<^TI*SOQ/'=^DL2NK]R3YDT/*@R MA0^TB^;"*%\L(S+PK#61HOGLR)$.V85#H8A#RO*=F4Z5O&]V7DO^AYN-1POE MX-YI2"YPA`&^OI'UY3AOJ$0$VPSA^HCC[)!521@=BI7%:0*()/_LNG]D8%46 M!W[W.4P@L$:_UXJ<]D2L0*@E/(9A27RHU$F&&7CKW:6W9J-\$,1#H%&CG<'B MT(C4GG$P`+6"8YW.X306V6WW!W<48AJV.U^'.UO.1)I7LZX('C`4[?@V'LG< M>X%[A$[*%BR.7N8E1ZWOJ-Y^U6:08*8MIK8]HYNO^"V)E@N0I#HIP"SZ[D22 MZJE`QT#W-4FB&,QW9`D%2%=3'P9D:,Z?RCQX3GK$NVA"-T?\5R`F#;.I$ M[P3G4=[8=6]TMZ*-V5-O*`_]U9SL]TYT%WU)\/YULA4G*PO4_LV8;^H!!,L< MX7*@"\MJ@`@2"^XB0`6G9QCS^E+:<2/%Z3*28BSU#&P=`PXO=LA2!LRXX=$, M/&)(?+%+7L(('U-H_]@';^@!6MT,<=:>S!H`1L6!0IYV4!WE8`.8:!5AX'`] MU``J5@8RP-08%B-`=!/'.W$`I4_K!`\U07@#Q'PV9P.'RC($-#T<8P/&8WJF M#2S53.,"I10*(T!RMTOB!(T@V>4HN*_HA$O)#N&9M^ELQ,9,2:`AP.GK(AL] M(=]';1!JR$,NCNJ1T0PF[KFL^F-Z0-/IW,EH.EHV`&6X0U5=L-'=DP8\_//H M_6AD%4,:?&:(@N0,6*/1V8C^[[";A@\;_=4(MDEAG"-0%FHZ+'>'CYJ>Y[3V5Y:!]ZB*]$TPR1 MMJRKH84;"4D+90%91M\Y_L5S!"&>?;][\CU2M.)3&$'7B1-Z(J%Y34/\=?7+ M9\*VB1Y_GX_&\VPE+1<.F!'=5K:L-X;IGB>=M"VS#NVW7WG=S] M,'=_G;G//GVL:/6M,[!+"W'=`C@8$_W?G1.A;^WO,Z7Q`S[Z%<%5-TIJE6," M-[49*9BK\_%X.>615*XGARHNB$0U&4-74H/!X2U=P>C.8%(CPJ&RW_*(K/.( M1%E$#"0U48[@LIM0/1N M+?()NTQ><6B%BDSGNH&E:]@BS5&[YFBXQGOST;\2#Y=K0V."-<3%"ND@=X(@D:W6,TQHV(U!'IQOIKY,.P#MX3R?VZL8(5\L8C6TV_-)I\URL M,0@\RMV.(/0"`1@>'0.D_BE4&06K(0Q!F.!92Q&'M?$."ZY;`!.$S::/\9'4)8D022$7II)3C_++K?FU1ZGIQ'$9[ M`B7]N&$FVB%:FD-A$$9:MN?RWM&/ETX;74>+13&/ST"-]CV\LMP\`%$K.6B& M$&^C;UM0-,/I/NO:B.QWY[^E!U)-I@@7$ICFI>]*V99+-&1KO#Q7#X!5<]40 M:/%RD@$N9FB,@E=Y.]C7;1@4G=*N'Y\CR008LLT3WHX^MJ?MT*QL?`18$RA4 M&89723$A&'YP$E@,4IN&K!T&JMH1W@X+(=2W!+@_$\30??\;'K^'^%3G0=K#ZB+U7+%.ZC"M#+TR_:3YN-LJOPLDOCJ"B` M98%KO'G):1[M#(=`:7[9??P:&D4B"89ATAH%'2WB1_B4%'#,)UUN@CB)R-(I MG0AF3;0*OZZP[1.U27@Q8#Y.&SPLN=2,E>9:"^'9,HBFV==!G&^=A*W,I-`S MT([K1KCI1PT=1)XF)JV/=$WZ%8)+QI-QI-F2&72`9DP2RMW%`I,@)FT`-CT$HW4X8C,$`8BZ\]'>RRP466H MCUYBFX.A8*1IIJ8_?METU!HQ_01UZP7P!M_&()0"Q=/:J"ZZ77+CN;K/S\93" M1]3A"Y[K;_!SX1C!ZD%ZA+7"S8!=C'ER"8"(`(56D*H%);V`*@8'[\D%^Y)& M*X"DOH,`W)4%;4*C1@/CE`*SHH%9E0(3LP*CF",D`*N!1HX-N1:FR=<5[]:X MF!$,8M*S>(#$VJLP3F*R1?/)B>'JWMG3TO\M.T>.$ZJ288ZR5+CIG"TR=BG6 MV._6H*P1I"H!T0D*I2#3JG_;BKI@V;5@A;Q@G=%HG7<*ES+&D0*P"ML<_QF, M9IK+LMFMNW".E&HBUS2;*EQ6UAHO^I`-N*S!1_\>((4!HQ-?A$9H',H*3X(_ M^+#I12"5C MJXEQRK1289^R%>!RW\0_@)AB&`FICNG!;#R+H*H1?=I7'JQ$U!0JDXA?%K7) M^EI2*B=^3*L-9O^]"%9HE.@E^YM@'48;:EKSJ*K[^ZHK)78Q3K2:YV22E7'- MI(+\!WR&A"H`)0U#CX^:F'=8]ZUF]R^TN,^OACA8#.S&&/3*`"7E#_L`/2][ MV#F*PQ^/S4RAQQ)II<5/Z'?U#6/\9Q4=D&4:('Z2=#:IP2X]2DJ%`2)-_0E9 M.8[9?1Q3<42V-#*O'!2[TZ2)@A48<4VD*Q*XHT/Z<8&Q7EXF0ZKO>4TIZ$OCHBQSMD M=W5(9>XW)E,]Z0]]5Y?MCT@LY[.0/RO.;:Q3/`/L.L_CU_7E<6?C;2'C5>9L M.27JJ9J[IV,QX=J)`B]XCK,KI5NV-#`?5SB]S[)!=$YY.E^D-<(S2<5-Z-HW M%TAQSN[EG*KY[[:4*T]D<\-A`EXNG=AS+U`SX_F[A'EY<]M;&M%3,T4XSZSE M@@DB(I/,SZ92S<#2,:X22%&_\*3KBHH``4S(77WD,LZL=A/691+`&#G*PUE3 MJ$R`6]NJ-?MYC1#KO.HYGEL6NX72OA8LQS]Z]A#AYQ;C)_?/).!PUUCY4=`" MEO4:NLG=^OK-?<&+N_B\_5UPY<0O",GX/]>_[;Q7Q\=KOJQ/VT6$2DAUL$MT MW[8]F:9G%ZETO%43RP@%S(]0#=\#KR_9?RD>28\#S_MSH>YD?38 M1PR(F37.1(;B0M@`F=K0&436@I*YNFZM,/B;$&K]"\050U#8G%<8X7H1$=PX M'IXA!=@D_-\MT60\M4KGC<[L*_;3N[X&.^W6FIK9*%CZ5+JO2 M^!/&_1I$19A.?CPNBPR4D.WI=((?G;=+&,"UE^!N?/DOUS0QCLGY=N&FL62K MQ>*7?BT[TR!2#E+M=&A>^>LU&ZB&4)SSH1Q MUYFOQ+Z"5D(JV)%;!Y/]O`[:J!LA7#!XN1C5F:#49]%<]5*.>Q2K;3TQY0!D MY5DCIAH#,/RA`')PV8-Q4_WOP[\K.A9042I^/&J9)7KZNIXBW\/?!"OX]B>X9\7_X#F5V5M7WN&29+N4Q7N0R@%$ M$$"2-&7S40[971U2EMVL9*ID>:/ORK*=;-LNW<)^MTMB7%K#"Y[9'XOWDEH< M<"P1SZ&L,F>60W0K.VWRJ5A0DJL-(K)\M1F^G@DZJQ`^`ME9PU);D%0!ZV.( M5P"8'S/]LU*P4)T=*B5,*[#XF;ZOJ\/3QWQ;T'QU&5U-BVKNEAQ4E:6?/!]& M5TX"G\.(W=6I/J4T9RNJQ;_]:%1)72(%9&)T)7!_7^Q.OJC+YL;TJ2;UH=.J M:,NPYN3 MJ)KB#7YKF8'\;8>,:3O#7GU(Y5QC1;/H'HO1=)$==2#OZS^CWM\-6]@-99.) MC2E3F4$\=%=*+=3K-X_LB[DAZX]AU'QI%/=1U15.&7:(I[7%2F5X8E4\R25IFO&7YI;=[):V4J(M.,FKAO)\U]$8?7*\Z,^.OX,7 M<0R3^"(H'W/Z"3JX///J+GB`[B["E^&@!SZ'>$\'_2<^@A_?MMQ++5>'PJ90 MJN'"39"=E7/$Z@'1#Z@!Y(QO^>1@9@,^!)Q;09XJVT%*7<0&7*&M+YYV-9YG M64`=5D##[(%F>_!.CN"[KF]9H/!F(WG3> MY:PGC#56R^)%[DLXX_&7`==!2T>C;,+JNZ+-&$C53+K%EPK>!1";AG]\_!8^ M1DX0KU&F-1[&[BE$]>"KLX6BO?[%?#FAPS*2\*\DX1W*&SX6C9IL2#*=_BOY M%H(D4P4-#M7QC">-ZF^/1/ M,/D&84!#$0.+Y(BM;:#8FP?R(62_,!K0XVH@7LJT+?72.HO1UW]JM4WX3JGI M9,&">'.W*.L%Z2Z\-FA$:'V96ABO0?@4 MP^@5=[!N@NV.G%D)7-0](]V*RSUY_]>*9L M$"`6@:I)^*Y`(@<0JS3M2C$JS`5Y"<3$,(+JC=D>1-;O*V@EO+)-%V]>ZTSX MP?,Z**=NA&@RVR/;.N",.MRQ0-U@/\K!0[0R75*.55:Z-8*M,0J:T9+_^)\> MC%`$7O9D["(&'=[+>G#$L4B\)OYTW@2JTK]RX>FPWA",R7+^8(VF\-]3BGFL'*%=TKL1L\*!TX)B+_`2>(NKX-X$"?IH MWI.?SK!>[G]R_C>,6J[)7D%TQU@:AN?"0GR"C=\N=Y1B!JZ;3!,N`K6P M;2%LES,:J]'=/`\8#@&,GW6+AP%`YZ%`$.S,P,K9Z[E+4&\!5[IS$[CZB+OZ MX19W'BZ"U0-\WOE8TO[>V6\.;\3J(4#Y'L\NU@GNX;-F\]$HW=])Q)/BBE@^ M6!4*R)Q*E*L`6ZI#];[.P?RW2OYG\D%)`=G36:@`J0X=>SD'BX'=+P?T;>CL M`_9B,V?G.`[+4(5.9,`7QX?Q3YZ/3RH&,#6B/H@X7IXQ_"5@K&#KNYPMK$DK MG9V5\QBG=8QU@DVF-,MMU>>.E06HE>]*7(>ICZ@$NAC`9W*)IQI')]A3XB1R;$6D.3ZYL_BW MG;?5O08HE([ED51[9+2@"@8PKM.9@\H#`+4(I`^36P"%:-HU1E0 M-0MD=@W#-OC.*1[;F!+H6=[W?J)A]&@8$ZQ1)S,I@'"9SX;^'OI8\$N"AG)D MDI2_49WUM'+V.3!!M-%=+D>+"G/DDK1O3)?AF=W#,[5H9:;:(=*:0V$`2FZQ M)H1WS@X@WAOZT%(V0_SL7G;3U4%>9>*T[N:1Y6(S=`1DAQ;5+RS9!A%C.[#N'1[+PF M8$30B>%'2/][$URX+B[A%=\[>T[IT?;WU(*%;XQH;HU'TZ+Q(:)`)A/)#*-V$Z8H@0$$!>O:`'80R\`(2YXTY10=POBLO^8!98 MV[*;CUIN!`V!;_("(\0NT0Z6:_R*)PGC?;W@;39*>)E\-)GQL(NE@U1\N=ZV M,<"5X#[!+?7423V%M(^GNV_:+8%;`,J)E$'XS'F$N^%-\&7]R*Q9)#K),%_, MQZVP+!I6O7OAAG!]4F"RWHP:B$E&T@H`LBE(4G;M'^J[C^#6\59XSP)E@0<8 M0WPH&?VFM#V0N;;N)/%=#]9FE[$J4ZR"_+ M!U2RAD;QKGVU86$3618KLBTJC56FF/RRO,'_FM,H#\ES.B(VZ9U)VK;N2V.< M?/^^G)A+HM-;ST4R,5-'$1[B83U789S$7[>?HC!(.$E5&G@ONXM%XMTUNPA7B=X%*]2R>\&YGZD'3J$_!NLP`KOM^1I; MP#V4,B1%#A&:E`I!+AN4A`,B'7S=`B)?XY'-89PG`ZVOM<^JD:\Z0KK$2UVB M(XE_TCL@']&K#9LS&`^IYY.:!8*MWG@^M=*;5(MK1[&,(?=?<*!_C!>66B_: M@'R,*W8G5Q2AE@&$$CJ;7):/PL:M''U3S_D[@TQ-/;P MI!&/6O:A2'&G$9,:]YNT`:,9EU)VE<30??\_W**Q MG7\=)/C6\\.FL^D)!1.'#6I%5YNFRV7:S!`!@$K0TL@#C$^Q)Z/[Z$OIH3!5?_[9#QC%F:EM?4SAAWF:+\"'JV2B=82I? M!TLJ0)1D`BI4SVD7J:Z2(RN/6&5Y+9E6GR(N>3L_.D5-,TZO\&3CP90L MYT$]V$NU"R^03F?+0Y2E0K0W<'V<*35I+GV]W+09@I1:,C$P47;?C.P7;Y?J M+VA%0]=[:Z;SZ82)"I/:FF/\HSL,#R&B=2=A>\KQL6)2BX&/,(LV&J5G]2"E M,$!X`#&VQH<@*>1H!T=/EP@NT+OGYC8?AYG%0$4M!%+FK>ER%;QXCB`]VT7_ M_0BC35.M?[%W5,]HMQDDN+(QL:=3BTYOIQ)`+A)DOR%"M:P]2?72TNPE?R9< MJJOV<:XJF247A6$^92X4H<$9@KW0)?"622S1:;5E,5J.1'E"R[J89$_%N$+? MNIED=\7X0O>ZFC@LA3A#]N4%=5WQ57@7P"_>V[7W_)*@_S;6_NOTJF[^8-@E MFFNSJ36MDHB32P97=^?6;#%3O/=W"`^;R0-Y&`(D&R"A@$@G/^DI=#B8[W10 M3C^E,431@D0F6_`",B!E_`^,\'^ZTD7U-3.HHF*38"+-YJ/ZF*1&$R/+");H M[UP+0V#!Y`?CR*&_RSDQC+1/'6B@>%H[^G-3!)-D M/)UP^@9(FF[$]W.(!?0_@1OP:!2\^_G7/'`@'\P#KGP!2`Z@>8\CK^"BTWD]:"KAM>-8:I#VT0ST\:7!;:2%)6?C@),X:A')X&_0KB%40_^.7C9&/:I6R9:DVAL M6ZRM,*4D+*0/B\'N!'24WZWTH\KOGMQSE/.MS%-(-X]V6"AN)YW&F`U+.?=K M[V^]Z*;RHC%44[9*=,+`7LXF[5T<*MF4ODUO/UMIA4HVDE)Z.]U*)U2R>532 MA,YV&CF(T[`4$G]V-LSB4`)O&4,>N4F"R36:C1;3U@Y*#+!8(W;U'^EI&W<, M[VE/XNCG;AMKM+JKESL.8-E.'-4X*6`-\3W^C>^9Q1R=MH/;\_%L+LP=1NST M/]I;4?XP9[?_T2Z+L3@BEVG4W.4M)O;2LEO@;<:PO:=K?(@;-$[OZ1\? MYL8-S+N,R(\:BLNJH%FUB10;:ARTB[RAM)HFTPS1PJSV?,J:[LJJ2&D9QJE3;YX=`#G]]VWLI+]A^]V/7#>!=!UO!7Z!6E`&+;(5HX M?SZ>YUM:4FF@$*=QV"C=2;OBI%[4M*=<%38M(9#2Q_S)>?,VN\U-'.^<)Q_^ MV?%W\&Y]CUZ!^-I0*E8$KEXBM6 MMYED>M^$XIEAZ=Y:96\SL8#(!7=KD$NF=XMHZ)I*]]CN]'VU=5:[@#3OM0H' M2R:/9+M@2C=#DTM:'Z"W>=I%,;:$\V6%7M?$*B*VB>YXF"ZRI:8L^8I[F\LW MC-,[G),0/$$0I7I0-C[MB^W;VX-;G;-^EAXZDAZF"BOE;I=OJ:=W.)<5Z.,F MZ>Y7*"H_D9$G`PE`8]9D-W_K9JTNE%`G+^%HZAA#_!0&5CAN:+9`=$`ZFF8C!B('4$&`2-(\W);@F%UW3.=`@9]7Y2$"QW,=@/@, MDRLG?KF/PE=O!5>7^Z^HL;H)/GF!$[CXYG8W\5[I/6;\&Y)Z"%((I.[6"=]G M-UND\$(!\!*0*8%7.X!U@-N`I!K`H4J[?7IA.I_1.^C.*> MD3,;X5=AD'C!#OWN#O502=^ZOAXM2:B1R&^R5/3PA&6->K-`H1<4BO7<4*@P M6+,L6"X.UC8+%AHFK4^6,7@`ZL<>S#`;Q"3TQGH)?06>(/V,P;%.N%6`&TMT7.;(0?WU<0%6HD\H]I_I`MR[XL8'Y? M88A@L?L*O]OA:'G![]'_3I4[CNPU=`FX09R26G9\KX$G2#]W<*P3G>T:+^@ZRHD%Y#X;C1R!=(>`&TMT7.;(0?WVL0%6HD\H]H"$?+\734EP7, M[S4,$:QJKR'M*(#P9-GBR'Y"EQ!K8I&;P`TW\#:,.:10>D8MQ@O%PI>N3V8E MR-+W`1:@K2WNZ8.=^>`/9KP`;_0T?M9FO$*D'R9X#;@U'Z5L\_F,3$-\<.'^ MMO,BS`2(&5P8QP\PALC\EXM@55JK;]HGT5&"ZLT^WPZ7697M2#YYZ0- M<5(->//.ENH`4:H$.,&JO*-#\4Z>`6-@I3$@(<@4X+Y&J@)D.@!24M[DHV%' MSX!AL'NG@K;=//V0GV_HZ1%,'1V'O&-S_;;%AQ;:YA'8SROL4#"-$.[B+K,* M=467/Y.E?=@OQSN[V;L?=#;BK^V_JOQ_HSJ_JCNR_+R:-&`!S5KY64^M&S$WA_([U(-/"-0]];D7^@9NP> M-]UI#_-NG:[#._X7]!MZ>E3\R)ET-2I!)]EVT0R?+.U%BMB2!:!B`NEO`(<+T(Z(ID0Y1<."YYLS'4SZBR5]Z M5D_^%P8(+P@L["8(%(*THZ"G3R4@&`6`PWQB8*#FMS88(#O"ZJ`UG;OA?3KV M2ZJ!P;1$N+,QS=8L:3:5!6:S**E(C5B1XV8)-![U['=IS^KW9R#0>Z!0+!D/ MP,0/C`Y4W3L1[MT]AGBS`9[[W#DHB!'Z.F14U5#SLLN;"O$E8(YH]N$N/059 M*A0\AJ`D%I3D:JD<.93/=MGGI(_/JO#7(6W+(!0-F(%(Y!Z%%WO7'#1V.D\^ M6HZ6Y[=U)@)(S/]F3CM2]FR7+0K+CKB+JK#5FL25A'%CXN4K6OI-2IW MP2.,(@^]M4?=62>(O3!@7W;2_I+J#6JM%@G?#HS_,TXSB981"D"2"<7SPE2J MXLUGNLW>ZLMNUCPNC+=XR)Q493$TL6\>[6I(@> MJ;"'O">5J=C,SWY%;2/+M$-X#\EH-*H`*\;+YT0>R`32FFS:6EDY/M)SY)E' M+LLCA8UJ:]K56E5^''1BYS%,MX)>O#J>CUO_3V'TQ?'A%^CN(K*(]Q$^<;JL MG:1H0)B@::().5],[!KHT+@R50%R'0`I`5@+*-0`K$ M?=,$]?&OT6^;SH?T$*`3V$RKA)/8GG(PG8D'1#X9R.8:C$&SI!@<`GF;>8]' MMY#GMS8$MZ8U%[S\R,D9\:Z]O\$(+]U$VY`>R>2,=)D/*Q_ALBP1O1]V.IZD M%X-14:`B2_5X5HHW%LL;K:-7*:[9A6OZ1J=M2"E&I5R?M32WE8KN]TYT%Y%] MIBM2\?T>1E]>G(BUY4#P997-K)!%PM5]%]E-6[7;"P"2#.XBNM=[E5YR@*0# M(E[3P%6^ZW;5=7*-P1G8(M_))0=:V]-.>5MI2\7CI!^0Q);X8I>\A!&BCI70 MMS]X21L`ZY:(9M\T+T]8!QZ5"`J1)H#M*#>;0193/QVNGWK`QLI)-L@:XV,* MN/#,5B=@I2]H!A6U0GC/BY75[&$`BHHS!TP]W.,"R6/ZIQ-$U=QK`U`I)J:` MYVZ7Q`D:9'O!/6WY+,XQ*I@A7B;4F,RZ62C+-`51?1[FH"OF>ZH160V:V MX:L>(OT@(UU2H8],G]0&)J)>>'EL;"V;`?1GUK!"-6:Z^],R5@+_/'H_&EGD MPBT"GG\#UNAL-"+_.^SMG8$@K#9=9"JSA#?@)."_=@$$X]$9P,E$'O@(73*? M`,86^:UM#BPKN,?[9)=]8A5"R@^N#N+E*XR>PJ']M`I']]D];ML(NDB;Y^(=LT84E>0" MJL8"C(#(61!6$"52^?#!$@JQJ@5'2Q5Q@%ATH'F7@=JRM#>&[W3PV4%OC[QUER MH,>2$/UCLT%_T7L_;E=J*%9SNL183V\F="%YR#FHH&6':Q&S&5#JAXD,G7U4$:POV\KNXV M"P$&"+W4&H<`]2W*6#U#P*8QV=*8A)R8J.MJ=,SV:O>C2UA-`?/=^HI\E.9L M/A;-W39('@;/)"CFW=[JE$;'Y&!),0"F#-.$KU"R)_R6EH"V&#S4I@?-PK", M6!!$7Z572=&`(!176]WR6*HRNV@BH%L0(`)O7EPE305T4HQZ17?K\O&'YN'6 MD3+53QT<9[#H)KW)?#K.IA2:&RYF?C/:,>53"`H#U9\;`>Z\HTW0]0UKS3./\CAH]*\A(1OH(IJL^G!SWAVZ,"4^HE(65(-I-L6DP6!L5@L M)XLFPF5W*BH3M/')L*[,>'7BW3Q>1',C\2H^NZHC9`W<>V2*F4S`@BS5A8)% M/H8Y@UNZ0^9KL"+'%Q#5>:]XOIO\^M*)X0J-R_'*'6%`?"HI1H_Y.[Q3@30R M=UO>%8O#ZM0^<);DB/",[FS#7P(WV#D>C'A0]+S!"$53(\E;K9^N(4-[ MR?AOGPB0^0UUTR@^7HUL_PG??^`E^[LU^^RU0)YWD::)^CJ8*#P#/I]/FTB- ME"O`M)4IP^S&K6B@GZF&"@_AH%2JE];VP@-BPXL;'(<4%I5T#;(FDF@^QHWZ M@^P\8K^B%NY,.X3GP"?S?"<]NUP!'F%IPZP<'^V*CY6B!-KK.XOD8`UC_*!H M`5+:>\*K@UZ"K;E^2WL#MV'PC+[TIOC3K1?`FP1NF(UM/V$JP=?+0N'35+-E MUM1FG=)"&L@U@4Q5^:\_8VV`J--5)G/XV-B,V)S5@G/>-3K*,'\47"ILT#_: M9O#$`\2UA)&Y/Z'_O]EM+C;A+DCHWQ/VN=#.XN0ZSX"V8Y7QDBX1-RK+1`WS>^?CI_4\>&KTD80#3 M"DCL"D2M[ZA>\FDS2+0XZWPTM^F"3B$1;#*1(#W]H7A]1JIS5LVY7"3(RM%J M+%,DU5.[S5-M:R"BD,M7.(3BHJ.);[X3OJ6*?`M1;1^K':R5[P@UV+>@NCR'2F99EP3--5-YL*I=@.&Z)DN*S M(GA)$;RU>/`T4THO)`H03_=/8Q`]X:L=T]JI*V+JXXL3/+Y$X>[YY3*]C1R- M9)Z\@'3H_Q+A(4UPMUYW2]_^:O335F_;Q8^MCV9M%(:-R(H8KRC@`+8#I(84 M5\>73`&I+?AHGE%LIB:DZ8W<:-I" MW5GYF&())$?930!2G1J.):B.TF$_TV@RZ82/=MX0CZ=Q%,&]=E3D35,@WZF, MNC4>34:"T-9[X:ALG_D#0L[5XD8`EGW#J&B<-`$PB3PW@2M\ZA59B/^#=Y"\ M.CZ^X*+YMVW(["]2+61[VRE<4'IA%$HV^U]Z[F(JG#GX3F"9,*I\1A@9QFJ M5X"[&BA:BVLTLM,R;43#X6)P#';D7`<:W?J9&N#D>A2O%0\:!JL(P\%B:G&\ M!>1J0*%'PV+RH*&P>1FA;6&Y+]+SA>9>,=/1MR&&/J`>5["#/X;A*F9OXFY\ M5&%?I$F_:,.YL&:+,NQ2,8#(T;=7^VB7TN$`$:#U/`0OC\HM.=-C+2PB>530XL MI:4S2^(!D0]^QAH`4:&I-SY0#`C>Z`)/YOTUIRBS,O1U3N0*)KO%2C-2@\1; M>?X.'ZTL#D/1J3NXPF>H\!G+'>W@WJVOG0AO_HRS*[*(/^TY(T.)'L1+L%P8 M$79VY*+""B4+REC"Q%)\E['7L#H_E\-"CW&=1_TA%92H('-U/5 M.<_Q7;R?.^6\C]A*]#=N")%B<0I4+8^+4PHV0G1OLMDL9@=$F)F#$BM M8=?I*2S"[Q4V`6H4K5!F%#'J#'3!C^<-LED%R$CKU MB)GS;@OIQ=Z&C&('`GXS80[Q'?7RYA%[H<7&QT8W*5]++Z$Q.+EP(;[<%\^DRVT7WYQH)<9G MQ\K70F='&BV\[6R6U9HMLQF['U?2#R[WE0>SD]'$"%/(3&48#[B,=N&>6L+X MM*\\*!Q&]4PF":C-1";C2YG(8^72C^D%F/N.RX^]!1O$7.W6"I^O7MH-DW-, MRJJ4A,VN(-T;N)2I)&Z4HW:;C1/M"44U1L=DNA''4Q>>$0RS%H)I-)B53LT/ MJR2"1@M$SZM8LUD&;@:@-<'T>*]*LSJTI7?+-`7U;^[G)UH%3>QHF(.04M>! MU7.X;:G^($&P=N1UL5:XY.!T-N:CM#+OP1\HW.JN^Z`X;@<\P(P;?V30$C>] MK-$'?.T,T_F;G!0;I=V/Z[1&?WP3T!GHQS!Q_)L@B;P@]MP_._Z..>>A0O4I M,%H'?X2K)B\M2Q;G9?WMW#YR'IDNA1$306XC($:>&#$.%7Y"G45H7K$`/(K) M+K'(KK=H+.MI/"'VP+\4RNSZM4Z15#^%T1IZR2XJW!LHZ9LTG1!E-I@OO*`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`M!K;&^2*#O\WA3%*7H/[N MK]")XM]K)W`]+'-`YAJ^\RF.2_X,8^Q>L,)51'#)]<<0_RIMM?"!IWPV4\GT M?7][3FCLTMM)X8GIQ53Z:(8:3>I99&;CNA7XUZ!D>;?9;_,7"=1\*T+]5-5W MNGYP--'([*X?]U&_3YX?=%E"6/UWQ>(=YY!G^641RDE[P`4.`QBZQW>H$/)W M.8'?E1'4\N^)3_>W.ZAA%>!(H[XK:I8PSVI-!SC?(DK8.F;##6!R:9^MPN_? M\9RX'")2R_W?Y0QZ9[=95Z+TL]L4:F5(6$:OG>;P9E- MMDYSBE[3Y^2W)M_WI+U\8I,YER\Y(;ZCL4AI&&O$%+^`/:<_`FEW4KC^Q5S^ M\5->0U)>Z_W[F.*7_*U*;02I90VS""$6__ON:]Q=G'P5C#\$O_7V2OXYY M_Y,^I2#JD_@U[U/IAQ=$F?P[G/<_[CNTL_3?TV*`DDW^G;[C]\G!YBP&?(@E?_CM:(>B^&U7Q"D$?`T]_ MA:"'U\*7QTQL6]T*0=]-_-_7"L'0G[-'$_-WN6QP!-LI6#;HFR5&CEJ8]R>Q MZO\.,4J1:X1)HQ*IGHE73K0[K`JT7-G&JTI^FD,.?=^$\'_V^HEO.1J$.#H- M(.1_QY-DZ(:2Q3HXNJL9I\32'7T3/N\YGG0HARG(TXVUT;]3IA[RN]BUJNK? M,U?WI!"I;-WG6YXD7W-K?BJAZ@X6G!)+B[LE7$-E/.EPNX\@0;<7+/XNN'F@ MKU$M"/\]DW)WGI#*QQV_7S$7K%OV$831?9OP8K&)4N9+U' MR1+?1S!QWJJ[=*[\,/:"9_)H$XT.J4DR7:Y"=X>_"S%.G1MB@%R,%XN%_R6Z3&F&R1VV!80DVN%0[IU8HO-`5MB#_!JMW>YU*3TC2TVZOT@/-C4 M()D267[#DVX](;94+FP&Q!Q`[:EO(@2I2>D;&AH84Z)+&I+[QO0[:\H_'6V) M`E+$;<;0GT1>V_`2^LB2^/JWG9?L;QGW]+8^KH6EFVT13%E[LER6J385!JBT MX6_+Y=.D!-/V+@>T*.ND.[N%AO.;+$P2O"FCX_P*7E$ MVB[>//:]FTW/*LWO!@/$#SU;^69G)(9N2L*"`)8$?L:R%!.\/+_LW*_S)//K MK,TQ=2#@Y%@5#ZPX&`&-CR'>+R7Z#=.G=<*#FB">2!,N0*@T4R#2PS<>2#C. M:8-)-=^X0"E%0PM4O.?`6WNN$R07KAON@L0+GN]#WW,]&#_"M^02*?^5]6G% M7E8))"&+A*\]MZ89K@JYH!`,,LFH.XYD`R)<%\SD>TY1M]MLG&B/^V@M0="* MP$YI7`&D>-RTX#-Q$K*,=N4[<7RW)C.>O)X>\WF5*&09(9I^EK6%&OPG:OE"&I+>$JX.$&0BM>6)/VG`=U(*3C+"]*G=EX M6H>&OKEK2?[8W?Q1CH7&6>H6W[5F_]WZRHE?/OGAM_CB*29'1-J^7-,K.A#1 M8(=P+>5E?JU:GDNHP<#R`!&(^#45J1LGQWI90TS8P4OEZ.$D8R..6+'1C*A/ M7N`$KN?X]V'LD4U.PLABOZH'84Q[1+?(+>;S@U8((2V7"S+!)B%.CM>'R.OL MM08$MB8O`XG\F&E%9--*+>,A'2CKLMAG68OQP8!'R\JE!#?JG3E]*Y7\E&G, M>,VKDWC\5%DM97Z>@P>5YGA=NVB"+.:SO-TH9*2+VL-D>I@X/C_3CW)FAIUY MQ$KH&F8JZ5\!9/JD+NU9V51-_4;_S4C_UBX6\P6M<.C:L9A;RQ$3%@9TH:3X M9]?]RS#R@UD@X?>,N*$P`S2?PP1^]&*\MW@7P=9%'.'WM4**893PCA,KW_S9 M@#`L'!3235C.&20`=,HY#%YAE'BX2/\]2D0817"5SC_C8C%5B+*;9GT(;4EP M/F!Y<=2&WYLXWL'5QUV$%Y_H-?!D0_QG^(W\B3V++?2R:N2V6B0\H!CE=0Y) M?E+!@$K.SC6F)U20T:,=EL)Y>X!) ML4`9!\C2X92\[L>J3T(T"S(%J(W6"9<@FX\7HJ`M'R@K:O\T)G;_:"QI-`)2 M:GW5&\,2@C*I%>8QL[QS;P`(HYP=2CG'.IIUDZ-CZ$=B`ZMI[2%`^1&0+M8) M'A^:+.UQ=C"$C5IZMO,>GP0EN\X';G.;^&O@"+3QEN((M!PQ&2P,!SV/:L?C M3.\F_?X@+PZF=`Z=EK[([BF&O^T0&5R_XEH*;?-AK,=5]BL8-@C/%[CF[*VOR7A*BT\+QHFH*5UZHOYO$:\=)[9F4X6,R9@]$]D M27&O&3,F`84_"\4-@@ZHY!:TM"B'SRF$QH%RX>WK=K81K,A_[8W'<=[8G;Q1 MA0)F&I6SO]GQ_ED?0_?]<_CZ804]FO#HAWJ>HU_]\A@Y>"C]9;]Y"NL?Y?#O M"O+Z0*EHOV&:;VQ,7P?T?;6)?)SYMICY0V MO_A3`[* MMCZN'.)L6T2+G5GV))T__+H]7V-IP*?BP);*4UQ93Y9/%-Y;0*2!5%Q><_5G M*E%'@1E9#MJ\CZ8/WNUH*N#=$@D=(ZRO,;Q;7\>)MW$2YOI][2&%8ZNJ9N&A MR-).]V^B]_&._UR"GC'5$5[8F1=ABQ>JQE+-"5,>2#5XJR.S:S5ZZ7VI=VLR M95Y:PKQT8L^]"%8?/7^7,!?)>PI3B)1^%HKORYJE.UP.:DQ33>3(,UEJ*M^= M1K21*]92?7KPIR`V!*?47;P[;45%@&]9M)PT6FZZ6$67J4(SEM*/@TH9^T=$ MFF(E#<,M$HS^C?Z%?L"%E-$__C]02P,$%`````@` M`Y>CI"#@0%B"_>M\4^R<_>C\\NK\P^6[-^*=_9EU^",.?#`!LP&7X6.X7H&? MS@AU?_#;>!&2[J,-G\ZR+M#(0S7#V@6 MX"67_FS`VO\R>=@9ANL'KY`$=`7[P7S-%U.8K,T+5OY"J>F+N@.8T)J_/-// M`+`^1K,'*M`2#/T08$2[>`45I9/P`A-@!MA3(^>:X=`4O4+K]!3@\/;+H0' MNE=COL>0(?*V?2?BL)\//8\O%5:V]K[6G``-@C&BRQX/71='P+M[6P%$0/UI MS6VT0:%O`D0)40BG/ACC8`D)"?#Z*0@!:6?"RO;7UE#!#&#ZG3R'@?LK73#\ MST7@>Y2!W?T6T2/R",.O*$.#D#POZ'9]S?@J8WQTDG5&MXU@CN`WX#T@ MN@)C2DAWD>W>24:ST8IQ8EJG_DIO4I;6(6IG=93IJ\DA1LNE@]>C&5^!HQ7' M<.A2GD778/U!25MOE>@T+ MT2`HC]!EW\]PCD'<:3LK5[&;IK]+,HI"IB0R#?[NS?4C#WCW]%BY<7PW\GF? MH]DM]*,0>$\@?`P(&0/,JS;SL=81H-&C;;F$X8;]T$,FI/(`2HS:.\9+=MB, M)L")PDNP97V9[1_/'7H^\,ZH."3PH1=_<,C+VFDRRDM:.1W7"W@+KWVZ3U5$ MZ(@"GAJB8]H`6Q^=1W8K:-L(/T-*:6944:;[/N4T$?^(-KVWMQ(5NVU[]%L= M+9V"%@T- M4MR3MC&VM+Z+^FM[O!+E^QC'1O[7[&XIZ2,:XRVB:+ M!]D9+"T,D,>\R?%/666XBS%S. M]W3I.?X_@8/OD'=+IRQ'-&'1+E'VDU_VIV>8,SW#*0FQP]S6.\*5K]\^ MKALQ8K3H7@<#[Y[^C.0`*RY[;#G9K*I)F98\GHR9F:3[`WB@&XM,T-SBQY,V MGD?QYY1?[GCRO=!F)6+Q7[6,'?XYXNS^_DCRK&\H`)B9X#WP]C>P M%LEU4.YH\E$2$2"N>1XX4L3"RBH=2_+;8.E`))0Q^?6QI+F'/L`W]+N;!U@\ MR[NECB7;!,PA.ZY0^.0LA9_&?K'VI7L$<\>/^QZ^P;P->+]$^S*]8(>MXN?U MH,!\LJ M'&4C39"W$0X"[`',H[#I?V>#U28M%!2+F8(,`&\)*L)`TQ%^.GLZFP0 M$3K*8!4[(+7@I'K>;V#9/EI'"?_>1&`$-HW=+VAC MNCK>"OGQ8M\G=A1/F?3J:&5;SLPA4PY&1,[GCK.*#3K`#\GF)_N6G>3'O[`H M"`P6`!$J0"S1$Z#"O3AO>[8>E1K5K5'51[#O\V97"=TA/<7CV';!*(IJF6*S MK8[K)X``I8PLULY;0L3)-5NER;TG`:Y%M72,)%ZD[(8#OP#!PP(B.OGIM:QK M0/?E9#'3=0S(W1N5FVY&$#EXS;?I)_914Q(=^%2^^0.B7RT@^][28_2H#\'M MWB7P%1>5UBK8%<>^4%14$G'.%@B&);^\^4=E*6.)K-!"-O MO)ON8)7,7GS?D,[I9CP/:(P#EP]`>&;6:5$'`L^.#\B$2HHB\"D(/$(W/L'0 M-IO0@<4U9-H??.U#"<%H&?'<+5P/RMGH&=DJB&@JVXJ6D6YS5XX=Z#V@&V<%*044C4A06HOD//V[ M2-#XE_KD*@@-V"ND3\Z"G6.GC'8IE4#=+ZM#:O;"`LL40_]@Z<5>'1^PW#'A MC8,Q2^+-LQ2*XB"5ZFH9E3@-CCBF4UA#UPB2@'KI%.P7TR%KYBRD%&H.[IA= MB)(\`F[!#+HPS!POMQ%[[&*_AF!T#31L2A2K65%T&8*7^[B"8#T45NOB6`J. M`N7JFL2O8P96JVLA-F9R*[*LC?*LTPU+A5!K,\/G6EZP97F!1V/HGKLP,B"D& M1KY%I_B8E4]&'1\!P4F!,3,01O6+RB)A9KR*U!:YXQ=6,__5"N$\F96C@)>` MTJ;XF/QE*>"3IPJFX)B5I:DT.$)D MNK]BAS$HL!,OT*DAE*9""_3[Q257E>B*#U3<_-6`TJ.4!75K_M;E%I\^;[I MQ=3,O.5043\<3R"EJ'1YSI7LGJ M*&T.4-/=D=41RG]OK=<9#Y6T:^NH+%3;>^.;+`?1X9YDJB.E$CR"#W8UZ=X/OI('NI=@0+\C37GL`%\8RP"'\!L?]VAV"TDG*N_3M*^G$)L"E4P9]L)/&]R5@,S3&=$;I ME%^OOQ#V&L4V7?G0#>%K'`%5D!*KC:Z:R1K(8]N82/3#\^X#_/,"NHNQLV;" M_M4A3T'X3Q".7'[)8-_*5Z4%+3/]ZD"?[4)4.O90P3.@PG`P/V$*_00X/F.# MGQR($@^V:![+-V3SGIW,J'ZYZM"XJ!8'`[H#T.W482$"\9^EAB=H0M<8V4'' MKBO1O\9;/]O6D)=PRNP6QTX+/R`1!@7[:NUF];@RJ9B8\'.1ZQ3TJ*1'8ZQR M70J=F=)*>C+C3<-4K/AO(3NT*+;\.?181-&(E*OK&1LE@5318>Q%*'^FB`X9 M[V8SRAA'L[LW=^&@.9A06CE"^5N!8`REFC#%95[CS>SD7!\ANI6L$A5X-).F MP)77T?1F\LZ!\(#V[EX)1E)AN#@6I/Z\`3U M.S2Z5.V1?5J*E1O1DP[[2K)EL)?WJF9>K]^H#1R*EP+5M/+4YQP26+`;5&BH MV^/->PRK]MAS&^T0#JDB4'/>90UU>[SUYUVUT0[A4-XR5Z&A;H^W_KRK-JH) MA^PC:Z)A9\H[YD"UJ"(V.3+7D)$BG%UDZFNXN")4NV MTHF1"G,NJ@Y2W("F++\N`!Y_#)-9B.CQ#4:SC!=;&.A:5*^1KTG4#;<`0;I2 M=F.`^(6R3;GX"?##[ZMVF\<:6;"$A`1X_12$@!R(D:LF--!J=U9A'$#Q!7D` MTUV:?B'P%;#\`S]QH)3O2VNU3-XIL^Z1R M?W9"MH.N1S/QWJJ`3YG6M(17YTZ/*,PZO[`-S2\5FK^-1U`/R3^L8D/Q%=)J MMAA[L'OI..O',#UT]EBHBG8FT^-MCX5OU8@D\Y\B/]8,%'BZJH4%6Z!SEGJ% MT*1J`<<6_13]2D8=T[/!'&O)E_'8FIY"IJFXJ-W;"O+X(M.S';>!J7JLD^DY MD9M$MU($2WV5E3U**CM$5+?-Y>N-C,)4#V02[AH4R#-)#IM M`MF8ES&=!#/3EAQGRRAT>J#[NPH):*#JCU7 M>THTOR5,BV++JKUSVT-@JX:'F/Y>;C/PUHVW-OTMWNIQV'LH9Z-Z34^HUPQH M[;AK3$_3U]B"K16.7R_57_>W!;6T6E7FHMH+"*>S/FLA)SW5-.!<4T/[4>F%_Q&:#RX+`WD/UR5?-1 M]1BT.]1QO5H=LGIA#*:_MJYR+<"F^]R__H/ M;QC>.Q#SK7F$)LPRQ]Y\NW8(72TZ%)WI)& MV0B-S8K(+`-:@)Y,>&=5')QG>Q/1;!^GBI+L`EAS[7<`G1QYN8!?4#`E`+\R M.1_0*@HWML'X%MCUFE?G#P7F?B^M=Z<5NZP\.?F,BLMKEG[[U[]"@%D@Y_J1 MA7&J#4566>NXTD.CZ.:IM(K6,?#%3SB@EY_!<@IPT1!R:F@=0?*)8MM*'GP5CX!S0+\#).]V2=&M:IT6.GAB`%ZIXX?)\=(78O M@?_UY6OP@AU$Z+9"XIP9>\.JV$B_S==',(OJ5[&:,R]67:BFT@1K:CP))*VM MQNIE78'6:A9BS2*;B&6;64G/P\[LW*(KY;&Y8#C#A MJPSB\LT\E7S0O$AY*2S>DCQY:H*TJ,99'>-@!@CA'^X]4)Q:424MSV\N5WZP M!F`"?'[97'65%MI^OW,_ MKG@_,%5_K`)7T3%@:EA/%:R*MAY3_<`UUI4<)K/2'ZFPP=Y98E1!*5YCYMI' MK!(O5N+%^>L:]@969Z2":[_BJP"2"CH8-9-#&O*<*:!%OOU$^G%6R6WV]TN1 MV(7U](V&+VB^C),\R_()D-;1,0J6'4Z<5'Y/?$%A77*G@0;WC@MRO9^%Q?7+ M_H#H1@Y(R/)_\"N]WAA@EF+5F8M)_VXIIDK"[U30 M+[\LRB&OI!Z)^:,)P'L![@)Q&C&!\T4HO[M35.N4+7X"Z_0=917,N!1GU@AP M/D#2HEIB.B""(7B$KRPK5.B@.3O[8C?@]?JS\^\`%UX=+=%"QT:82O?D+('\ MPE_)5AI94]L%\D*KYDR!H%#S?>="(RQF+>CQFAD[F*O@`4N*R)A8Y/A#C%DR M,1YE*?ZF5&IV<$32,T&M;C//DL_@-YX(/\"K($Y"*=Z-Q85U(#RA7Q.&+B6) M^,A(DV/KD93LAM?0\$976_=29W+Z2-3S76ZFF MFF'5]/;]I_8.=((^P"-10<7X9"T)IKH7:X,D-UG4\C2^`CP-C`5NUZ)@JINQ M`DP*IN%:WL837%;]=C@Z:3.?98/3'GF,DY`GF1HK4,(\K?I+YMF?3Z4)%8_SN:BSP2*6)RLW" M4.X2R*<3IJ^K(E?%%A6A>RY%IL(3`1U&IL.Q;GJVGA+>F!(4M"_VS%*>G_2I M7+$C)@7,S.RD#B"I6:$OFUF!L^G0=">,@TR1JO"N MT`F'."?#Y,9,]E(Z^W,1^!0,PKY'>F)V)NR9<>+$["KU*>84U!-XNUP&B$M1 M$&R[7\X&/3<8]+R[Q%7#GG-K=6HD,F4`Q0;NNX= M;X+R@/.]0JOVNC&XTRYR9 M)4:U6Z]+HQ'LS"7')FJED6^?GQ([S/#`4Y[]Y&7%6Y)'F`9%5%1/>!R594PU M8M&-ATP!+?)M7NO+LFA9X*&PO![IDRT9>+<1V[/B-W=CAO,$OO)?B8>B5+F9 MU9O?%S\9Z5]YGR)Y*S30B,Q?J`**OU+=EO;&-E+(\S?DG96%Q;6&=PKUR%US MP8'V9OI+ZJK`%*A6IC^;GJ\1;&V]PG/)5%N<];!DG7`*-&GW<5RU`\O4&-\R MF%4Y.(U.)U1VK66HIZDQO55P*:%`UTLE9`9LQ5S05+]$B+(@`GA*TB6E33L2*VNCE&QB.4EV*[] M1]83V]3$[D!9C0Z-0!H_**]S^L$]C67H`?2`8L';R54D!I;*>E>IJ<5Y["Z` M%_ET"\P_(C)Q_N1ZG99)ML/A5P=[LER&S;6O+7#A0&99$,-AX>[(G<%:!/6! MBJHB6.45`ZFTQU#59&39'# MFNHZM'$,^T:%IOE0[\Q\K2*I=)88:QT\"K1-<,<>&!\;8]C%V!\S$JJCELK. M7,@TRQ)9_T709X!?H2N:-=]/-N;1+#4RQ\%K?%`WS@J&CL]^*GTBI*W>.HO< M4\!SE5!!V9Y!7MB#;-G?L_$\!>$_0;@_TOL`)S]BY40W6(\LA%$X"!' M'!S$`VLS6]O8=Q`98T`YX@,*,40$NCS<[X:R).Z8ID7S[A.VV9.U6_?,;FUM M8]8V=DI(6@..?@-.4_38U*MO'4"_BE'"=+=9L]/1*M\SU1/7@2^COC'$U*N" M)SHY`HO@\:XJZOR3H=N"%^IV-9_8%8DL[6767O9Z=G+-..1 M[(GTD)@!&$;LJAZ*SXVF`9+T=(J(?:(%P^T0/N&`-+ZD)#V=(F*C*"2A@SS^ M%$.6YK>$F[B_$T?O*9+<-&B^'XM6B7Y^N3IUO'X&[$D=JFB\`NS,P=T;P"XD MQ?D;C]"[1;:EWG6NVFGQZ*:E1SZP^C:\%E6"L,>Q4?:Z&# M0SL=#<57V$#L2E-1@;I5B[/^(48:<7.;UTNLVPC$JA97;2>CC>B.>N'3\:%P MA^QTM&K\-O6-F9.T;&\]WB62%,?[.GX%)5T@)CZ M3E#'9ZFT^\34YXB,.)5VJ'>5UZ@M]=88&V'Z`]DG-6O*,8WIK-G[W"5G[=A1 M[>E4F?7^;+>GJLE0I70&KH7W"5"YUI1/6MFE#?RZ9!@)';,J9CJ>LOW'(8@)<`%^!Q[+S;12B MW0Q"`E":[,$FY=D7R";EL4EY^I64Y\#-P+.^'>56G5+7IXBIU+O&?WE+#[![ M!^(VX2TKA0V`MP'P-@#>!L!W%DD;`'_Z9H#21Z/-4JYCFM18H8V4;RT5LZJ- MX'BIRK7;QAXI6(B`X1R#^.#HS(.--RQO-B:0I?OGTQ/?>HA_3+\A":8,0$+JP)=8$46D=DM^":?B`J$X0L?5!=RM`T0PG]$#AK_BR7.4N M6ZIST6!*-'#*MC/!\UGW$8MCV]CG,P^\#Y$W`?/(9RVMDWUN3Z(*#;0K<]H? M[?S9\0'Y#.G_P@"!C?I8:@@J[34RH@<4;W3,A96>-%P#_K*B1P$*)3.@7OGT MK:T"_/:/B>3?S'U.KM2/?WQY>2HB5EFY'FO@'`6;;P_H:!F-*.9;.`W)+R%C4 M1LN2,Z/?OP`"KO/E;X^A5T7P_"9:EOL5^L[+@FJZ*Q"%T"55!!>TT:[D-[Y# M27H\RQ6$SJG>KKR?*%?[%8`5P!6D/:C?IW6)2N!W&&M=J2;1*ZS'\]?<^56IT0BBGYTWN(R6F_T@H^QQA6D"X'(:89)C M_"A=O1%YD\]OA"@2&#)5E.JI#F+V(_&'4EQ)QVH88[!RH)>\17H387RHT,K+ M-H,HALB%*\>_=GP'N8"J]D/7Q1'POB#6Y\8"E`NL:MU&)$W-#_MF!_'4%];1 M,?,30("#W06%*VL@DD<"%E3JT#BR1I%S,EX6#7A8XB.:+ZXA0D0G5QI=3B+@%_V>Z384`C6:S MJ`I9L978U.0':NXZ\>;5WUU+LIR40JU,S=_5$%HY`72F)F&JC]B!X_]X MJ3].#:I,5&$*DEG$H9S+,/_R;WT7A:FG01N.S.UR+1'$;OH%OZ;Q;<_9:OIU MOE96>LE+,\>[KV<0QN5=Z]4>L^DOS(5W_VH]2--C0,M<233]09E6]@;U$#[3 MWX-I=T^0WFZN]99+#Z%MX.JJZ:^RM+6:!9''M9Y/H=_!-.@;H.5#Z(U_^J3Q MP$B;/ZI1*!4=G=O<4!;=VN@>AE=NT+5KMX&UFQ-:N,'WRN);']_#3>&#A;4, MK,VRCV-F[=.>[RI6LS(O&MR]N7[DQ?G`;AS?94H"U\INH1]1%>()A(\!(10_ M7E5')JPAY2@>DP:^@F?@1A1A",B.X,%R%86)X'<.9J^<;$4>+H-(>`^PF;9U MW)BI*?GU.K^!G(O(Q^CQ!!$\4&":A>M1ZZV[?.&%21&4JVEY/V'_HY7?"Q46 MU_KV0YJ@47J_75S^E'/+=3%36-/W'FMN%VIW'QOI1">A/,*IEV68Q=N@Z4:3 MI@_)8G1+$SO30PQ4S^+FOR_E_D M8/JI^>M-AV0"X@#CXPC["X?BZ/`9K3&5VFORJR MM%9LK!OCWC[+_IG^?QDM8ZTV_GT(]K^#ZNWHI`^53H"M`[5X(S:5'I%H&ON]R$'Z&V>71_,9F.OG.WRYZ9SPH MAD.V$'O@8SH>Y=T<`_VBO@)?R;5#(!G-LCCRCM8B[J5:RQ+S+A+S1_A;!#V& MBS+)EE:QA+EEPGQ$.;\0,)K=D1`NJ2@B3/<*66+?-:)AB7TI8J]\"/:&ITOU MG_T]PG3KMAHJ\E/5]'1I5L.S&EX]#>\9SA&<0==!X>&A;ET55B-JDYVKK3T! M:U>K;+4DZU:PVH?5/H0$4G43ZHT28JFDI9*5J.2]`_'?'3\"J2K6!(/L%@.K M?LKFP5/`:*55NC*&(J(FKV.YL.6,Q]C/5;X^RQHM:U1DC04;H26+EBQ:LEB9 M+'(8:P2)&$<9^;,\Y#-P&$[>"$W8M7E,%57N/E-F8*K-=(5:ZJ''EEA:8FF) MI266>HFE\I9ON:;EFI9KRKAF8M??O$:6/O'T")TI]'GZH6[=SRLMJM0C7KHU MZR[O(I-+9I%LIM'QBPBRK(;EHN9P43DY:AHY;/(,E++2"TC M;8&1FF47M>RL8^PLS?QZL!CYRBL,R51OP+)/RSZ-/1`M^VPB+K/$;F0)IR6< MEG#*".FU6Z3=TL-V]VQY=]\'\F0)P61:GQ%"N'I^CQV-U" MEDKUD$H=54[5SUP^MGXWL298$6Q*L:B6MN_E;:FRIL:7&+5+CNI&R0/9NR@2XP1S!;YM7*_FGHAYHVW1_>M'+%Y^;]$;\/"!#-X2O=*I+QB-7 M;MBJ8U8=L^J85<<:"F5N_'CHC:*F"'#U$\0^I]$**[8O<%A+@K4DR"P)C_0@ M0`1LGUXW+V=R5Y0]P3N,D@G8E:"HM%46S`FWVLYJ@>7KL)PEYETZAW+93N%G MWQM:;5G+:;`6/;@(-\%N&#\Z1^7N'(P@FA.JJW/%2&LDU+XP1>'LHN):`O"% M0*H);QTF'7>8](FUZ@BC+_CVN[%_6X[<#=8CM0A*MF++DBU+[A1+/AU"J"_^ M1S\MM,3J*#G]*,0OH)GECN>9TZZ>W/]B"[V>_IE,Z].%":.QK*,NX6. M+!&U1-0244M$BQ/"-;:U609K&:QEL#(&2[^D)0SC"#CDW03\>6R`W.X\F:$D M80'++=>&CH._Y#S4&*:UG7:VB*0&_1?2O=Z\V@-(2F"X1F&/*N?<9%.@\PN)=D+W0_"PL;YE0EPXQN45/ M/.F6]%C2TRG2HPF7@BV]&VIG+B'\\8))R*[0TG_\/U!+`P04````"`!S;P=# M?`-8FHD-```/@P``$0`<`&-L=G,M,C`Q,S`V,S`N>'-D550)``,)BP)2"8L" M4G5X"P`!!"4.```$.0$``.T=:V_C-O)[@?X'GC_<;8$ZCI-F;S=(6CBOUF@V MSCG97J]?"EJB;:(2Z26IQ.ZOOR$EV;0DTY+MW;4!?4GTF"=G.#-\B+[X:1H& MZ(4(23F[;+2/CAN(,(_[E(TN&Q^?FIVGZVZW\=./WWYS\8]F$_7[Z(8S1H*` MS-#O'@F(P(J@9SSEC(_1R5$;H;%2D_-6Z_7U M]8CX(RR:G`64D2./ARW4;*8#*''V(Y,-#)BU;%[P MLMQB7L!?J.3@>@$?S8Q3:,3CMZ?'%AH#(T5A<3/X2K0TQQ8`-0&*".K9J.OQ M$">P6N0OOC8[ZZ35241LJ7A6S?`2AO<=^--<>#KPH,(CW<)\@)Q`NQ(F`6,K4!I@+R5;C)4]3(^W4=D\@ MM'&UWK`+4"'I!(H(!IJ\D-AF?0#[TPGF-M@I6&F.CG3>8I('5.""[KF4M3G+F_..,DBZ%`>/7!J)K@,L91)`B@SK M0G";^`>7B:]PH),_>AH3HFH+[L:"CQB2J!H31:&)*IO38*^QZ5EYFZ(W2^)\ M5]NXO(VOL1S?!?Q5=IE/!?%4L3'S8&[KO2T?=#5I9&C7=EMCMP>NB'SF\YZU M:,B>&&%&_S8Z+=H:;B"//5KZ6MUR@7Q#);"6D2#/9*JN`N[]97G!%V3J]JE_ MZW)KC@4W#UCI"_"AJTC"X%=*4X5=84F-9]DRU+ZUL6\]T1&#L.UAICJ>&7E1 M-GH$8WL4,"IY3$E2;C]XE_6#IR@,L9AIDUL,T((#2EG47K"Q%]QA*G[#0406 M35_1^&X*;IN_S]I\3A]&6U*)*$XGNOMK-LCP01$UN#Z76WYC2V?]"/YB&=X M$!`([O!$1,2_IWA``Y"9;)Q"-J7M]);V<=9;>E`;"I201K?3"8SIZFBPA4_< MD(':U.:K<-TV;6=M"A7'"Q&*@MM`IN?LI MHFJF83>U=7EJ;NN?N*U/AD0(,[(`4B8+V(S_A6+6M5=LWM_G;0]C01[J^> MZY-`#^FNN01;CV$4?J67JB":&ZR*<6%+'FX/.LU5C9I4T]!"-KO:2S;VDGOJ MZ<3:&0E"-G``![K;MC]D;9M00@M2M54WMNHM%@P&4?*1"--GJAEU-;;;IF>Y MT3Y19@X>`:6X\]8VW=BF$/!"JN(2G$%H-<-DPKPM2OF*)-W6?YO/]W/J)K\O MT:\=8?-R+QI(\BF"R]N7ZA%[-;;;O+FIO`4A%%.J3;HW<\'IY-E7F1.>,W<[ M5&Y.L,K<,'J3O)0O0FYE.[PQ>?-:S@*-MQ M<+K02Y<_.2^5%J M;>C2^SCG#=F1DBB99&2_H^8U00\ZJ][!"Q8SI5RRK7,#1+==<[.%,>&T2/`1 M5G;M`-UY3CZI,=_<$(5IO1FI@M7GO=.JTB"KSVUH56@=WS$.UJP1Y0A6X#5W[;4WK4C[RH5C*J@NKTC-Z^YTCOJP+)#T\>[ MBWM#$$[$].'.IZB+Q#"<\9V`CO->YJ;<[3W-9M$DM!#*<':G!N8TQL3/PH( MF*BX8PJ!V2B.FU>SW'1@YQ4+/V?U7=!T.T=^7C'A:;QC51RP&:/!;`DP88X, M]]J3JGM2;KM2J710$LOM#;EIQ_R&ISH'[#K]RUZD]$$2^C2/VZD71#[Q[V!D M>+UHF=[PA@:1(OX#47H6.)U4+JP)MJ'G=H_BO8X260Q1RA$-@26R>.J`DG`M MG,VNO:?Z"'?ESJB2P]F*^&[OR,U;VGNK.MF]574<@SE4VF,6V7:+Y$JI3`6 M9'C9T.?!--/S//X$C*-I&*0@BBK-Q>[QFI#\'N$@:+3V5_-E,Y90'!`*%+^9 MDSD0O0,$$%)E0&V0.5[3>%`M,UV\Q)*`TJ!TDL[O`ITOVC99]'`W?)9-1>@ M.A<*L<+SEV#G/P5K%UK`L/'BK10(EY[2:"UK56S]WWE6I1LAB MZ99XKYN__78;$:RCNBJ*P=G#9I*X#C;;PC#Z256[K#LAS"E.$5YZLYT@!>>- ME9/$1IS?-1=DJLN2.<2LE!@ICK[8JB&RQZ&5XCY',E=;\<\?K%9*`@LMN=Y* MBNQ!;:5DF".9J^8"W>:?'-EF!+ALY+="0@HD747"9'E#I]`_G5!Q"6`.5SR7 M2F]MT2]T==Q`>`!/L*?#9X?B60PPV@0Z!U0*:R,`)FJ M2+_]6?!HDC*A0+ZL-F9/E5.3!.(+:^&K\S%@"B\:F'9TZJ-/P(2B:@R#KAOR M0@(^T3#+NQ=L[=;!V[J&G,'P3,R*M!WB0!:J&QN-D,O(7+!^X^A]1/<\$/-]N@XJ(6S?&PO:9UO#)8$>- M8;:*]89VJ6H^19AE/L,Q#5`&.%8Z/MCS7*7/-U1[!PHZIBZR/7@]Z%YV92VH M9ASA8#[YVAL$=*2W%(.7$@]+]6CD6%*V`I:M=ZK%US1I7O3_1%@H(H)9*CKT MTT\1A7Y82O/UZ/O5!-EC1#L%QXAV$IDLU:NA[5'ZO9U2J7MCU]0_7,@/)!P0 M8:FV$F(I(/D\Q+30;E]$C?G&SSB5W.L4VF/ZPQ%S^?S*GP5F!QRHJ0+$^&>D)0BYF29*UFZ,:WN=KBAU6)BMU6BBD M]X_A@,@/--!NSDCZD4B9IBE%YB!:JLN`&);DAL3_NPR*D@FF_N(;K-*E[0YH M'4B;Q6NT$"2M57GSS=''R9V`K)CO915P#B'8S).#YMB9TF4WR+W[\N6>3T/= MVG%I44*'&Y//5FF1OMVG%)C=?9#JM_4@/^YPJSTAC[K^8?1.A_)57,0.^U>K]VG]=K90'MM3+Q`RYTQII= M4?XXQC"V@32_7L6UJ(>AN!;C#$@)/OQUWOE5]![!>9AJ/U"`_P\)@)/"!#T M\H/$ZJ@'H?AU@%^HC'VUO,Y%6`>A[L]8D;\(`<;EE57!'P0M=^RX&NKOV+PO39C,OXK&%"M!ST,$UIBKS=@`?!>FZ\? M>7B"!1VLCS$YT+U6K&C]R@6T;^M6>5E+]+!#ZUKE^M2^=J8/>$K#*.Q*&6E* M\2D?P^7O?2V]RH$?P@IZHDF:K*PI43,SV"EN.. M%Z\4ZGEC[A$IBV>+K9:HBG@(C9$DOAY[!F^F>HWA=CK!)B#D4DL)V'WJYW%1 MK7_U3TQX3#>OTFJ8O5(%,H%')SA(?K]LL<3QD>DECRY31!!I.VMYE(-8!3%= MC?A2?^=D0C$PT(>QK3BOX8'H'WQ,X'2<6FJ9;4D=1,=>K^72V2T>C MG/4A_B.PEQ`5%)Y"V(3`*JEGZL#K@$MS9(<^<%A0SZZ;/A>#SU9I[JX;&267 MCLHIVD/LA/K"`Z%JVF1W(*Z$^/+#N1(;#XTSZ>!,_)M(RQ3OE3/^EGXG_$!> M#<22O:KA)>$/8M\D>;F9E^[`@J:[O4+)"D*;W:)2UZS9).>$.H3LE6SM2`;B MJQ*7$^HKYJR+5OQ%`US^'U!+`0(>`Q0````(`'-O!T.3<,E@>FT``*O;!``1 M`!@```````$```"D@0````!C;'9S+3(P,3,P-C,P+GAM;%54!0`#"8L"4G5X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`'-O!T/8DH&T)`P``(N<```5`!@` M``````$```"D@<5M``!C;'9S+3(P,3,P-C,P7V-A;"YX;6Q55`4``PF+`E)U M>`L``00E#@``!#D!``!02P$"'@,4````"`!S;P=#!(_?'H8D``!,O0(`%0`8 M```````!````I($X>@``8VQV&UL550%``,)BP)2 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@``Q0````(`'-O!T/.L_)+E28``'(O`P`5 M`!@```````$```"D@8?F``!C;'9S+3(P,3,P-C,P7W!R92YX;6Q55`4``PF+ M`E)U>`L``00E#@``!#D!``!02P$"'@,4````"`!S;P=#?`-8FHD-```/@P`` M$0`8```````!````I(%K#0$`8VQV`L``00E#@``!#D!``!02P4&``````8`!@`:`@``/QL!```` ` end XML 64 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events
6 Months Ended

Jun. 30, 2013

Subsequent Events

11. Subsequent Events

The Company evaluated events up to the filing date of these interim financial statements and determined that no subsequent activity required disclosure.

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R22.xml IDEA: Assets Measured at Fair Value on Recurring Basis (Detail) 2.4.0.8123 - Disclosure - Assets Measured at Fair Value on Recurring Basis (Detail)truefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$eol_PE807381--1310-Q0005_STD_0_20130630_0http://www.sec.gov/CIK0001466301instant2013-06-30T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE807381--1310-Q0005_STD_0_20121231_0http://www.sec.gov/CIK0001466301instant2012-12-31T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]2false 4us-gaap_AssetsFairValueDisclosureRecurringus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse147985000147985USD$falsetruefalse2truefalsefalse135385000135385USD$falsetruefalsexbrli:monetaryItemTypemonetaryThis element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.No definition available.false2Assets at fair value3false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3false USDtruefalse$eol_PE807381--1310-Q0005_STD_0_20130630_0_712021x710575http://www.sec.gov/CIK0001466301instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseMoney Marketus-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MoneyMarketFundsMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Money Market4true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]5false 4us-gaap_AssetsFairValueDisclosureRecurringus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse147985000147985USD$falsefalsefalse2truefalsefalse135385000135385USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThis element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.No definition available.false2Assets at fair value6false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse5false USDtruefalse$eol_PE807381--1310-Q0005_STD_0_20130630_0_715757x707740http://www.sec.gov/CIK0001466301instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseFair Value, Inputs, Level 1us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel1Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Fair Value, Inputs, Level 17true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]8false 4us-gaap_AssetsFairValueDisclosureRecurringus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse147985000147985USD$falsefalsefalse2truefalsefalse135385000135385USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThis element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.No definition available.false2Assets at fair value9false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse7false USDtruefalse$eol_PE807381--1310-Q0005_STD_0_20130630_0_712021x710575_715757x707740http://www.sec.gov/CIK0001466301instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseFair Value, Inputs, Level 1us-gaap_FairValueByFairValueHierarchyLevelAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_FairValueInputsLevel1Memberus-gaap_FairValueByFairValueHierarchyLevelAxisexplicitMemberfalsefalseMoney Marketus-gaap_FairValueByAssetClassAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MoneyMarketFundsMemberus-gaap_FairValueByAssetClassAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Fair Value, Inputs, Level 1 | Money Market10true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]11false 4us-gaap_AssetsFairValueDisclosureRecurringus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse147985000147985USD$falsetruefalse2truefalsefalse135385000135385USD$falsetruefalsexbrli:monetaryItemTypemonetaryThis element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.No definition available.false2Assets at fair valuefalseAssets Measured at Fair Value on Recurring Basis (Detail) (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/DisclosureAssetsMeasuredAtFairValueOnRecurringBasis211 XML 66 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Share-Based Compensation
6 Months Ended

Jun. 30, 2013

Share-Based Compensation

7. Share-Based Compensation

Share-based compensation expense for all equity based programs, including stock options and the employee stock purchase plan, for the three and six months ended June 30, 2013 and 2012, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows:

 Three Months Ended June 30, Six Months Ended June 30,

 2013 2012 2013 2012

Research and development
 $ 1,103 $ 592 $ 1,957 $ 1,032

General and administrative
 1,005 576 1,915 1,082









Total share-based compensation expense
 $ 2,108 $ 1,168 $ 3,872 $ 2,114









The Company did not recognize a tax benefit related to share-based compensation expense during the three and six months ended June 30, 2013 and 2012, respectively, as the Company maintains net operating loss carryforwards and has established a valuation allowance against the entire net deferred tax asset as of June 30, 2013. No share-based compensation expense was capitalized on our Consolidated Balance Sheets as of June 30, 2013 and December 31, 2012.

The following table summarizes the activity relating to the Company’s options to purchase common stock for the six month period ended June 30, 2013:

 Option Shares
Outstanding Weighted-
Average
Exercise
Price Weighted-
Average
Remaining
Contractual
Term (Years) Aggregate
Intrinsic
Value

Balance at December 31, 2012
 1,599,044 $ 14.05

Granted
 1,046,158 28.53

Exercised
 (130,732 ) 9.09

Forfeited
 (29,400 ) 16.75





Balance at June 30, 2013
 2,485,070 $ 20.38 8.79 $ 116,427,809





Vested and expected to vest at June 30, 2013
 2,261,717 $ 19.90 8.72 $ 107,015,622





Vested at June 30, 2013
 721,162 $ 11.00 7.84 $ 40,368,071





The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $66.98 as of June 30, 2013, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.

 Three Months Ended June 30,

 2013 2012

Weighted-average grant-date fair value per share
 $ 43.22 $ 12.60

Intrinsic value of options exercised
 $ 5,540,488 $ 162,845

Cash received from stock option exercises
 $ 1,101,935 $ 32,108

 Six Months Ended June 30,

 2013 2012

Weighted-average grant-date fair value per share
 $ 17.61 $ 15.02

Intrinsic value of options exercised
 $ 5,716,374 $ 223,319

Cash received from stock option exercises
 $ 1,188,312 $ 42,149

As of June 30, 2013, the unrecognized share-based compensation expense related to nonvested options, adjusted for expected forfeitures was $23.7 million and the estimated weighted-average remaining vesting period was 2.8 years.

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 67 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies
6 Months Ended

Jun. 30, 2013

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 2 of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 69 R13.xml IDEA: License Agreements 2.4.0.8114 - Disclosure - License Agreementstruefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4clvs_LicenseAgreementsTextBlockclvs_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 8. License Agreements CO-1686 In May 2010, the Company entered into a worldwide license agreement with Avila Therapeutics, Inc. (“Avila”) to discover, develop and commercialize a covalent inhibitor of mutant forms of the epidermal growth factor receptor gene product. In March 2012, Avila was acquired by Celgene Corporation (“Celgene”). CO-1686 was identified as the lead drug candidate to be developed under the license agreement. The Company is responsible for all preclinical, clinical, regulatory and other activities necessary to develop and commercialize CO-1686. The Company made an up-front payment of $2.0 million upon execution of the license agreement which was recognized as acquired in-process research and development expense. The Company is obligated to pay royalties on net sales of CO-1686, based on the volume of annual net sales achieved. Celgene has the option to increase royalty rates by electing to reimburse a portion of the development expenses incurred by the Company. This option must be exercised within a limited period of time after Celgene is notified of our intent to pursue regulatory approval of CO-1686 in the United States or European Union as a first line therapy. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> In January 2012, the U.S. Food and Drug Administration (FDA) accepted our investigational new drug (IND) application to begin clinical investigation of CO-1686. Following the FDA’s acceptance of the IND application, the Company made a milestone payment of $4.0 million to Avila as required by the license agreement and recognized the payment as acquired in-process research and development expense. The Company may be required to pay up to an additional aggregate of $115.0 million in development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, the Company may be required to pay up to an aggregate of $120.0 million in sales milestones if certain annual sales targets are achieved. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> In January 2013, the Company entered into an exclusive license agreement with Gatekeeper Pharmaceuticals, Inc. (“Gatekeeper”) to acquire exclusive rights under patent applications associated with mutant epidermal growth factor receptor (“EGFR”) inhibitors and methods of treatment. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. If CO-1686 is approved for commercial sale, the Company will pay royalties to Gatekeeper on future net sales. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 18px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> Rucaparib <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> In June 2011, the Company entered into a worldwide license agreement with Pfizer Inc. to acquire exclusive development and commercialization rights to Pfizer’s drug candidate known as rucaparib. This drug candidate is a small molecule inhibitor of poly (ADP-ribose) polymerase, or PARP, which the Company is developing for the treatment of selected solid tumors. Pursuant to the terms of the license agreement, the Company made an up-front payment by issuing to Pfizer a $7.0 million convertible promissory note with a 5% annual interest rate, due in 2012. Upon completion of the Company’s initial public offering in November 2011, the principal balance and all accrued and unpaid interest due on this note of $7.2 million was converted into 551,222 shares of common stock. The Company is responsible for all development and commercialization costs of rucaparib and, if approved, Pfizer will receive royalties on the net sales of the product. In addition, Pfizer is eligible to receive up to $259 million of further payments, in aggregate, if certain development, regulatory and sales milestones are achieved. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> In April 2012, the Company entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of rucaparib for the uses claimed by these patents. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. The Company may be required to pay up to an aggregate of $0.7 million in milestone payments if certain regulatory filings, acceptances and approvals are achieved. If approved, AstraZeneca will also receive royalties on any net sales of rucaparib. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 0px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> CO-101 <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> In November 2009, the Company entered into a license agreement with Clavis Pharma ASA (“Clavis”) to develop and commercialize CO-101 in North America, Central America, South America and Europe. Under terms of the license agreement, the Company made an up-front payment to Clavis in the amount of $15.0 million, which was comprised of $13.1 million for development costs incurred prior to the execution of the agreement that was recognized as acquired in-process research and development and $1.9 million for the prepayment of preclinical activities to be performed by Clavis. In November 2010, the license agreement was amended to expand the license territory to include Asia and other international markets. The Company made a payment of $10.0 million to Clavis for the territory expansion and recognized the payment as acquired in-process research and development. As part of the amended license agreement, Clavis also agreed to reimburse up to $3.0 million of the Company’s research and development costs for certain CO-101 development activities subject to the Company incurring such costs, all of which was completed in 2011. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> On November 12, 2012, the Company reported results from a pivotal study for CO-101 as compared to gemcitabine in metastatic pancreatic cancer. The study results failed to demonstrate a difference in overall survival between the two study arms. Based on the results of the study, the Company has ceased development of CO-101 and terminated the license agreement. <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 18px; TEXT-INDENT: 0px; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> Drug Discovery Collaboration Agreement <p style="TEXT-TRANSFORM: none; MARGIN-TOP: 6px; TEXT-INDENT: 4%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> In July 2012, the Company entered into a drug discovery collaboration agreement with Array BioPharma Inc. for the discovery of a novel cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. Under the terms of the agreement, the Company is responsible to fund all costs of the discovery program, as well as costs to develop and commercialize any clinical candidates discovered. If any clinical candidates are discovered and the Company seeks to pursue clinical development of such clinical candidates, the Company may be required to pay Array up to an aggregate of $192.0 million in milestone payments if certain development and regulatory objectives and annual net sales targets are achieved. </div>falsefalsefalsenonnum:textBlockItemTypenaLicense AgreementsNo definition available.false0License AgreementsfalseLicense AgreementsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementsTextBlock11 XML 70 R23.xml IDEA: Financial Instruments and Fair Value Measurement - Additional Information (Detail) 2.4.0.8124 - Disclosure - Financial Instruments and Fair Value Measurement - Additional Information (Detail)truefalsefalse1false USDfalsefalse$eol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]2false 4clvs_FairValueAssetsLevelOneAndLevelTwoTransfersAmountclvs_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00USD$falsetruefalsexbrli:monetaryItemTypemonetaryFair value assets level one and level two transfers amount.No definition available.false2Security transfers between Levels 1 and 2falseFinancial Instruments and Fair Value Measurement - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/DisclosureFinancialInstrumentsAndFairValueMeasurementAdditionalInformation12 XML 71 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments And Contingencies - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
1 Months Ended

Feb. 28, 2013

Jun. 30, 2013

Purchase Commitment, Excluding Long-term Commitment [Line Items]

Purchase commitment $ 2.6

Contractual agreement quarterly forecasts required period 24 months

Contractual agreement obligated forecast period 12 months

X

- Definition

Contractual Agreement Obligated Forecast Period

+ References

No definition available.

+ Details

Name: clvs_ContractualAgreementObligatedForecastPeriod

Namespace Prefix: clvs_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Contractual Agreement Quarterly Forecasts Required Period

+ References

No definition available.

+ Details

Name: clvs_ContractualAgreementQuarterlyForecastsRequiredPeriod

Namespace Prefix: clvs_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a)(19))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 72 R26.xml IDEA: Convertible Preferred Stock and Stockholders' Equity - Additional Information (Detail) 2.4.0.8127 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Additional Information (Detail)truefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_30_20111130_0http://www.sec.gov/CIK0001466301duration2011-11-01T00:00:002011-11-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares02false USDfalsefalse$eol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE807381--1310-Q0005_STD_182_20120630_0http://www.sec.gov/CIK0001466301duration2012-01-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$eol_PE807381--1310-Q0005_STD_1533_20130630_0http://www.sec.gov/CIK0001466301duration2009-04-20T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDtruefalse$eol_PE807381--1310-Q0005_STD_30_20130630_0_711196x713713http://www.sec.gov/CIK0001466301duration2013-06-01T00:00:002013-06-30T00:00:00falsefalseCommon Stockus-gaap_StatementClassOfStockAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CommonStockMemberus-gaap_StatementClassOfStockAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0USDUSD$6false USDtruefalse$eol_PE807381--1310-Q0005_STD_30_20120430_0_711196x713713http://www.sec.gov/CIK0001466301duration2012-04-01T00:00:002012-04-30T00:00:00falsefalseCommon Stockus-gaap_StatementClassOfStockAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CommonStockMemberus-gaap_StatementClassOfStockAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0USDUSD$7false USDtruefalse$eol_PE807381--1310-Q0005_STD_30_20111130_0_711196x713713http://www.sec.gov/CIK0001466301duration2011-11-01T00:00:002011-11-30T00:00:00falsefalseCommon Stockus-gaap_StatementClassOfStockAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CommonStockMemberus-gaap_StatementClassOfStockAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0USDUSD$8false USDtruefalseeol_PE807381--1310-Q0005_STD_31_20090531_0_711196x713713http://www.sec.gov/CIK0001466301duration2009-05-01T00:00:002009-05-31T00:00:00falsefalseCommon Stockus-gaap_StatementClassOfStockAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CommonStockMemberus-gaap_StatementClassOfStockAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instanceshares0iso4217_USD_per_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0$9false truefalseeol_PE807381--1310-Q0005_STD_30_20111130_0_711196x710593http://www.sec.gov/CIK0001466301duration2011-11-01T00:00:002011-11-30T00:00:00falsefalseConvertible Preferred Stockus-gaap_StatementClassOfStockAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ConvertiblePreferredStockMemberus-gaap_StatementClassOfStockAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instanceshares010false USDtruefalse$eol_PE807381--1310-Q0005_STD_365_20091231_0_711196x710593http://www.sec.gov/CIK0001466301duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseConvertible Preferred Stockus-gaap_StatementClassOfStockAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ConvertiblePreferredStockMemberus-gaap_StatementClassOfStockAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11false USDtruefalse$eol_PE807381--1310-Q0005_STD_0_20090531_0_711196x710593http://www.sec.gov/CIK0001466301instant2009-05-31T00:00:000001-01-01T00:00:00falsefalseConvertible Preferred Stockus-gaap_StatementClassOfStockAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ConvertiblePreferredStockMemberus-gaap_StatementClassOfStockAxisexplicitMemberiso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3clvs_ShareholdersEquityLineItemsclvs_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Shareholders Equity [Line Items]2false 4us-gaap_StockIssuedDuringPeriodSharesNewIssuesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse38194443819444falsefalsefalse6truefalsefalse37500003750000falsefalsefalse7truefalsefalse1070000010700000falsefalsefalse8truefalsefalse12068991206899falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of new stock issued during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Common stock, shares issued3false 4clvs_StockIssuedDuringPeriodValuePerShareNewIssuesclvs_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8truefalsefalse0.00290.0029USD$falsetruefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalStock Issued During Period Value Per Share New IssuesNo definition available.false3Common stock shares issued, per share4false 4us-gaap_SharePriceus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse72.0072.00USD$falsetruefalse6truefalsefalse20.0020.00USD$falsetruefalse7truefalsefalse13.0013.00USD$falsetruefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalPrice of a single share of a number of saleable stocks of a company.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258 false3Sale of stock price per share5false 4us-gaap_ProceedsFromIssuanceInitialPublicOfferingus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse129400000129400000USD$falsetruefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow associated with the amount received from entity's first offering of stock to the public.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 false2Net proceeds from issuance of common stock, initial public offering6false 4clvs_UnderwritingCommissionCostsclvs_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse69000006900000falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryUnderwriting Commission CostsNo definition available.false2Underwriting commission cost7false 4us-gaap_PaymentsOfStockIssuanceCostsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse28000002800000falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse174000174000falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow for cost incurred directly with the issuance of an equity security.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585 false2Issuance costs8false 4us-gaap_ProceedsFromIssuanceOfCommonStockus-gaap_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:monetaryItemTypemonetaryThe cash inflow from the additional capital contribution to the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 false2Proceeds from sale of common stock, net of issuance costs9false 4clvs_MaximumIssuableValueOfPreferredStockclvs_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11truefalsefalse146300000146300000falsefalsefalsexbrli:monetaryItemTypemonetaryMaximum issuable value of preferred stock.No definition available.false2Maximum issuable value of preferred stock10false 4us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStockus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse7550000075500000USD$falsetruefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 false2Cash proceeds on issuance of convertible preferred stock11false 4us-gaap_ConversionOfStockSharesConverted1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse27577882757788falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9truefalsefalse72445237244523falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 false1Conversion of convertible preferred stock into common stock12false 4us-gaap_ConvertiblePreferredStockSharesIssuedUponConversionus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse2.92.9falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of shares issued for each share of convertible preferred stock that is converted.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644 false1Rate of conversion of convertible stock into common stockfalseConvertible Preferred Stock and Stockholders' Equity - Additional Information (Detail) (USD $)NoRoundingNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformation1112 XML 73 R28.xml IDEA: Share-Based Compensation - Additional Information (Detail) 2.4.0.8129 - Disclosure - Share-Based Compensation - Additional Information (Detail)truefalsefalse1false USDfalsefalse$eol_PE807381--1310-Q0005_STD_91_20130630_0http://www.sec.gov/CIK0001466301duration2013-04-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$eol_PE807381--1310-Q0005_STD_91_20120630_0http://www.sec.gov/CIK0001466301duration2012-04-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$eol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$eol_PE807381--1310-Q0005_STD_182_20120630_0http://www.sec.gov/CIK0001466301duration2012-01-01T00:00:002012-06-30T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDfalsefalse$eol_PE807381--1310-Q0005_STD_366_20121231_0http://www.sec.gov/CIK0001466301duration2012-01-01T00:00:002012-12-31T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Share-based Compensation Arrangement by Share-based Payment Award [Line Items]2false 4us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpenseus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse00USD$falsetruefalse2truefalsefalse00USD$falsetruefalse3truefalsefalse00USD$falsetruefalse4truefalsefalse00USD$falsetruefalse5falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false2Share-based compensation expense, tax benefit recognized3false 4us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmountus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false2Capitalized share-based compensation expense4false 4clvs_ShareBasedCompensationSharesUnderStockOptionPlansPretaxIntrinsicValueClosingStockPriceclvs_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse66.9866.98falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse66.9866.98falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryShare based compensation shares under stock option plans pretax intrinsic value closing stock price.No definition available.false2Pretax intrinsic value, closing stock price5false 4us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptionsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse2370000023700000USD$falsetruefalse2falsefalsefalse00falsefalsefalse3truefalsefalse2370000023700000USD$falsetruefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryUnrecognized cost of unvested options awarded to employees as compensation.No definition available.false2Unrecognized share-based compensation expense6false 4us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1us-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse002 years 9 months 18 daysfalsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaWeighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Weighted average remaining vesting periodfalseShare-Based Compensation - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformation56 XML 74 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Accrued Expenses (Tables)
6 Months Ended

Jun. 30, 2013

Other Accrued Expenses

Other accrued expenses are comprised of the following (in thousands):

 June 30, 2013 December 31, 2012

Accrued personnel costs
 $ 1,811 $ 2,441

Accrued corporate legal fees and professional services
 350 63

Accrued expenses – other
 63 198





Other accrued expenses
 $ 2,224 $ 2,702





X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 75 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies
6 Months Ended

Jun. 30, 2013

Commitments and Contingencies

10. Commitments and Contingencies

Royalty and License Fee Commitments

The Company has entered into certain license agreements, as identified in Note 8, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. The Company’s payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly no amounts have been recorded in the Company’s accompanying Consolidated Balance Sheets at June 30, 2013 and December 31, 2012.

Development and Manufacturing Agreement Commitments

In February 2013, the Company entered into a development and manufacturing agreement with a third-party supplier for the production of the active ingredient for rucaparib. Under the Development and Manufacturing Agreement, the Company will provide the third-party supplier a rolling 24-month forecast that will be updated by the Company on a quarterly basis. The Company is obligated to order the quantity specified in the first twelve months of any forecast. As of June 30, 2013, $2.6 million of purchase commitments were established under this agreement.

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 76 R33.xml IDEA: Commitments And Contingencies - Additional Information (Detail) 2.4.0.8134 - Disclosure - Commitments And Contingencies - Additional Information (Detail)truefalseIn Millions, unless otherwise specifiedfalse1false falsefalseeol_PE807381--1310-Q0005_STD_28_20130228_0http://www.sec.gov/CIK0001466301duration2013-02-01T00:00:002013-02-28T00:00:002false USDfalsefalse$eol_PE807381--1310-Q0005_STD_0_20130630_0http://www.sec.gov/CIK0001466301instant2013-06-30T00:00:000001-01-01T00:00:00iso4217_USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Purchase Commitment, Excluding Long-term Commitment [Line Items]2false 4us-gaap_PurchaseCommitmentRemainingMinimumAmountCommittedus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse26000002.6USD$falsetruefalsexbrli:monetaryItemTypemonetaryMinimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 25 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 17 -Article 9 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.(a)(19)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 false2Purchase commitment3false 4clvs_ContractualAgreementQuarterlyForecastsRequiredPeriodclvs_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse0024 monthsfalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaContractual Agreement Quarterly Forecasts Required PeriodNo definition available.false0Contractual agreement quarterly forecasts required period4false 4clvs_ContractualAgreementObligatedForecastPeriodclvs_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse0012 monthsfalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaContractual Agreement Obligated Forecast PeriodNo definition available.false0Contractual agreement obligated forecast periodfalseCommitments And Contingencies - Additional Information (Detail) (USD $)HundredThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation24 XML 77 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Assets Measured at Fair Value on Recurring Basis (Detail) (USD $)
In Thousands, unless otherwise specified

Jun. 30, 2013

Dec. 31, 2012

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets at fair value $ 147,985 $ 135,385

Money Market

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets at fair value 147,985 135,385

Fair Value, Inputs, Level 1

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets at fair value 147,985 135,385

Fair Value, Inputs, Level 1 | Money Market

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets at fair value $ 147,985 $ 135,385

X

- Definition

This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.

+ References

No definition available.

+ Details

Name: us-gaap_AssetsFairValueDisclosureRecurring

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 78 R15.xml IDEA: Commitments and Contingencies 2.4.0.8116 - Disclosure - Commitments and Contingenciestruefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:001false 4us-gaap_CommitmentsAndContingenciesDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> 10. Commitments and Contingencies Royalty and License Fee Commitments The Company has entered into certain license agreements, as identified in Note 8, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. The Company’s payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly no amounts have been recorded in the Company’s accompanying Consolidated Balance Sheets at June 30, 2013 and December 31, 2012. Development and Manufacturing Agreement Commitments In February 2013, the Company entered into a development and manufacturing agreement with a third-party supplier for the production of the active ingredient for rucaparib. Under the Development and Manufacturing Agreement, the Company will provide the third-party supplier a rolling 24-month forecast that will be updated by the Company on a quarterly basis. The Company is obligated to order the quantity specified in the first twelve months of any forecast. As of June 30, 2013, $2.6 million of purchase commitments were established under this agreement. </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for commitments and contingencies.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308 false0Commitments and ContingenciesfalseCommitments and ContingenciesUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock11 XML 79 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Share-Based Compensation (Tables)
6 Months Ended

Jun. 30, 2013

Share-Based Compensation Expense Recognized in Accompanying Statements of Operations

Share-based compensation expense for all equity based programs, including stock options and the employee stock purchase plan, for the three and six months ended June 30, 2013 and 2012, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows:

 Three Months Ended June 30, Six Months Ended June 30,

 2013 2012 2013 2012

Research and development
 $ 1,103 $ 592 $ 1,957 $ 1,032

General and administrative
 1,005 576 1,915 1,082









Total share-based compensation expense
 $ 2,108 $ 1,168 $ 3,872 $ 2,114









Summary of Stock Options Activity

The following table summarizes the activity relating to the Company’s options to purchase common stock for the six month period ended June 30, 2013:

 Option Shares
Outstanding Weighted-
Average
Exercise
Price Weighted-
Average
Remaining
Contractual
Term (Years) Aggregate
Intrinsic
Value

Balance at December 31, 2012
 1,599,044 $ 14.05

Granted
 1,046,158 28.53

Exercised
 (130,732 ) 9.09

Forfeited
 (29,400 ) 16.75





Balance at June 30, 2013
 2,485,070 $ 20.38 8.79 $ 116,427,809





Vested and expected to vest at June 30, 2013
 2,261,717 $ 19.90 8.72 $ 107,015,622





Vested at June 30, 2013
 721,162 $ 11.00 7.84 $ 40,368,071





Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award

The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $66.98 as of June 30, 2013, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.

 Three Months Ended June 30,

 2013 2012

Weighted-average grant-date fair value per share
 $ 43.22 $ 12.60

Intrinsic value of options exercised
 $ 5,540,488 $ 162,845

Cash received from stock option exercises
 $ 1,101,935 $ 32,108

 Six Months Ended June 30,

 2013 2012

Weighted-average grant-date fair value per share
 $ 17.61 $ 15.02

Intrinsic value of options exercised
 $ 5,716,374 $ 223,319

Cash received from stock option exercises
 $ 1,188,312 $ 42,149

X

- Definition

Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 80 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
6 Months Ended

Jun. 30, 2013

Aug. 01, 2013

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2013

Document Fiscal Year Focus 2013

Document Fiscal Period Focus Q2

Trading Symbol CLVS

Entity Registrant Name CLOVIS ONCOLOGY, INC.

Entity Central Index Key 0001466301

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 30,171,392

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 81 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Net Loss Per Share (Tables)
6 Months Ended

Jun. 30, 2013

Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share

The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):

 Three and Six Months Ended June 30,

 2013 2012

Common shares under option
 2,343 1,718





Total potential dilutive shares
 2,343 1,718





X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 82 R1.xml IDEA: Document and Entity Information 2.4.0.8101 - Document - Document and Entity Informationtruefalsefalse1false falsefalseeol_PE807381--1310-Q0005_STD_181_20130630_0http://www.sec.gov/CIK0001466301duration2013-01-01T00:00:002013-06-30T00:00:002false falsefalseeol_PE807381--1310-Q0005_STD_0_20130801_0http://www.sec.gov/CIK0001466301instant2013-08-01T00:00:000001-01-01T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares01true 3dei_DocumentInformationLineItemsdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Document Information [Line Items]2false 4dei_DocumentTypedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse0010-Qfalsefalsefalse2falsefalsefalse00falsefalsefalsedei:submissionTypeItemTypestringThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".No definition available.false0Document Type3false 4dei_AmendmentFlagdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:booleanItemTypenaIf the value is true, then the document is an amendment to previously-filed/accepted document.No definition available.false0Amendment Flag4false 4dei_DocumentPeriodEndDatedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse002013-06-30falsefalsetrue2falsefalsefalse00falsefalsefalsexbrli:dateItemTypedateThe end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.No definition available.false0Document Period End Date5false 4dei_DocumentFiscalYearFocusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse002013falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:gYearItemTypepositiveintegerThis is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.No definition available.false0Document Fiscal Year Focus6false 4dei_DocumentFiscalPeriodFocusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00Q2falsefalsefalse2falsefalsefalse00falsefalsefalsedei:fiscalPeriodItemTypenaThis is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.No definition available.false0Document Fiscal Period Focus7false 4dei_TradingSymboldei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00CLVSfalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:normalizedStringItemTypenormalizedstringTrading symbol of an instrument as listed on an exchange.No definition available.false0Trading Symbol8false 4dei_EntityRegistrantNamedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00CLOVIS ONCOLOGY, INC.falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:normalizedStringItemTypenormalizedstringThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false0Entity Registrant Name9false 4dei_EntityCentralIndexKeydei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse000001466301falsefalsefalse2falsefalsefalse00falsefalsefalsedei:centralIndexKeyItemTypenaA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false0Entity Central Index Key10false 4dei_CurrentFiscalYearEndDatedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00--12-31falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:gMonthDayItemTypemonthdayEnd date of current fiscal year in the format --MM-DD.No definition available.false0Current Fiscal Year End Date11false 4dei_EntityFilerCategorydei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00Accelerated Filerfalsefalsefalse2falsefalsefalse00falsefalsefalsedei:filerCategoryItemTypestringIndicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.No definition available.false0Entity Filer Category12false 4dei_EntityCommonStockSharesOutstandingdei_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse3017139230171392falsefalsefalsexbrli:sharesItemTypesharesIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.No definition available.false1Entity Common Stock, Shares OutstandingfalseDocument and Entity InformationUnKnownNoRoundingUnKnownUnKnowntruefalsefalseSheethttp://www.clovisoncology.com/taxonomy/role/DocumentDocumentandEntityInformation212

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2013
Subsequent Events	11. Subsequent Events The Company evaluated events up to the filing date of these interim financial statements and determined that no subsequent activity required disclosure.

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2013
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2 of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

Commitments And Contingencies - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	1 Months Ended
	Feb. 28, 2013	Jun. 30, 2013
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Purchase commitment		$ 2.6
Contractual agreement quarterly forecasts required period	24 months
Contractual agreement obligated forecast period	12 months

Assets Measured at Fair Value on Recurring Basis (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets at fair value	$ 147,985	$ 135,385
Money Market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets at fair value	147,985	135,385
Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets at fair value	147,985	135,385
Fair Value, Inputs, Level 1 \| Money Market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets at fair value	$ 147,985	$ 135,385

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2013	Aug. 01, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2
Trading Symbol	CLVS
Entity Registrant Name	CLOVIS ONCOLOGY, INC.
Entity Central Index Key	0001466301
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		30,171,392